Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(+/-)-3-O-(4-cyanomethylphenyl)-1,2-O-di-n-heptylglycerol + H2O
?
(+/-)-3-O-(4-hydroxymethylphenyl)-1,2-O-di-n-heptylglycerol + H2O
?
(2'R,2S)-2,3-dihydroxypropyl 2'-octadecanoyloxy-5'-hexadecyloxy-5'-oxopentan-1'-yl phosphate + H2O
?
(2S,2'S,3R)-2,3-dihydroxypropyl 2',3'-octadecanoyloxy-nonadecyl phosphate + H2O
?
(2S,2'S,3S)-2,3-dihydroxypropyl 2',3'-octadecanoyloxy-nonadecyl phosphate + H2O
?
(3E)-3-[(3aS,7aS)-3-methyl-2-oxo-6-(propan-2-ylidene)hexahydro-1-benzofuran-7(4H)-ylidene]propanoic acid + H2O
?
-
-
-
-
?
(3R,3aS,5aS,8bR)-3,5a,5b-trimethyl-3a,4,5,5a,5b,8b-hexahydro-2H-cyclopenta[2,3]cyclopropa[1,2-g]benzofuran-2,6(3H)-dione + H2O
?
-
-
-
-
?
(3R,3aS,5aS,9bR)-3,5a,9-trimethyl-3a,4,5,5a-tetrahydronaphtho[1,2-b]furan-2,8(3H,9bH)-dione + H2O
?
-
-
-
-
?
(3R,3aS,6R,8S,9bS)-6,8-dihydroxy-3,6,9-trimethyl-3,3a,4,5,6,6a,7,8-octahydroazuleno[4,5-b]furan-2(9bH)-one + H2O
?
-
-
-
-
?
(3R,3aS,6R,8S,9bS)-8-hydroxy-3,6,9-trimethyl-2-oxo-2,3,3a,4,5,6,6a,7,8,9b-decahydroazuleno[4,5-b]furan-6-yl acetate + H2O
?
-
-
-
-
?
(3R,3aS,6R,9bS)-3,6,9-trimethyl-2,8-dioxo-2,3,3a,4,5,6,6a,7,8,9b-decahydroazuleno[4,5-b]furan-6-yl acetate + H2O
?
-
-
-
-
?
(3R,3aS,6R,9bS)-6-hydroxy-3,6,9-trimethyl-3a,4,5,6,6a,7-hexahydroazuleno[4,5-b]furan-2,8(3H,9bH)-dione + H2O
?
-
-
-
-
?
(3S)-5a-(1-bromo-1-methylethyl)-3-methyl-3,3a,5,5a,8,9b-hexahydro-4H-furo[2,3-f]chromene-2,7-dione + H2O
?
-
-
-
-
?
(R)-1,2-dipalmitoyl-glycero-3-phosphocholine + H2O
?
(R)-1,2-dipalmitoyl-glycero-3-phosphoglycerol + H2O
?
(R)-1,2-dipalmitoyl-sn-glycero-3-phosphocholine + H2O
?
-
enzyme adsorbs to monolayers of L-alpha-1,2-dipalmitoyl-sn-glycero-3-phosphocholine, leading to hydrolysis of the monlayer
-
-
?
(R)-1-O-hexadecyl-2-palmitoyl-sn-glycero-3-phoshocholine + H2O
?
1,2-bis(heptanoylthio)-glycerophosphocholine + H2O
?
-
-
-
-
?
1,2-bis-(10-pyrenedecanoyl)-sn-glycero-3-phosphocholine + H2O
1-(10-pyrenedecanoyl)-glycero-3-phosphocholine + 10-pyrenedecanoate
1,2-bis-(4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-undecanoyl)-sn-glycero-3-phosphocholine + H2O
1-(4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-undecanoyl)-sn-glycero-3-phosphocholine + 4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-undecanoic acid
-
fluorescent substrate
-
?
1,2-bis-(4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-undecanoyl)-sn-glycero-3-phosphocholine + H2O
?
1,2-di-O-hexadecyl-sn-glycerol-3-phosphocholine + H2O
1-O-hexadecyl-sn-glycero-3-phosphocholine + hexadecanoate
-
-
-
-
?
1,2-diacyl-sn-glycero-3-phosphate + H2O
1-acyl-sn-glycero-3-phosphate + a carboxylate
-
substrate from soybean
-
-
?
1,2-diacyl-sn-glycero-3-phosphatide + H2O
1-acyl-sn-glycero-3-phosphatide + fatty acid
1,2-diacyl-sn-glycero-3-phosphatide + H2O
?
1,2-diacyl-sn-glycero-3-phospho-(1-D-myo-inositol) + H2O
1-acyl-sn-glycero-3-phospho-(1-D-myo-inositol) + a carboxylate
-
substrate from soybean
-
-
?
1,2-diacyl-sn-glycero-3-phosphocholine + H2O
1-acyl-sn-glycero-3-phosphocholine + a carboxylate
-
substrate from soybean
-
-
?
1,2-diacyl-sn-glycero-3-phosphorylcholine + H2O
1-acyl-sn-glycero-3-phosphorylcholine + fatty acid
1,2-didecanoyl-sn-glycero-3-phosphocholine + H2O
1-decanoyl-sn-glycero-3-phosphocholine + decanoate
1,2-didodecanoyl-sn-glycero-3-phosphocholine + H2O
1-decanoyl-sn-glycero-3-phosphocholine + decanoate
1,2-diheptanoyl phosphatidylcholine + H2O
1-heptanoyl-sn-glycerophosphocholine + heptanoic acid
-
-
-
-
?
1,2-diheptanoyl thio-phosphatidylcholine + H2O
?
-
-
-
?
1,2-diheptanoyl-sn-glycero-3-phophorylcholine + H2O
1-heptanoyl-sn-glycero-3-phophorylcholine + heptanoate
1,2-diheptanoyl-sn-glycero-3-phosphocholine + H2O
1-heptanoyl-sn-glycero-3-phosphocholine + heptanoate
-
-
-
-
?
1,2-diheptanoyl-sn-glycero-3-sulfate + H2O
1-heptanoyl-sn-glycero-3-sulfate + heptanoate
1,2-diheptanoylthio-phosphatidylcholine + H2O
?
-
-
-
?
1,2-dihexadecanoyl-rac-glycero-3-phosphorac-(1-glycerol) + H2O
?
pyrene-modified or unmodified phospholipid substrate
-
-
?
1,2-dihexanoyl-sn-glycero-3-phosphocholine + H2O
1-hexanoyl-sn-glycero-3-phosphocholine + hexanoate
1,2-dilauroyl-sn-glycero-3-phosphocholine + H2O
1-lauroyl-sn-glycero-3-phosphocholine + laurate
-
-
-
-
?
1,2-dilauroyl-sn-glycero-3-phosphocholine + H2O
1-lauroyl-sn-glycero-3-phosphocholine + laureate
1,2-dilinoleoyl-phosphatidylcholine + H2O
1-linoleoyl-glycerophosphorylcholine + linoleic acid
-
-
-
-
?
1,2-dilinoleoyl-phosphatidylcholine + H2O
1-linoleoyl-sn-glycero-3-phosphocholine + linoleic acid
-
-
-
-
?
1,2-dilinoleoyl-sn-glycero-3-phosphocholine + H2O
1-linoleoyl-sn-glycero-3-phosphocholine + linoleoate
-
-
-
-
?
1,2-dimyristol-sn-glycero-phosphomethanol lithium salt + H2O
myristic acid + 1-myristoyl-sn-glycerophosphomethanol
1,2-dimyristoyl-sn-glycero-3 phosphocholine + H2O
1-myristoyl-phosphorylcholine + myristic acid
-
-
-
-
?
1,2-dimyristoyl-sn-glycero-3-phosphocholine + H2O
1-myristoyl-sn-glycero-3-phosphocholine + myristate
-
-
-
-
?
1,2-dimyristoyl-sn-glycero-3-phosphocholine + H2O
1-myristoyl-sn-glycero-3-phosphocholine + myristic acid
-
-
-
-
?
1,2-dimyristoyl-sn-phosphatidylcholine + H2O
1-myristoyl-phosphorylcholine + myristic acid
1,2-dimyristoyl-sn-phosphatidylinositol + H2O
1-myristoyl-sn-phosphatidylinositol + myristic acid
-
-
-
?
1,2-dimyristoyl-sn-phosphatidylserine + H2O
1-myristoyl-sn-phosphatidylserine + myristic acid
-
-
-
?
1,2-dinonanoyl-sn-glycero-3-phosphocholine + H2O
1-nonanoyl-sn-glycero-3-phosphocholine + nonanoate
1,2-dinonanoyl-sn-glycero-3-phosphocholine + H2O
?
-
-
-
?
1,2-dioctanoyl-sn-glycero-3-phosphocholine + H2O
1-octanoyl-sn-glycero-3-phosphocholine + octanoate
1,2-dioctanoyl-sn-glycero-3-phosphoglycol + H2O
1-octanoyl-sn-glycero-3-phosphoglycol + octanoate
1,2-dioleoyl-L-alpha-phosphatidylcholine + H2O
?
1,2-dioleoyl-sn-glycero-3-phosphocholine + H2O
1-oleoyl-sn-glycero-3-phosphocholine + oleate
-
preferred substrate
-
-
?
1,2-dioleoyl-sn-glycero-3-phosphocholine + H2O
1-oleoyl-sn-glycero-3-phosphocholine + oleic acid
1,2-dioleoyl-sn-glycero-3-phosphocholine + H2O
1-oleoylglycerophosphocholine + oleic acid
-
-
-
-
?
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine + H2O
1-oleoyl-sn-glycero-3-phosphoethanolamine + oleate
-
-
-
-
?
1,2-dioleoyl-sn-glycero-3-phosphorac-(1-glycerol) + H2O
1-oleoyl-sn-glycero-3-phosphorac-(1-glycerol) + oleate
-
-
-
-
?
1,2-dioleoyl-sn-glycero-3-phosphoserine + H2O
1-oleoyl-sn-glycero-3-phosphoserine + oleate
-
-
-
-
?
1,2-dioleoyl-sn-glycerol + H2O
1-oleoyl-sn-glycerol + oleic acid
-
-
-
-
?
1,2-dioleoyl-sn-glycerol + H2O
?
-
-
-
-
?
1,2-dioleoyl-sn-phosphatidylcholine + H2O
1-oleoyl-sn-phosphatidylcholine + oleate
1,2-dioleoyl-sn-phosphatidylethanolamine + H2O
1-oleoyl-sn-phosphatidylethanolamine + oleic acid
1,2-dipalmitoyl-L-3-phosphatidylcholine + H2O
1-palmitoylphosphocholine + palmitate
-
-
-
-
?
1,2-dipalmitoyl-phosphatidylcholine + H2O
1-palmitoyl-glycerophosphocholine + palmitate
1,2-dipalmitoyl-phosphatidylcholine + H2O
1-palmitoyl-glycerophosphocholine + palmitic acid
-
1,2-dipalmitoyl-phosphatidylcholine, small unilamellar vesicles
-
-
?
1,2-dipalmitoyl-phosphatidylcholine + H2O
1-palmitoyl-glycerophosphorylcholine + palmitic acid
1,2-dipalmitoyl-phosphatidylethanolamine + H2O
1-palmitoyl-glycerophosphoethanolamine + palmitate
substrate from egg yolk
-
-
?
1,2-dipalmitoyl-phosphatidylethanolamine + H2O
1-palmitoyl-phosphatidylethanolamine + palmitic acid
1,2-dipalmitoyl-sn-glycero-3-phosphocholine + H2O
1-palmitoyl-sn-glycero-3-phosphocholine + palmitate
1,2-dipalmitoyl-sn-glycero-3-phosphocholine + H2O
1-palmitoyl-sn-glycero-3-phosphocholine + palmitic acid
1,2-dipalmitoyl-sn-glycero-3-phosphocholine + H2O
1-palmitoyl-sn-glycero-3-phosphorylcholine + palmitate
1,2-dipalmitoyl-sn-glycero-3-phosphocholine + H2O
1-palmitoylglycerophosphocholine + palmitic acid
-
-
-
-
?
1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) + H2O
1-palmitoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) + palmitic acid
-
-
-
-
?
1,2-dipalmitoyl-sn-glycero-3-phosphoglycerol + H2O
1-palmitoyl-glycero-3-phosphoglycerol + palmitate
1,2-dipalmitoyl-sn-glycero-3-phosphoglycerol + H2O
1-palmitoyl-sn-glycero-3-phosphorylglycerol + palmitate
-
-
-
?
1,2-dipalmitoyl-sn-glycero-3-phosphorylcholine + H2O
1-palmitoyl-sn-glycero-3-phosphorylcholine + palmitate
-
-
-
-
?
1,2-dipalmitoyl-sn-glycero-3-phosphorylcholine + H2O
1-palmitoyl-sn-glycero-3-phosphorylcholine + palmitic acid
1,2-dipalmitoyl-sn-glycero-3-phosphorylcholine + H2O
?
-
-
-
-
?
1,2-dipalmitoyl-sn-phosphatidylcholine + H2O
1-palmitoyl-sn-phosphatidylcholine + palmitate
1,2-dipalmitoyl-sn-phosphatidylserine + H2O
1-palmitoyl-sn-phosphatidylserine + palmitic acid
1,2-dithio-deheptanoyl phosphatidylcholine + H2O
?
-
-
-
?
1,2-dithio-heptanoylphosphatidylcholine + H2O
?
-
detection of reaction product with 5,5'-dithio-bis-(2-nitrobenzoic acid)
-
-
?
1-acyl-2-arachidonoyl-glycerophosphocholine + H2O
1-acyl-glycerophosphocholine + arachidonic acid
-
-
-
?
1-acyl-2-arachidonoyl-sn-glycero-3-phosphoethanolamine + H2O
1-acyl-sn-glycero-3-phosphoethanolamine + arachidonic acid
1-acyl-2-arachidonoyl-sn-glycerol phosphoethanolamine + H2O
1-acyl-sn-glycerol phosphoethanolamine + arachidonate
radiolabeled substrate
-
-
?
1-acyl-2-arachidonoyl-sn-glycerophosphocholine + H2O
1-acyl-sn-glycerophosphocholine + arachidonic acid
-
-
-
?
1-acyl-2-arachidonoyl-sn-glycerophosphoethanolamine + H2O
1-acyl-sn-glycerophosphoethanolamine + arachidonic acid
1-acyl-2-linoleoyl-3-phosphoethanolamine + H2O
1-acyl-3-phosphoethanolamine + linolic acid
1-acyl-2-linoleoyl-glycerophosphocholine + H2O
1-acyl-glycerophosphocholine + linolic acid
-
-
-
?
1-acyl-2-linoleoyl-sn-glycerophosphocholine + H2O
1-acyl-sn-glycerophosphocholine + linoleic acid
-
-
-
?
1-acyl-2-oleoyl-sn-glycerophosphocholine + H2O
1-acyl-sn-glycerophosphocholine + oleic acid
-
-
-
?
1-acyl-2-palmitoyl-sn-glycerophosphocholine + H2O
1-acyl-sn-glycerophosphocholine + palmitic acid
-
-
-
?
1-decanoyl-2-(4-nitrophenylglutaryl)glycerol 3-phosphate + H2O
?
-
HSD-PLA2
-
-
?
1-hexadecanoyl-2-(1-pyrenedecanoyl)-glycero-3-phosphatidic acid + H2O
?
-
group V sPLA2
-
-
?
1-hexadecanoyl-2-(1-pyrenedecanoyl)-glycero-3-phosphocholine + H2O
1-hexadecanoyl-glycero-3-phosphocholine + 1-pyrenedecanoate
1-hexadecanoyl-2-(1-pyrenedecanoyl)-glycero-3-phosphoethanolamine + H2O
1-hexadecanoyl-glycero-3-phosphoethanolamine + 1-pyrenedecanoate
1-hexadecanoyl-2-(1-pyrenedecanoyl)-glycero-3-phosphoglycerol + H2O
1-hexadecanoyl-glycero-3-phosphoglycerol + 1-pyrenedecanoate
1-hexadecanoyl-2-(1-pyrenedecanoyl)-glycero-3-phosphoserine + H2O
1-hexadecanoyl-glycero-3-phosphoserine + 1-pyrenedecanoate
-
group V sPLA2
-
?
1-hexadecanoyl-2-(1-pyrenedecanoyl)-sn-glycero-3-phosphocholine + H2O
?
-
fluorometric determination
-
-
?
1-hexadecanoyl-2-(1-pyrenedecanoyl)-sn-glycero-3-phosphoglycerol + H2O
?
-
micellar substrate
-
-
?
1-hexadecanoyl-2-(1-pyrenedecanoyl)-sn-glycero-3-phosphogylcerol + H2O
1-hexadecanoyl-glycero-3-phosphoethanolamine + 1-pyrenedecanoate
-
-
-
?
1-hexadecanoyl-2-(1-pyrenedecanoyl)-sn-glycerol-3-phosphatidyl choline + H2O
?
-
-
-
?
1-hexadecanoyl-2-(1-pyrenedecanoyl)-sn-glycerol-3-phosphocholine + H2O
?
-
-
-
-
?
1-hexadecanoyl-2-(10-(1-pyrene)decanoyl)-sn-glycero-3-phosphoglycerol + H2O
1-hexadecanoyl-sn-glycero-3-phosphoglycerol + 10-(1-pyrene)decanoic acid
1-hexadecanoyl-2-(10-pyrenedecanoyl)-sn-glycero-3-phosphoglycerol + H2O
1-hexadecanoyl-glycero-3-phosphoethanolamine + 10-pyrenedecanoate
-
-
-
-
?
1-hexadecanoyl-2-9(cis)-octadecanoyl-rac-glycero-phosphorylcholine + H2O
?
-
-
-
-
?
1-hexadecanoyl-2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)aminohexanoyl]-sn-glycero-3-phosphocholine + H2O
1-hexadecanoyl-sn-glycero-3-phosphocholine + 6-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]hexanoic acid
1-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine + H2O
1-hexadecanoyl-glycero-3-phosphoglycerol + acetate
-
i.e. PAF or platelet activating factor
-
-
?
1-hexadecyl-2-acetyl-sn-glycerol-3-phosphocholine + H2O
1-hexadecyl-sn-glycerol-3-phosphocholine + acetate
i.e. platelet-activating factor
-
-
?
1-O-hexadecyl-2-arachidonyl-glycero-3-phosphocholine + H2O
1-O-hexadecyl-glycero-3-phosphocholine + arachidonic acid
1-O-hexadecyl-2-oleoyl-sn-glycero-3-phosphocholine + H2O
1-O-hexadecyl-sn-glycero-3-phosphocholine + oleate
-
-
-
?
1-O-hexadecyl-2-[(cis)-9-octadecenoyl]-rac-glycero-3-phosphocholine + H2O
1-O-hexadecyl-rac-glycero-3-phosphocholine + cis-9-octadecenoate
-
-
-
?
1-oleoyl-2-isolauroyl phosphatidylethanolamine + H2O
1-oleoyl phosphatidylethanolamine + isolauric acid
-
-
-
?
1-oleoyl-2-palmitoyl-phosphatidylcholine + H2O
1-oleoyl-phosphatidylcholine + palmitic acid
-
-
-
?
1-oleoyl-2-palmitoyl-sn-glycero-3-phosphocholine + H2O
1-oleoyl-sn-glycero-3-phosphocholine + palmitate
1-oleoyl-2-stearoyl-sn-glycero-3-phosphocholine + H2O
1-oleoyl-sn-glycero-3-phosphocholine + stearate
-
-
-
-
?
1-oleoyl-sn-glycero-3-phosphocholine + H2O
?
-
-
-
-
?
1-palmitoyl-2-(10-pyrenyldecanoyl)-sn-glycero-3-phosphate + H2O
10-pyrenyldecanoic acid + 1-palmitoyl-sn-glycero-3-phosphate
1-palmitoyl-2-(12-(3-(4-hydroxyphenyl)propionyl)amino dodecanoyl)phosphatidylcholine + H2O
1-palmitoyl-sn-glycerophosphorylcholine + 12-(3-(4-hydroxyphenyl)propionyl)amino dodecanoate
-
-
-
-
?
1-palmitoyl-2-arachidonoyl-phosphatidylcholine + H2O
?
-
-
-
-
?
1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine + H2O
1-palmitoyl-glycero-3-phosphocholine + arachidonate
-
-
-
-
?
1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine + H2O
1-palmitoyl-sn-glycero-3-phosphocholine + arachidonate
1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine + H2O
?
-
isoform cPLA2-beta and cPLA2-gamma hydrolyse this substrate at a lower rate than isoform cPLA2-alpha
-
?
1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphoethanolamine + H2O
1-palmitoyl-sn-glycero-3-phosphoethanolamine + arachidonate
-
the enzyme has similar activities toward 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine and 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphoethanolamine
-
-
?
1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine + H2O
1-palmitoyl-sn-glycero-3-phosphorylcholine + arachidonic acid
1-palmitoyl-2-arachidonoylglycerophosphocholine + H2O
1-palmitoyl-glycerophosphorylcholine + arachidonic acid
-
GIVA cPLA2 substrate and GIVA iPLA2
-
-
?
1-palmitoyl-2-arachidonoylphosphatidylcholine + H2O
1-palmitoyl-glycerophosphorylcholine + arachidonic acid
1-palmitoyl-2-arachidonoylphosphatidylethanolamine
1-palmitoyl-glycerophosphorylethanolamine + arachidonic acid
1-palmitoyl-2-arachidonyl-phosphatidylcholine + H2O
1-palmitoyl-sn-glycero-3-phosphocholine + arachidonic acid
-
-
-
-
?
1-palmitoyl-2-arachidonyl-phosphatidylcholine + H2O
?
-
-
-
-
?
1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphocholine + H2O
1-palmitoyl-sn-glycero-3-phosphocholine + arachidonic acid
-
-
-
-
?
1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphocholine + H2O
1-palmitoyl-sn-glycero-3-phosphorylcholine + arachidonic acid
-
-
-
-
?
1-palmitoyl-2-arachidonyl-sn-glycerol-3-phosphocholine + H2O
?
1-palmitoyl-2-arachidonylphosphocholine + H2O
1-palmitoyl-glycerophosphocholine + arachidonic acid
-
-
?
1-palmitoyl-2-arachidonylphosphoethanolamine + H2O
1-palmitoyl-glycerophosphoethanolamine + arachidonic acid
-
-
?
1-palmitoyl-2-linoleoyl-phosphatidic acid + H2O
1-palmitoyl-sn-glycero-3-phosphate + linoleic acid
-
-
-
-
?
1-palmitoyl-2-linoleoyl-phosphatidylcholine + H2O
1-palmitoyl-sn-glycero-3-phosphocholine + linoleic acid
-
-
-
-
?
1-palmitoyl-2-linoleoyl-phosphatidylcholine + H2O
1-palmitoyl-sn-glycerophosphocholine + linoleate
in sn-2 position, linoleate is preferred over palmitate
-
-
?
1-palmitoyl-2-linoleoyl-phosphatidylethanolamine + H2O
1-palmitoyl-sn-glycerophosphoethanolamine + linoleate
-
-
-
-
?
1-palmitoyl-2-linoleoyl-phosphatidylethanolamine + H2O
1-palmitoyl-sn-glycerophosphoethanolamine + linoleic acid
-
-
-
-
?
1-palmitoyl-2-linoleoyl-phosphatidylinositol + H2O
1-palmitoyl-3-phosphoinositol + linoleic acid
-
-
-
-
?
1-palmitoyl-2-linoleoyl-phosphatidylserine + H2O
1-palmitoyl-sn-glycero-3-phosphoserine + linoleic acid
-
-
-
-
?
1-palmitoyl-2-linoleoyl-sn-glycero-3-phosphocholine + H2O
1-palmitoyl-sn-glycero-3-phosphocholine + linoleate
1-palmitoyl-2-linoleoyl-sn-glycero-3-phosphocholine + H2O
1-palmitoyl-sn-glycero-3-phosphocholine + linoleic acid
-
-
-
?
1-palmitoyl-2-linoleoyl-sn-glycero-3-phosphocholine + H2O
1-palmitoyl-sn-glycero-3-phosphocholine + linolic acid
1-palmitoyl-2-linoleoyl-sn-glycerophosphorylethanolamine + H2O
1-palmitoyl-glycerophosphorylethanolamine + linoleic acid
-
-
-
-
?
1-palmitoyl-2-linoleoylphosphatidylcholine + H2O
1-palmitoyl-glycerophosphorylcholine + linolic acid
1-palmitoyl-2-linoleoylphosphatidylethanolamine + H2O
1-palmitoyl-glycerophosphorylethanolamine + linolic acid
1-palmitoyl-2-linoleoylphosphocholine + H2O
1-palmitoyl-glycerophosphocholine + linolic acid
-
-
-
?
1-palmitoyl-2-oleoyl-phosphatidylcholine + H2O
1-palmitoylphosphocholine + oleate
-
-
-
-
?
1-palmitoyl-2-oleoyl-phosphatidylcholine + H2O
?
1-palmitoyl-2-oleoyl-phosphatidylethanolamine + H2O
1-palmitoyl-lysophosphatidylethanolamine + oleate
phosphatidylethanolamine-specific activity. The enzyme displays phospholipases A2 activity to phosphatidylethanolamine, but not to other phospholipids and generates 1-acylated lyso-phosphatidylethanolamine
-
-
?
1-palmitoyl-2-oleoyl-phosphatidylethanolamine + H2O
?
1-palmitoyl-2-oleoyl-phosphatidylglycerol + H2O
?
1-palmitoyl-2-oleoyl-phosphatidylinositol + H2O
?
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphate + H2O
?
1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-rac-(1-glycerol) + H2O
1-palmitoyl-sn-glycero-3-phospho-rac-(1-glycerol) + oleate
-
-
-
-
?
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine + H2O
1-palmitoyl-sn-glycero-3-phosphocholine + oleate
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine + H2O
1-palmitoyl-sn-glycero-3-phosphocholine + oleic acid
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine + H2O
oleic acid + 1-palmitoyl-sn-glycero-3-phosphocholine
-
from egg yolk
-
?
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine + H2O
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol + H2O
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol + H2O
1-palmitoyl-sn-glycero-3-phosphoglycerol + oleic acid
-
-
-
?
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol + H2O
1-palmitoyl-sn-glycero-3-phosphorylglycerol + oleate
1-palmitoyl-2-oleoylglycerophosphocholine + H2O
?
-
-
-
?
1-palmitoyl-2-oleoylphosphatidylcholine + H2O
1-palmitoyl-glycerophosphocholine + oleic acid
1-palmitoyl-2-palmitoyl-sn-glycerophosphocholine + H2O
1-palmitoyl-sn-glycerophosphocholine + palmitate
-
-
-
-
?
1-palmitoyl-2-palmitoylphosphatidylcholine + H2O
1-palmitoyl-glycerophosphorylcholine + palmitic acid
-
-
?
1-palmitoyl-2-stearoyl-dibromo-sn-glycero-3-phosphocholine + H2O
?
1-palmitoyl-2-[12-[(7-nitro-2-1,3-benzoxadiazol-4-yl)amino]dodecanoyl]-sn-glycero-3-phosphocholine + H2O
?
-
-
-
-
?
1-palmitoyl-2-{6-[(7-nitro-2-1,3-benzoxadiazol-4-yl)amino]hexanoyl}-sn-glycero-3-phosphocholine + H2O
1-palmitoyl-sn-glycero-3-phosphocholine + 6-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]hexanoic acid
-
-
-
?
1-palmitoyl-sn-glycero-3-phosphocholine + H2O
?
1-palmitoyl-sn-glycerol-3-phosphocholine + H2O
?
-
-
-
-
?
1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine + H2O
1-stearoyl-sn-glycero-3-phosphocholine + arachidonate
1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine + H2O
1-stearoyl-sn-glycero-3-phosphocholine + arachidonic acid
1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphoethanolamine + H2O
1-stearoyl-sn-glycero-3-phosphoethanolamine + arachidonic acid
-
-
-
?
1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphoinositol + H2O
1-stearoyl-sn-glycero-3-phosphoinositol + arachidonic acid
1-stearoyl-2-arachidonoylphosphatidylcholine + H2O
1-stearoyl-glycerophosphorylcholine + arachidonic acid
1-stearoyl-2-arachidonyl-phosphatidylinositol 4,5-bisphosphate + H2O
1-stearoyl-sn-glycero-3-phosphoinositol 4,5-bisphosphate + arachidonic acid
-
-
-
-
?
1-stearoyl-2-arachidonyl-sn-glycerol-3-phosphocholine + H2O
1-stearoyl-sn-glycero-3-phosphocholine + arachidonic acid
-
-
-
?
1-stearoyl-2-arachidonylphosphocholine + H2O
1-stearoyl-glycerophosphocholine + stearic acid
-
-
?
1-stearoyl-2-linolenoyl-sn-glycerol-3-phosphocholine + H2O
?
-
preferred substrate
-
?
1-stearoyl-2-linoleoyl-sn-glycerol-3-phosphocholine + H2O
1-stearoyl-sn-glycero-3-phosphocholine + linoic acid
-
-
-
?
1-stearoyl-2-oleoyl-3-sn-glycerophosphorylcholine + H2O
?
-
-
-
-
?
1-stearoyl-2-oleoyl-sn-glycerol-3-phosphocholine + H2O
1-stearoyl-sn-glycero-3-phosphocholine + oleic acid
-
-
hydrolysis occurs only in sn2 position of phospholipids
-
?
1-stearoyl-2-palmitoyl-sn-glycerol-3-phosphocholine + H2O
1-stearoyl-sn-glycero-3-phosphocholine + palmitic acid
-
-
-
?
4-nitro-3-(octanoyloxy) benzoic acid + H2O
3-hydroxy-4-nitrobenzoate + octanoate
4-nitro-3-(octanoyloxy) benzoic acid + H2O
?
-
-
-
-
?
4-nitro-3-(octanoyloxy)benzoic acid + H2O
3-hydroxy-4-nitrobenzoate + octanoate
4-nitro-3-(octanoyloxy)benzoic acid + H2O
?
4-nitro-3-octanoyloxy benzoic acid + H2O
?
-
-
-
?
4-nitro-3-octanoyloxy-benzoic acid + H2O
?
4-nitro-3-octanoyloxybenzoic acid + H2O
?
4-nitrophenyl caprate + H2O
4-nitrophenol + capric acid
-
-
-
?
6-dodecanoyl-2-dimethylaminonaphthalene + H2O
?
-
-
-
-
?
acrylodan-labeled fatty acid-binding protein + H2O
?
-
-
-
-
?
arachidonyl phosphatidylethanolamine + H2O
glycerophosphoethanolamine + arachidonic acid
-
-
-
-
?
arachidonyl thio-PC + H2O
arachidonic acid + (7R)-4-hydroxy-N,N,N-trimethyl-7-sulfanyl-3,5,9-trioxa-4-phosphapentacosan-1-aminium 4-oxide
cardiolipin + H2O
?
-
-
-
-
?
choline plasmalogen + H2O
lysoplasmalogen + fatty acid
-
-
-
?
D,L-alpha-dipalmitoyl phosphatidylcholine + H2O
?
-
-
-
?
diarachidonylphosphatidylcholine + H2O
arachidonylphosphatidylcholine + arachidonic acid
-
-
-
?
diheptanoyl phosphatidylcholine + H2O
1-heptanoyl-sn-glycerophosphocholine + heptanoic acid
-
-
-
-
?
dihexanoyl-dithio-phosphatidylcholine + H2O
?
proPLA2, monomeric substrate
-
-
?
dimyristoyl phosphatidylcholine + H2O
1-myristoyl-sn-glycerophosphocholine + myristic acid
-
-
-
-
?
dimyristoyl phosphatidylinositol + H2O
1-myristoyl-sn-glycerophosphoinositol + myristic acid
-
-
-
-
?
dimyristoyl phosphatidylserinel + H2O
1-myristoyl-sn-glycerophosphoserine + myristic acid
-
-
-
-
?
dioctanoyl phosphatidylcholine + H2O
octanoyl phosphatidylcholine + octanoate
-
-
-
?
dioleolyl-sn- phosphatidylcholine + H2O
1-oleolyl-sn-glycerophosphocholine + oleic acid
-
-
-
-
?
dioleolyl-sn- phosphatidylethanolamine + H2O
1-oleolyl-sn-glycerophosphoethanolamine + oleic acid
-
-
-
-
?
dioleoyl phosphatidylglycerol + H2O
?
dipalmitoyl- phosphatidylcholine + H2O
1-palmitoyl-sn-glycerophosphocholine + palmitic acid
-
-
-
-
?
dipalmitoyl- phosphatidylethanolamine + H2O
1-palmitoyl-sn-glycerophosphoethanolamine + palmitic acid
-
-
-
-
?
dipalmitoyl-phosphatidylcholine + H2O
1-palmitoyl-glycerophosphocholine + palmitic acid
-
GIVA iPLA2 and GV sPLA2
-
-
?
diphosphatidylglycerol + H2O
?
-
-
-
-
?
egg yolk phospholipid + H2O
?
ethanolamine plasmalogen + H2O
lysoplasmalogen + fatty acid
-
-
-
?
glycerophospholipid + H2O
arachidonic acid + ?
-
-
-
-
?
hen egg phosphatidylcholine + H2O
?
-
-
-
-
?
L-1-acyl-2-arachidonyl-sn-glycerol-3-phosphatidylethanolamine + H2O
?
-
-
-
?
L-alpha-dipalmitoyl phosphatidylcholine + H2O
1-palmitoyl-sn-glycerophosphocholine + palmitate
-
-
-
-
?
L-alpha-dipalmitoyl phosphatidylcholine + H2O
?
-
-
-
?
L-alpha-phosphatidylcholine + H2O
1-acylglycerophosphocholine + a carboxylate
L-dipalmitoyl phosphatidylcholine + H2O
1-palmitoyl-sn-glycerophosphocholine + palmitate
l-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine + H2O
?
-
-
-
-
?
NBD-phosphatidylcholine + H2O
?
-
-
-
-
?
oxidized high density lipoprotein + H2O
?
-
-
-
-
?
oxidized low density lipoprotein + H2O
?
-
-
-
-
?
oxidized palmitoyl arachidonyl phosphatidylcholine + H2O
?
-
-
-
-
?
oxidized phosphatidylcholine + H2O
lysophosphatidylcholine + fatty acid
oxidized phosphatidylcholines + H2O
1-acylglycerophosphocholine + oxidized fatty acids
p-nitrophenyl laurate + H2O
p-nitrophenol + laurate
-
23.7% of the activity with p-nitrophenyl propionate
-
-
?
p-nitrophenyl octanoate + H2O
p-nitrophenol + octanoic acid
-
79.5% of the activity with p-nitrophenyl propionate
-
-
?
p-nitrophenyl propionate + H2O
p-nitrophenol + propionate
-
-
-
-
?
palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine + H2O
palmitoyl-sn-glycerophosphocholine + oleate
-
-
-
?
palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine + H2O
palmitoyl-sn-glycerophosphoethanolamine + oleate
-
-
-
?
palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol + H2O
palmitoyl-sn-glycerophosphoglycerol + oleate
-
-
-
?
phosphatidic acid + H2O
1-acylglycerophosphate + fatty acid
phosphatidylcholine + arachidonic acid
1-acyl-2-arachidonoyl-sn-glycero-3-phosphocholine + carboxylic acid
-
-
-
r
phosphatidylcholine + H2O
1-acylglycerophosphocholine + a carboxylate
phosphatidylcholine + H2O
1-acylglycerophosphocholine + fatty acid
phosphatidylcholine + H2O
?
-
the enzyme shows preferential hydrolysis of phosphatidylcholine
-
-
?
phosphatidylcholine + H2O
lysophosphatidylcholine + a fatty acid
phosphatidylcholine + linoleic acid
lineoyl phosphatidylcholine
-
-
-
?
phosphatidylethanolamine + arachidonic acid
arachidonoyl phosphatidylethanolamine
-
-
-
r
phosphatidylethanolamine + H2O
1-acylglycerophosphorylethanolamine + fatty acid
phosphatidylethanolamine + linoleic acid
lineoyl phosphatidylethanolamine + fatty acid
-
-
-
?
phosphatidylglycerol + H2O
1-acylglycerol + fatty acid
phosphatidylinositol + arachidonic acid
arachidonoyl phosphatidylinositol + fatty acid
phosphatidylinositol + linoleic acid
lineoyl phosphatidylinositol + fatty acid
-
-
-
?
phosphatidylserine + arachidonic acid
arachidonoyl phosphatidylserine + fatty acid
-
-
-
?
phosphatidylserine + H2O
1-acylglycerophosphoserine + fatty acid
phosphatidylserine + linoleic acid
lineoyl phosphatidylserine + fatty acid
-
-
-
?
phospholipid + H2O
lysophospholipid + fatty acid
pigment epithelium-derived 6 + H2O
?
-
i.e. PED6, a synthetic substrate
-
-
?
plasmalogen + H2O
?
-
-
-
-
?
platelet activating factor + H2O
?
platelet activating factor + H2O
lyso-platelet activating factor
-
-
-
-
?
rac-1,2-dihexanoyldithiopropyl-3-phosphocholine + H2O
?
-
-
-
-
?
sn-2-arachidonyl phosphatidylcholine + H2O
phosphatidylcholine + arachidonate
-
-
-
-
?
sn-3-phosphatidylcholine + H2O
?
-
-
-
?
soya lecithin + H2O
?
-
-
-
?
additional information
?
-
(+/-)-3-O-(4-cyanomethylphenyl)-1,2-O-di-n-heptylglycerol + H2O
?
-
-
-
-
?
(+/-)-3-O-(4-cyanomethylphenyl)-1,2-O-di-n-heptylglycerol + H2O
?
-
-
-
-
?
(+/-)-3-O-(4-hydroxymethylphenyl)-1,2-O-di-n-heptylglycerol + H2O
?
-
-
-
-
?
(+/-)-3-O-(4-hydroxymethylphenyl)-1,2-O-di-n-heptylglycerol + H2O
?
-
-
-
-
?
(2'R,2S)-2,3-dihydroxypropyl 2'-octadecanoyloxy-5'-hexadecyloxy-5'-oxopentan-1'-yl phosphate + H2O
?
-
-
-
-
?
(2'R,2S)-2,3-dihydroxypropyl 2'-octadecanoyloxy-5'-hexadecyloxy-5'-oxopentan-1'-yl phosphate + H2O
?
-
-
-
?
(2'R,2S)-2,3-dihydroxypropyl 2'-octadecanoyloxy-5'-hexadecyloxy-5'-oxopentan-1'-yl phosphate + H2O
?
-
-
-
?
(2S,2'S,3R)-2,3-dihydroxypropyl 2',3'-octadecanoyloxy-nonadecyl phosphate + H2O
?
-
-
-
-
?
(2S,2'S,3R)-2,3-dihydroxypropyl 2',3'-octadecanoyloxy-nonadecyl phosphate + H2O
?
-
-
-
?
(2S,2'S,3R)-2,3-dihydroxypropyl 2',3'-octadecanoyloxy-nonadecyl phosphate + H2O
?
-
-
-
?
(2S,2'S,3S)-2,3-dihydroxypropyl 2',3'-octadecanoyloxy-nonadecyl phosphate + H2O
?
-
-
-
-
?
(2S,2'S,3S)-2,3-dihydroxypropyl 2',3'-octadecanoyloxy-nonadecyl phosphate + H2O
?
-
-
-
?
(2S,2'S,3S)-2,3-dihydroxypropyl 2',3'-octadecanoyloxy-nonadecyl phosphate + H2O
?
-
-
-
?
(R)-1,2-dipalmitoyl-glycero-3-phosphocholine + H2O
?
-
-
-
-
?
(R)-1,2-dipalmitoyl-glycero-3-phosphocholine + H2O
?
-
-
-
?
(R)-1,2-dipalmitoyl-glycero-3-phosphocholine + H2O
?
-
-
-
?
(R)-1,2-dipalmitoyl-glycero-3-phosphoglycerol + H2O
?
-
-
-
-
?
(R)-1,2-dipalmitoyl-glycero-3-phosphoglycerol + H2O
?
-
-
-
?
(R)-1,2-dipalmitoyl-glycero-3-phosphoglycerol + H2O
?
-
-
-
?
(R)-1-O-hexadecyl-2-palmitoyl-sn-glycero-3-phoshocholine + H2O
?
-
-
-
-
?
(R)-1-O-hexadecyl-2-palmitoyl-sn-glycero-3-phoshocholine + H2O
?
-
-
-
?
(R)-1-O-hexadecyl-2-palmitoyl-sn-glycero-3-phoshocholine + H2O
?
-
-
-
?
1,2-bis-(10-pyrenedecanoyl)-sn-glycero-3-phosphocholine + H2O
1-(10-pyrenedecanoyl)-glycero-3-phosphocholine + 10-pyrenedecanoate
-
-
-
?
1,2-bis-(10-pyrenedecanoyl)-sn-glycero-3-phosphocholine + H2O
1-(10-pyrenedecanoyl)-glycero-3-phosphocholine + 10-pyrenedecanoate
-
-
-
-
?
1,2-bis-(10-pyrenedecanoyl)-sn-glycero-3-phosphocholine + H2O
1-(10-pyrenedecanoyl)-glycero-3-phosphocholine + 10-pyrenedecanoate
-
-
-
?
1,2-bis-(4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-undecanoyl)-sn-glycero-3-phosphocholine + H2O
?
-
-
-
-
?
1,2-bis-(4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-undecanoyl)-sn-glycero-3-phosphocholine + H2O
?
-
-
-
-
?
1,2-diacyl-sn-glycero-3-phosphatide + H2O
1-acyl-sn-glycero-3-phosphatide + fatty acid
-
-
-
?
1,2-diacyl-sn-glycero-3-phosphatide + H2O
1-acyl-sn-glycero-3-phosphatide + fatty acid
-
-
-
?
1,2-diacyl-sn-glycero-3-phosphatide + H2O
?
-
-
-
-
?
1,2-diacyl-sn-glycero-3-phosphatide + H2O
?
-
-
-
-
?
1,2-diacyl-sn-glycero-3-phosphorylcholine + H2O
1-acyl-sn-glycero-3-phosphorylcholine + fatty acid
-
-
-
?
1,2-diacyl-sn-glycero-3-phosphorylcholine + H2O
1-acyl-sn-glycero-3-phosphorylcholine + fatty acid
-
-
-
?
1,2-didecanoyl-sn-glycero-3-phosphocholine + H2O
1-decanoyl-sn-glycero-3-phosphocholine + decanoate
-
-
-
-
?
1,2-didecanoyl-sn-glycero-3-phosphocholine + H2O
1-decanoyl-sn-glycero-3-phosphocholine + decanoate
-
-
-
?
1,2-didecanoyl-sn-glycero-3-phosphocholine + H2O
1-decanoyl-sn-glycero-3-phosphocholine + decanoate
-
-
-
?
1,2-didecanoyl-sn-glycero-3-phosphocholine + H2O
1-decanoyl-sn-glycero-3-phosphocholine + decanoate
-
-
-
?
1,2-didecanoyl-sn-glycero-3-phosphocholine + H2O
1-decanoyl-sn-glycero-3-phosphocholine + decanoate
-
-
-
?
1,2-didecanoyl-sn-glycero-3-phosphocholine + H2O
1-decanoyl-sn-glycero-3-phosphocholine + decanoate
-
-
-
?
1,2-didodecanoyl-sn-glycero-3-phosphocholine + H2O
1-decanoyl-sn-glycero-3-phosphocholine + decanoate
-
-
-
?
1,2-didodecanoyl-sn-glycero-3-phosphocholine + H2O
1-decanoyl-sn-glycero-3-phosphocholine + decanoate
-
-
-
?
1,2-didodecanoyl-sn-glycero-3-phosphocholine + H2O
1-decanoyl-sn-glycero-3-phosphocholine + decanoate
-
-
-
?
1,2-diheptanoyl-sn-glycero-3-phophorylcholine + H2O
1-heptanoyl-sn-glycero-3-phophorylcholine + heptanoate
-
-
-
?
1,2-diheptanoyl-sn-glycero-3-phophorylcholine + H2O
1-heptanoyl-sn-glycero-3-phophorylcholine + heptanoate
-
-
-
-
?
1,2-diheptanoyl-sn-glycero-3-phophorylcholine + H2O
1-heptanoyl-sn-glycero-3-phophorylcholine + heptanoate
-
-
-
-
?
1,2-diheptanoyl-sn-glycero-3-phophorylcholine + H2O
1-heptanoyl-sn-glycero-3-phophorylcholine + heptanoate
-
-
-
-
?
1,2-diheptanoyl-sn-glycero-3-sulfate + H2O
1-heptanoyl-sn-glycero-3-sulfate + heptanoate
-
-
-
?
1,2-diheptanoyl-sn-glycero-3-sulfate + H2O
1-heptanoyl-sn-glycero-3-sulfate + heptanoate
-
-
-
?
1,2-diheptanoyl-sn-glycero-3-sulfate + H2O
1-heptanoyl-sn-glycero-3-sulfate + heptanoate
-
-
-
?
1,2-dihexanoyl-sn-glycero-3-phosphocholine + H2O
1-hexanoyl-sn-glycero-3-phosphocholine + hexanoate
-
-
-
?
1,2-dihexanoyl-sn-glycero-3-phosphocholine + H2O
1-hexanoyl-sn-glycero-3-phosphocholine + hexanoate
-
low activity
-
-
?
1,2-dihexanoyl-sn-glycero-3-phosphocholine + H2O
1-hexanoyl-sn-glycero-3-phosphocholine + hexanoate
-
-
-
?
1,2-dihexanoyl-sn-glycero-3-phosphocholine + H2O
1-hexanoyl-sn-glycero-3-phosphocholine + hexanoate
-
-
-
?
1,2-dihexanoyl-sn-glycero-3-phosphocholine + H2O
1-hexanoyl-sn-glycero-3-phosphocholine + hexanoate
-
-
-
?
1,2-dihexanoyl-sn-glycero-3-phosphocholine + H2O
1-hexanoyl-sn-glycero-3-phosphocholine + hexanoate
-
-
-
-
?
1,2-dilauroyl-sn-glycero-3-phosphocholine + H2O
1-lauroyl-sn-glycero-3-phosphocholine + laureate
-
-
-
?
1,2-dilauroyl-sn-glycero-3-phosphocholine + H2O
1-lauroyl-sn-glycero-3-phosphocholine + laureate
-
-
-
?
1,2-dilauroyl-sn-glycero-3-phosphocholine + H2O
1-lauroyl-sn-glycero-3-phosphocholine + laureate
-
-
-
?
1,2-dilauroyl-sn-glycero-3-phosphocholine + H2O
1-lauroyl-sn-glycero-3-phosphocholine + laureate
-
-
-
?
1,2-dimyristol-sn-glycero-phosphomethanol lithium salt + H2O
myristic acid + 1-myristoyl-sn-glycerophosphomethanol
-
-
-
?
1,2-dimyristol-sn-glycero-phosphomethanol lithium salt + H2O
myristic acid + 1-myristoyl-sn-glycerophosphomethanol
-
-
-
?
1,2-dimyristol-sn-glycero-phosphomethanol lithium salt + H2O
myristic acid + 1-myristoyl-sn-glycerophosphomethanol
-
-
-
?
1,2-dimyristoyl-sn-phosphatidylcholine + H2O
1-myristoyl-phosphorylcholine + myristic acid
-
-
-
?
1,2-dimyristoyl-sn-phosphatidylcholine + H2O
1-myristoyl-phosphorylcholine + myristic acid
-
-
-
?
1,2-dimyristoyl-sn-phosphatidylcholine + H2O
1-myristoyl-phosphorylcholine + myristic acid
-
-
-
?
1,2-dimyristoyl-sn-phosphatidylcholine + H2O
1-myristoyl-phosphorylcholine + myristic acid
-
-
-
?
1,2-dimyristoyl-sn-phosphatidylcholine + H2O
1-myristoyl-phosphorylcholine + myristic acid
-
-
-
?
1,2-dimyristoyl-sn-phosphatidylcholine + H2O
1-myristoyl-phosphorylcholine + myristic acid
-
-
-
?
1,2-dinonanoyl-sn-glycero-3-phosphocholine + H2O
1-nonanoyl-sn-glycero-3-phosphocholine + nonanoate
-
-
-
?
1,2-dinonanoyl-sn-glycero-3-phosphocholine + H2O
1-nonanoyl-sn-glycero-3-phosphocholine + nonanoate
-
-
-
?
1,2-dinonanoyl-sn-glycero-3-phosphocholine + H2O
1-nonanoyl-sn-glycero-3-phosphocholine + nonanoate
-
-
-
?
1,2-dioctanoyl-sn-glycero-3-phosphocholine + H2O
1-octanoyl-sn-glycero-3-phosphocholine + octanoate
-
-
-
-
?
1,2-dioctanoyl-sn-glycero-3-phosphocholine + H2O
1-octanoyl-sn-glycero-3-phosphocholine + octanoate
-
-
-
?
1,2-dioctanoyl-sn-glycero-3-phosphocholine + H2O
1-octanoyl-sn-glycero-3-phosphocholine + octanoate
-
-
-
?
1,2-dioctanoyl-sn-glycero-3-phosphocholine + H2O
1-octanoyl-sn-glycero-3-phosphocholine + octanoate
-
-
-
?
1,2-dioctanoyl-sn-glycero-3-phosphocholine + H2O
1-octanoyl-sn-glycero-3-phosphocholine + octanoate
-
-
-
?
1,2-dioctanoyl-sn-glycero-3-phosphocholine + H2O
1-octanoyl-sn-glycero-3-phosphocholine + octanoate
-
-
-
?
1,2-dioctanoyl-sn-glycero-3-phosphocholine + H2O
1-octanoyl-sn-glycero-3-phosphocholine + octanoate
-
-
-
?
1,2-dioctanoyl-sn-glycero-3-phosphocholine + H2O
1-octanoyl-sn-glycero-3-phosphocholine + octanoate
-
-
-
?
1,2-dioctanoyl-sn-glycero-3-phosphocholine + H2O
1-octanoyl-sn-glycero-3-phosphocholine + octanoate
-
-
-
?
1,2-dioctanoyl-sn-glycero-3-phosphocholine + H2O
1-octanoyl-sn-glycero-3-phosphocholine + octanoate
-
-
-
?
1,2-dioctanoyl-sn-glycero-3-phosphocholine + H2O
1-octanoyl-sn-glycero-3-phosphocholine + octanoate
-
-
-
?
1,2-dioctanoyl-sn-glycero-3-phosphocholine + H2O
1-octanoyl-sn-glycero-3-phosphocholine + octanoate
micellar substrate
-
?
1,2-dioctanoyl-sn-glycero-3-phosphoglycol + H2O
1-octanoyl-sn-glycero-3-phosphoglycol + octanoate
-
-
-
?
1,2-dioctanoyl-sn-glycero-3-phosphoglycol + H2O
1-octanoyl-sn-glycero-3-phosphoglycol + octanoate
-
-
-
?
1,2-dioctanoyl-sn-glycero-3-phosphoglycol + H2O
1-octanoyl-sn-glycero-3-phosphoglycol + octanoate
-
-
-
?
1,2-dioleoyl-L-alpha-phosphatidylcholine + H2O
?
-
-
-
-
?
1,2-dioleoyl-L-alpha-phosphatidylcholine + H2O
?
-
-
-
-
?
1,2-dioleoyl-sn-glycero-3-phosphocholine + H2O
1-oleoyl-sn-glycero-3-phosphocholine + oleic acid
-
-
-
-
?
1,2-dioleoyl-sn-glycero-3-phosphocholine + H2O
1-oleoyl-sn-glycero-3-phosphocholine + oleic acid
-
-
-
-
?
1,2-dioleoyl-sn-phosphatidylcholine + H2O
1-oleoyl-sn-phosphatidylcholine + oleate
-
-
-
?
1,2-dioleoyl-sn-phosphatidylcholine + H2O
1-oleoyl-sn-phosphatidylcholine + oleate
-
-
-
?
1,2-dioleoyl-sn-phosphatidylcholine + H2O
1-oleoyl-sn-phosphatidylcholine + oleate
-
-
-
?
1,2-dioleoyl-sn-phosphatidylcholine + H2O
1-oleoyl-sn-phosphatidylcholine + oleate
-
-
-
?
1,2-dioleoyl-sn-phosphatidylethanolamine + H2O
1-oleoyl-sn-phosphatidylethanolamine + oleic acid
-
-
-
?
1,2-dioleoyl-sn-phosphatidylethanolamine + H2O
1-oleoyl-sn-phosphatidylethanolamine + oleic acid
-
-
-
?
1,2-dioleoyl-sn-phosphatidylethanolamine + H2O
1-oleoyl-sn-phosphatidylethanolamine + oleic acid
-
-
-
?
1,2-dioleoyl-sn-phosphatidylethanolamine + H2O
1-oleoyl-sn-phosphatidylethanolamine + oleic acid
-
-
-
?
1,2-dioleoyl-sn-phosphatidylethanolamine + H2O
1-oleoyl-sn-phosphatidylethanolamine + oleic acid
-
-
-
?
1,2-dipalmitoyl-phosphatidylcholine + H2O
1-palmitoyl-glycerophosphocholine + palmitate
in sn-2 position, linoleate is preferred over palmitate
-
-
?
1,2-dipalmitoyl-phosphatidylcholine + H2O
1-palmitoyl-glycerophosphocholine + palmitate
substrate from egg yolk
-
-
?
1,2-dipalmitoyl-phosphatidylcholine + H2O
1-palmitoyl-glycerophosphorylcholine + palmitic acid
-
-
-
?
1,2-dipalmitoyl-phosphatidylcholine + H2O
1-palmitoyl-glycerophosphorylcholine + palmitic acid
-
-
-
?
1,2-dipalmitoyl-phosphatidylcholine + H2O
1-palmitoyl-glycerophosphorylcholine + palmitic acid
-
-
-
?
1,2-dipalmitoyl-phosphatidylcholine + H2O
1-palmitoyl-glycerophosphorylcholine + palmitic acid
-
-
-
?
1,2-dipalmitoyl-phosphatidylcholine + H2O
1-palmitoyl-glycerophosphorylcholine + palmitic acid
-
-
-
?
1,2-dipalmitoyl-phosphatidylcholine + H2O
1-palmitoyl-glycerophosphorylcholine + palmitic acid
-
-
-
?
1,2-dipalmitoyl-phosphatidylcholine + H2O
1-palmitoyl-glycerophosphorylcholine + palmitic acid
-
-
-
?
1,2-dipalmitoyl-phosphatidylcholine + H2O
1-palmitoyl-glycerophosphorylcholine + palmitic acid
-
-
-
?
1,2-dipalmitoyl-phosphatidylcholine + H2O
1-palmitoyl-glycerophosphorylcholine + palmitic acid
-
hydrolyzes the sn-2 position of a phospholipid liberating a fatty acid and a lysolipid
-
-
?
1,2-dipalmitoyl-phosphatidylcholine + H2O
1-palmitoyl-glycerophosphorylcholine + palmitic acid
-
-
-
?
1,2-dipalmitoyl-phosphatidylcholine + H2O
1-palmitoyl-glycerophosphorylcholine + palmitic acid
-
-
-
?
1,2-dipalmitoyl-phosphatidylcholine + H2O
1-palmitoyl-glycerophosphorylcholine + palmitic acid
-
-
-
?
1,2-dipalmitoyl-phosphatidylcholine + H2O
1-palmitoyl-glycerophosphorylcholine + palmitic acid
-
data for iPLA2
-
?
1,2-dipalmitoyl-phosphatidylcholine + H2O
1-palmitoyl-glycerophosphorylcholine + palmitic acid
-
-
-
?
1,2-dipalmitoyl-phosphatidylcholine + H2O
1-palmitoyl-glycerophosphorylcholine + palmitic acid
-
-
-
?
1,2-dipalmitoyl-phosphatidylcholine + H2O
1-palmitoyl-glycerophosphorylcholine + palmitic acid
-
-
-
?
1,2-dipalmitoyl-phosphatidylcholine + H2O
1-palmitoyl-glycerophosphorylcholine + palmitic acid
-
-
-
?
1,2-dipalmitoyl-phosphatidylcholine + H2O
1-palmitoyl-glycerophosphorylcholine + palmitic acid
-
-
-
?
1,2-dipalmitoyl-phosphatidylethanolamine + H2O
1-palmitoyl-phosphatidylethanolamine + palmitic acid
-
-
-
?
1,2-dipalmitoyl-phosphatidylethanolamine + H2O
1-palmitoyl-phosphatidylethanolamine + palmitic acid
-
-
-
?
1,2-dipalmitoyl-sn-glycero-3-phosphocholine + H2O
1-palmitoyl-sn-glycero-3-phosphocholine + palmitate
-
-
-
-
?
1,2-dipalmitoyl-sn-glycero-3-phosphocholine + H2O
1-palmitoyl-sn-glycero-3-phosphocholine + palmitate
-
-
-
-
?
1,2-dipalmitoyl-sn-glycero-3-phosphocholine + H2O
1-palmitoyl-sn-glycero-3-phosphocholine + palmitic acid
-
-
-
?
1,2-dipalmitoyl-sn-glycero-3-phosphocholine + H2O
1-palmitoyl-sn-glycero-3-phosphocholine + palmitic acid
-
-
-
?
1,2-dipalmitoyl-sn-glycero-3-phosphocholine + H2O
1-palmitoyl-sn-glycero-3-phosphorylcholine + palmitate
-
-
-
?
1,2-dipalmitoyl-sn-glycero-3-phosphocholine + H2O
1-palmitoyl-sn-glycero-3-phosphorylcholine + palmitate
-
-
-
-
?
1,2-dipalmitoyl-sn-glycero-3-phosphocholine + H2O
1-palmitoyl-sn-glycero-3-phosphorylcholine + palmitate
-
-
-
-
?
1,2-dipalmitoyl-sn-glycero-3-phosphocholine + H2O
1-palmitoyl-sn-glycero-3-phosphorylcholine + palmitate
-
-
-
?
1,2-dipalmitoyl-sn-glycero-3-phosphoglycerol + H2O
1-palmitoyl-glycero-3-phosphoglycerol + palmitate
-
-
-
-
?
1,2-dipalmitoyl-sn-glycero-3-phosphoglycerol + H2O
1-palmitoyl-glycero-3-phosphoglycerol + palmitate
-
-
-
?
1,2-dipalmitoyl-sn-glycero-3-phosphorylcholine + H2O
1-palmitoyl-sn-glycero-3-phosphorylcholine + palmitic acid
-
-
-
-
?
1,2-dipalmitoyl-sn-glycero-3-phosphorylcholine + H2O
1-palmitoyl-sn-glycero-3-phosphorylcholine + palmitic acid
-
in mixed micelles with Triton X-100
-
?
1,2-dipalmitoyl-sn-glycero-3-phosphorylcholine + H2O
1-palmitoyl-sn-glycero-3-phosphorylcholine + palmitic acid
-
in mixed micelles with Triton X-100
-
?
1,2-dipalmitoyl-sn-phosphatidylcholine + H2O
1-palmitoyl-sn-phosphatidylcholine + palmitate
the catalytic site for aiPLA2 activity is an S32-H26-D140 triad
-
-
?
1,2-dipalmitoyl-sn-phosphatidylcholine + H2O
1-palmitoyl-sn-phosphatidylcholine + palmitate
the catalytic site for aiPLA2 activity is an S32-H26-D140 triad
-
-
?
1,2-dipalmitoyl-sn-phosphatidylcholine + H2O
1-palmitoyl-sn-phosphatidylcholine + palmitate
the catalytic site for aiPLA2 activity is an S32-H26-D140 triad
-
-
?
1,2-dipalmitoyl-sn-phosphatidylcholine + H2O
1-palmitoyl-sn-phosphatidylcholine + palmitate
the catalytic site for aiPLA2 activity is an S32-H26-D140 triad
-
-
?
1,2-dipalmitoyl-sn-phosphatidylcholine + H2O
1-palmitoyl-sn-phosphatidylcholine + palmitate
the catalytic site for aiPLA2 activity is an S32-H26-D140 triad
-
-
?
1,2-dipalmitoyl-sn-phosphatidylcholine + H2O
1-palmitoyl-sn-phosphatidylcholine + palmitate
the catalytic site for aiPLA2 activity is an S32-H26-D140 triad
-
-
?
1,2-dipalmitoyl-sn-phosphatidylcholine + H2O
1-palmitoyl-sn-phosphatidylcholine + palmitate
-
the catalytic site for aiPLA2 activity is an S32-H26-D140 triad
-
-
?
1,2-dipalmitoyl-sn-phosphatidylcholine + H2O
1-palmitoyl-sn-phosphatidylcholine + palmitate
the catalytic site for aiPLA2 activity is an S32-H26-D140 triad
-
-
?
1,2-dipalmitoyl-sn-phosphatidylserine + H2O
1-palmitoyl-sn-phosphatidylserine + palmitic acid
-
-
-
?
1,2-dipalmitoyl-sn-phosphatidylserine + H2O
1-palmitoyl-sn-phosphatidylserine + palmitic acid
-
-
-
?
1-acyl-2-arachidonoyl-sn-glycero-3-phosphoethanolamine + H2O
1-acyl-sn-glycero-3-phosphoethanolamine + arachidonic acid
-
-
-
?
1-acyl-2-arachidonoyl-sn-glycero-3-phosphoethanolamine + H2O
1-acyl-sn-glycero-3-phosphoethanolamine + arachidonic acid
-
-
-
?
1-acyl-2-arachidonoyl-sn-glycero-3-phosphoethanolamine + H2O
1-acyl-sn-glycero-3-phosphoethanolamine + arachidonic acid
-
-
-
?
1-acyl-2-arachidonoyl-sn-glycerophosphoethanolamine + H2O
1-acyl-sn-glycerophosphoethanolamine + arachidonic acid
-
-
-
?
1-acyl-2-arachidonoyl-sn-glycerophosphoethanolamine + H2O
1-acyl-sn-glycerophosphoethanolamine + arachidonic acid
-
-
-
?
1-acyl-2-arachidonoyl-sn-glycerophosphoethanolamine + H2O
1-acyl-sn-glycerophosphoethanolamine + arachidonic acid
-
-
-
?
1-acyl-2-linoleoyl-3-phosphoethanolamine + H2O
1-acyl-3-phosphoethanolamine + linolic acid
-
-
-
?
1-acyl-2-linoleoyl-3-phosphoethanolamine + H2O
1-acyl-3-phosphoethanolamine + linolic acid
-
-
-
?
1-acyl-2-linoleoyl-3-phosphoethanolamine + H2O
1-acyl-3-phosphoethanolamine + linolic acid
-
-
-
?
1-acyl-2-linoleoyl-3-phosphoethanolamine + H2O
1-acyl-3-phosphoethanolamine + linolic acid
-
-
-
?
1-hexadecanoyl-2-(1-pyrenedecanoyl)-glycero-3-phosphocholine + H2O
1-hexadecanoyl-glycero-3-phosphocholine + 1-pyrenedecanoate
-
-
-
?
1-hexadecanoyl-2-(1-pyrenedecanoyl)-glycero-3-phosphocholine + H2O
1-hexadecanoyl-glycero-3-phosphocholine + 1-pyrenedecanoate
-
group V sPLA2
-
?
1-hexadecanoyl-2-(1-pyrenedecanoyl)-glycero-3-phosphoethanolamine + H2O
1-hexadecanoyl-glycero-3-phosphoethanolamine + 1-pyrenedecanoate
-
-
-
?
1-hexadecanoyl-2-(1-pyrenedecanoyl)-glycero-3-phosphoethanolamine + H2O
1-hexadecanoyl-glycero-3-phosphoethanolamine + 1-pyrenedecanoate
-
group V sPLA2
-
?
1-hexadecanoyl-2-(1-pyrenedecanoyl)-glycero-3-phosphoglycerol + H2O
1-hexadecanoyl-glycero-3-phosphoglycerol + 1-pyrenedecanoate
-
-
-
?
1-hexadecanoyl-2-(1-pyrenedecanoyl)-glycero-3-phosphoglycerol + H2O
1-hexadecanoyl-glycero-3-phosphoglycerol + 1-pyrenedecanoate
-
group V sPLA2
-
?
1-hexadecanoyl-2-(10-(1-pyrene)decanoyl)-sn-glycero-3-phosphoglycerol + H2O
1-hexadecanoyl-sn-glycero-3-phosphoglycerol + 10-(1-pyrene)decanoic acid
-
-
-
-
?
1-hexadecanoyl-2-(10-(1-pyrene)decanoyl)-sn-glycero-3-phosphoglycerol + H2O
1-hexadecanoyl-sn-glycero-3-phosphoglycerol + 10-(1-pyrene)decanoic acid
-
-
-
-
?
1-hexadecanoyl-2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)aminohexanoyl]-sn-glycero-3-phosphocholine + H2O
1-hexadecanoyl-sn-glycero-3-phosphocholine + 6-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]hexanoic acid
-
sensitive fluorescent substrate that is stable at 95°C
-
-
?
1-hexadecanoyl-2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)aminohexanoyl]-sn-glycero-3-phosphocholine + H2O
1-hexadecanoyl-sn-glycero-3-phosphocholine + 6-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]hexanoic acid
-
sensitive fluorescent substrate that is stable at 95°C
-
-
?
1-O-hexadecyl-2-arachidonyl-glycero-3-phosphocholine + H2O
1-O-hexadecyl-glycero-3-phosphocholine + arachidonic acid
-
-
-
?
1-O-hexadecyl-2-arachidonyl-glycero-3-phosphocholine + H2O
1-O-hexadecyl-glycero-3-phosphocholine + arachidonic acid
-
-
-
?
1-oleoyl-2-palmitoyl-sn-glycero-3-phosphocholine + H2O
1-oleoyl-sn-glycero-3-phosphocholine + palmitate
-
-
-
-
?
1-oleoyl-2-palmitoyl-sn-glycero-3-phosphocholine + H2O
1-oleoyl-sn-glycero-3-phosphocholine + palmitate
-
-
-
-
?
1-palmitoyl-2-(10-pyrenyldecanoyl)-sn-glycero-3-phosphate + H2O
10-pyrenyldecanoic acid + 1-palmitoyl-sn-glycero-3-phosphate
-
-
-
-
?
1-palmitoyl-2-(10-pyrenyldecanoyl)-sn-glycero-3-phosphate + H2O
10-pyrenyldecanoic acid + 1-palmitoyl-sn-glycero-3-phosphate
-
-
-
-
?
1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine + H2O
1-palmitoyl-sn-glycero-3-phosphocholine + arachidonate
-
the enzyme has similar activities toward 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine and 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphoethanolamine
-
-
?
1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine + H2O
1-palmitoyl-sn-glycero-3-phosphocholine + arachidonate
-
the enzyme has similar activities toward 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine and 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphoethanolamine
-
-
?
1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine + H2O
1-palmitoyl-sn-glycero-3-phosphorylcholine + arachidonic acid
-
in mixed micelles with Triton X-100
-
?
1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine + H2O
1-palmitoyl-sn-glycero-3-phosphorylcholine + arachidonic acid
-
in mixed micelles with Triton X-100
-
?
1-palmitoyl-2-arachidonoylphosphatidylcholine + H2O
1-palmitoyl-glycerophosphorylcholine + arachidonic acid
-
-
-
?
1-palmitoyl-2-arachidonoylphosphatidylcholine + H2O
1-palmitoyl-glycerophosphorylcholine + arachidonic acid
-
-
-
?
1-palmitoyl-2-arachidonoylphosphatidylcholine + H2O
1-palmitoyl-glycerophosphorylcholine + arachidonic acid
-
-
-
?
1-palmitoyl-2-arachidonoylphosphatidylcholine + H2O
1-palmitoyl-glycerophosphorylcholine + arachidonic acid
-
-
-
?
1-palmitoyl-2-arachidonoylphosphatidylcholine + H2O
1-palmitoyl-glycerophosphorylcholine + arachidonic acid
-
-
-
?
1-palmitoyl-2-arachidonoylphosphatidylcholine + H2O
1-palmitoyl-glycerophosphorylcholine + arachidonic acid
-
-
-
?
1-palmitoyl-2-arachidonoylphosphatidylcholine + H2O
1-palmitoyl-glycerophosphorylcholine + arachidonic acid
-
cPLA2 cleaves selectively arachidonoyl phospholipids
-
?
1-palmitoyl-2-arachidonoylphosphatidylcholine + H2O
1-palmitoyl-glycerophosphorylcholine + arachidonic acid
-
-
-
?
1-palmitoyl-2-arachidonoylphosphatidylcholine + H2O
1-palmitoyl-glycerophosphorylcholine + arachidonic acid
-
substrate for measurement of PLA1-activity of the 80-kDa PLA2
-
?
1-palmitoyl-2-arachidonoylphosphatidylcholine + H2O
1-palmitoyl-glycerophosphorylcholine + arachidonic acid
-
-
-
-
?
1-palmitoyl-2-arachidonoylphosphatidylcholine + H2O
1-palmitoyl-glycerophosphorylcholine + arachidonic acid
-
-
-
?
1-palmitoyl-2-arachidonoylphosphatidylcholine + H2O
1-palmitoyl-glycerophosphorylcholine + arachidonic acid
-
,data for iPLA2
-
?
1-palmitoyl-2-arachidonoylphosphatidylethanolamine
1-palmitoyl-glycerophosphorylethanolamine + arachidonic acid
-
-
?
1-palmitoyl-2-arachidonoylphosphatidylethanolamine
1-palmitoyl-glycerophosphorylethanolamine + arachidonic acid
-
-
-
?
1-palmitoyl-2-arachidonyl-sn-glycerol-3-phosphocholine + H2O
?
-
-
-
-
?
1-palmitoyl-2-arachidonyl-sn-glycerol-3-phosphocholine + H2O
?
-
-
-
-
?
1-palmitoyl-2-linoleoyl-sn-glycero-3-phosphocholine + H2O
1-palmitoyl-sn-glycero-3-phosphocholine + linoleate
-
-
-
-
?
1-palmitoyl-2-linoleoyl-sn-glycero-3-phosphocholine + H2O
1-palmitoyl-sn-glycero-3-phosphocholine + linoleate
-
the enzyme has similar activities toward 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine and 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphoethanolamine
-
-
?
1-palmitoyl-2-linoleoyl-sn-glycero-3-phosphocholine + H2O
1-palmitoyl-sn-glycero-3-phosphocholine + linoleate
-
the enzyme has similar activities toward 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine and 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphoethanolamine
-
-
?
1-palmitoyl-2-linoleoyl-sn-glycero-3-phosphocholine + H2O
1-palmitoyl-sn-glycero-3-phosphocholine + linolic acid
-
-
-
?
1-palmitoyl-2-linoleoyl-sn-glycero-3-phosphocholine + H2O
1-palmitoyl-sn-glycero-3-phosphocholine + linolic acid
-
-
-
?
1-palmitoyl-2-linoleoylphosphatidylcholine + H2O
1-palmitoyl-glycerophosphorylcholine + linolic acid
-
-
?
1-palmitoyl-2-linoleoylphosphatidylcholine + H2O
1-palmitoyl-glycerophosphorylcholine + linolic acid
-
group V sPLA2
-
?
1-palmitoyl-2-linoleoylphosphatidylcholine + H2O
1-palmitoyl-glycerophosphorylcholine + linolic acid
-
-
-
?
1-palmitoyl-2-linoleoylphosphatidylcholine + H2O
1-palmitoyl-glycerophosphorylcholine + linolic acid
-
-
-
?
1-palmitoyl-2-linoleoylphosphatidylcholine + H2O
1-palmitoyl-glycerophosphorylcholine + linolic acid
-
iPLA2
-
?
1-palmitoyl-2-linoleoylphosphatidylethanolamine + H2O
1-palmitoyl-glycerophosphorylethanolamine + linolic acid
-
-
-
?
1-palmitoyl-2-linoleoylphosphatidylethanolamine + H2O
1-palmitoyl-glycerophosphorylethanolamine + linolic acid
-
-
-
?
1-palmitoyl-2-linoleoylphosphatidylethanolamine + H2O
1-palmitoyl-glycerophosphorylethanolamine + linolic acid
-
-
-
?
1-palmitoyl-2-linoleoylphosphatidylethanolamine + H2O
1-palmitoyl-glycerophosphorylethanolamine + linolic acid
-
-
-
?
1-palmitoyl-2-linoleoylphosphatidylethanolamine + H2O
1-palmitoyl-glycerophosphorylethanolamine + linolic acid
-
-
-
-
?
1-palmitoyl-2-linoleoylphosphatidylethanolamine + H2O
1-palmitoyl-glycerophosphorylethanolamine + linolic acid
-
data for iPLA2
-
?
1-palmitoyl-2-oleoyl-phosphatidylcholine + H2O
?
-
-
-
-
?
1-palmitoyl-2-oleoyl-phosphatidylcholine + H2O
?
-
-
-
-
?
1-palmitoyl-2-oleoyl-phosphatidylethanolamine + H2O
?
-
-
-
-
?
1-palmitoyl-2-oleoyl-phosphatidylethanolamine + H2O
?
-
-
-
-
?
1-palmitoyl-2-oleoyl-phosphatidylglycerol + H2O
?
-
-
-
-
?
1-palmitoyl-2-oleoyl-phosphatidylglycerol + H2O
?
-
-
-
-
?
1-palmitoyl-2-oleoyl-phosphatidylinositol + H2O
?
-
-
-
-
?
1-palmitoyl-2-oleoyl-phosphatidylinositol + H2O
?
-
-
-
-
?
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphate + H2O
?
-
-
-
-
?
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphate + H2O
?
-
-
-
-
?
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine + H2O
1-palmitoyl-sn-glycero-3-phosphocholine + oleate
-
-
-
?
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine + H2O
1-palmitoyl-sn-glycero-3-phosphocholine + oleate
-
-
-
-
?
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine + H2O
1-palmitoyl-sn-glycero-3-phosphocholine + oleate
-
-
-
?
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine + H2O
1-palmitoyl-sn-glycero-3-phosphocholine + oleate
-
-
-
-
?
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine + H2O
1-palmitoyl-sn-glycero-3-phosphocholine + oleate
-
-
-
?
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine + H2O
1-palmitoyl-sn-glycero-3-phosphocholine + oleate
-
preferred substrate
-
-
?
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine + H2O
1-palmitoyl-sn-glycero-3-phosphocholine + oleate
-
-
-
-
?
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine + H2O
1-palmitoyl-sn-glycero-3-phosphocholine + oleate
-
-
-
-
?
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine + H2O
1-palmitoyl-sn-glycero-3-phosphocholine + oleate
-
the enzyme has similar activities toward 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine and 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphoethanolamine
-
-
?
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine + H2O
1-palmitoyl-sn-glycero-3-phosphocholine + oleate
-
the enzyme has similar activities toward 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine and 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphoethanolamine
-
-
?
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine + H2O
1-palmitoyl-sn-glycero-3-phosphocholine + oleic acid
-
-
-
?
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine + H2O
1-palmitoyl-sn-glycero-3-phosphocholine + oleic acid
-
-
-
?
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine + H2O
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol + H2O
-
-
-
?
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine + H2O
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol + H2O
-
-
-
?
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol + H2O
1-palmitoyl-sn-glycero-3-phosphorylglycerol + oleate
-
-
-
?
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol + H2O
1-palmitoyl-sn-glycero-3-phosphorylglycerol + oleate
-
-
-
-
?
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol + H2O
1-palmitoyl-sn-glycero-3-phosphorylglycerol + oleate
-
-
-
?
1-palmitoyl-2-oleoylphosphatidylcholine + H2O
1-palmitoyl-glycerophosphocholine + oleic acid
-
-
-
?
1-palmitoyl-2-oleoylphosphatidylcholine + H2O
1-palmitoyl-glycerophosphocholine + oleic acid
-
-
-
?
1-palmitoyl-2-oleoylphosphatidylcholine + H2O
1-palmitoyl-glycerophosphocholine + oleic acid
-
-
-
?
1-palmitoyl-2-oleoylphosphatidylcholine + H2O
1-palmitoyl-glycerophosphocholine + oleic acid
-
-
-
?
1-palmitoyl-2-oleoylphosphatidylcholine + H2O
1-palmitoyl-glycerophosphocholine + oleic acid
-
-
-
?
1-palmitoyl-2-oleoylphosphatidylcholine + H2O
1-palmitoyl-glycerophosphocholine + oleic acid
-
-
-
?
1-palmitoyl-2-oleoylphosphatidylcholine + H2O
1-palmitoyl-glycerophosphocholine + oleic acid
-
data for iPLA2
-
?
1-palmitoyl-2-oleoylphosphatidylcholine + H2O
1-palmitoyl-glycerophosphocholine + oleic acid
-
-
-
?
1-palmitoyl-2-stearoyl-dibromo-sn-glycero-3-phosphocholine + H2O
?
-
-
-
?
1-palmitoyl-2-stearoyl-dibromo-sn-glycero-3-phosphocholine + H2O
?
-
-
-
-
?
1-palmitoyl-2-stearoyl-dibromo-sn-glycero-3-phosphocholine + H2O
?
-
-
-
?
1-palmitoyl-sn-glycero-3-phosphocholine + H2O
?
-
-
-
-
?
1-palmitoyl-sn-glycero-3-phosphocholine + H2O
?
-
-
-
-
?
1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine + H2O
1-stearoyl-sn-glycero-3-phosphocholine + arachidonate
-
-
-
-
?
1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine + H2O
1-stearoyl-sn-glycero-3-phosphocholine + arachidonate
-
1-stearoyl-2-[14C]arachidonoyl-sn-glycero-3-phosphocholine
-
-
?
1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine + H2O
1-stearoyl-sn-glycero-3-phosphocholine + arachidonic acid
-
preferred substrate
-
?
1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine + H2O
1-stearoyl-sn-glycero-3-phosphocholine + arachidonic acid
-
good substrate
-
?
1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine + H2O
1-stearoyl-sn-glycero-3-phosphocholine + arachidonic acid
-
-
-
-
?
1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine + H2O
1-stearoyl-sn-glycero-3-phosphocholine + arachidonic acid
-
-
-
?
1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine + H2O
1-stearoyl-sn-glycero-3-phosphocholine + arachidonic acid
-
preferred substrate
-
?
1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphoinositol + H2O
1-stearoyl-sn-glycero-3-phosphoinositol + arachidonic acid
-
-
-
?
1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphoinositol + H2O
1-stearoyl-sn-glycero-3-phosphoinositol + arachidonic acid
-
-
-
?
1-stearoyl-2-arachidonoylphosphatidylcholine + H2O
1-stearoyl-glycerophosphorylcholine + arachidonic acid
-
cPLA2 cleaves selectively arachidonoyl containing phospholipids
-
?
1-stearoyl-2-arachidonoylphosphatidylcholine + H2O
1-stearoyl-glycerophosphorylcholine + arachidonic acid
-
-
-
?
1-stearoyl-2-arachidonoylphosphatidylcholine + H2O
1-stearoyl-glycerophosphorylcholine + arachidonic acid
-
-
-
?
1-stearoyl-2-arachidonoylphosphatidylcholine + H2O
1-stearoyl-glycerophosphorylcholine + arachidonic acid
-
-
-
?
1-stearoyl-2-arachidonoylphosphatidylcholine + H2O
1-stearoyl-glycerophosphorylcholine + arachidonic acid
-
data for iPLA2
-
?
4-nitro-3-(octanoyloxy) benzoic acid + H2O
3-hydroxy-4-nitrobenzoate + octanoate
-
-
-
-
?
4-nitro-3-(octanoyloxy) benzoic acid + H2O
3-hydroxy-4-nitrobenzoate + octanoate
-
-
-
-
?
4-nitro-3-(octanoyloxy)benzoic acid + H2O
3-hydroxy-4-nitrobenzoate + octanoate
-
synthetic substrate
-
?
4-nitro-3-(octanoyloxy)benzoic acid + H2O
3-hydroxy-4-nitrobenzoate + octanoate
-
-
-
?
4-nitro-3-(octanoyloxy)benzoic acid + H2O
3-hydroxy-4-nitrobenzoate + octanoate
-
-
-
-
?
4-nitro-3-(octanoyloxy)benzoic acid + H2O
?
-
-
-
?
4-nitro-3-(octanoyloxy)benzoic acid + H2O
?
-
a synthetic chromogenic substrate
-
-
?
4-nitro-3-octanoyloxy-benzoic acid + H2O
?
-
-
-
-
?
4-nitro-3-octanoyloxy-benzoic acid + H2O
?
-
-
-
-
?
4-nitro-3-octanoyloxy-benzoic acid + H2O
?
-
-
-
-
?
4-nitro-3-octanoyloxybenzoic acid + H2O
?
-
-
-
?
4-nitro-3-octanoyloxybenzoic acid + H2O
?
-
-
-
-
?
arachidonyl thio-PC + H2O
arachidonic acid + (7R)-4-hydroxy-N,N,N-trimethyl-7-sulfanyl-3,5,9-trioxa-4-phosphapentacosan-1-aminium 4-oxide
-
-
-
-
?
arachidonyl thio-PC + H2O
arachidonic acid + (7R)-4-hydroxy-N,N,N-trimethyl-7-sulfanyl-3,5,9-trioxa-4-phosphapentacosan-1-aminium 4-oxide
-
-
-
-
?
DBPA + H2O
?
-
fluorogenic Dabcyl- and BODIPY-containing phospholipd-analogue
-
-
?
DBPA + H2O
?
-
fluorogenic Dabcyl- and BODIPY-containing phospholipd-analogue
-
-
?
DBPA + H2O
?
-
fluorogenic Dabcyl- and BODIPY-containing phospholipd-analogue
-
-
?
DBPA + H2O
?
-
fluorogenic Dabcyl- and BODIPY-containing phospholipd-analogue
-
-
?
DBPA + H2O
?
-
fluorogenic Dabcyl- and BODIPY-containing phospholipd-analogue
-
-
?
DBPC + H2O
?
-
fluorogenic Dabcyl- and BODIPY-containing phospholipd-analogue
-
-
?
DBPC + H2O
?
-
fluorogenic Dabcyl- and BODIPY-containing phospholipd-analogue
-
-
?
DBPC + H2O
?
-
fluorogenic Dabcyl- and BODIPY-containing phospholipd-analogue
-
-
?
DBPC + H2O
?
-
fluorogenic Dabcyl- and BODIPY-containing phospholipd-analogue
-
-
?
DBPC + H2O
?
-
fluorogenic Dabcyl- and BODIPY-containing phospholipd-analogue
-
-
?
DBPE + H2O
?
-
fluorogenic Dabcyl- and BODIPY-containing phospholipd-analogue
-
-
?
DBPE + H2O
?
-
fluorogenic Dabcyl- and BODIPY-containing phospholipd-analogue
-
-
?
DBPE + H2O
?
-
fluorogenic Dabcyl- and BODIPY-containing phospholipd-analogue
-
-
?
DBPE + H2O
?
-
fluorogenic Dabcyl- and BODIPY-containing phospholipd-analogue
-
-
?
DBPE + H2O
?
-
fluorogenic Dabcyl- and BODIPY-containing phospholipd-analogue
-
-
?
DBPG + H2O
?
-
fluorogenic Dabcyl- and BODIPY-containing phospholipd-analogue
-
-
?
DBPG + H2O
?
-
fluorogenic Dabcyl- and BODIPY-containing phospholipd-analogue
-
-
?
DBPG + H2O
?
-
fluorogenic Dabcyl- and BODIPY-containing phospholipd-analogue
-
-
?
DBPG + H2O
?
-
fluorogenic Dabcyl- and BODIPY-containing phospholipd-analogue
-
-
?
DBPG + H2O
?
-
fluorogenic Dabcyl- and BODIPY-containing phospholipd-analogue
-
-
?
dioleoyl phosphatidylglycerol + H2O
?
-
-
-
-
?
dioleoyl phosphatidylglycerol + H2O
?
-
-
-
-
?
dioleoyl phosphatidylglycerol + H2O
?
-
-
-
-
?
egg yolk + H2O
?
-
-
-
-
?
egg yolk + H2O
?
-
-
-
-
?
egg yolk + H2O
?
-
-
-
-
?
egg yolk + H2O
?
-
-
-
-
?
egg yolk + H2O
?
-
Scol/Pla contains conserved residues in positions His46, Asp47 and Tyr50 found to be important for the catalytic activity, and contains five disulfide bridges
-
-
?
egg yolk phospholipid + H2O
?
-
-
-
?
egg yolk phospholipid + H2O
?
-
-
-
-
?
L-alpha-phosphatidylcholine + H2O
1-acylglycerophosphocholine + a carboxylate
-
-
-
-
?
L-alpha-phosphatidylcholine + H2O
1-acylglycerophosphocholine + a carboxylate
-
-
-
-
?
L-dipalmitoyl phosphatidylcholine + H2O
1-palmitoyl-sn-glycerophosphocholine + palmitate
-
-
-
-
?
L-dipalmitoyl phosphatidylcholine + H2O
1-palmitoyl-sn-glycerophosphocholine + palmitate
-
-
-
-
?
oxidized phosphatidylcholine + H2O
lysophosphatidylcholine + fatty acid
-
great amount of oxidized phosphatidylcholine of oxidized LDL is hydrolyzed at the sn-2 position
-
-
?
oxidized phosphatidylcholine + H2O
lysophosphatidylcholine + fatty acid
-
-
-
-
?
oxidized phosphatidylcholines + H2O
1-acylglycerophosphocholine + oxidized fatty acids
-
oxidized 1-palmitoyl-2-arachidonoylphosphatidylcholine for substrate
-
?
oxidized phosphatidylcholines + H2O
1-acylglycerophosphocholine + oxidized fatty acids
-
-
-
?
oxidized phosphatidylcholines + H2O
1-acylglycerophosphocholine + oxidized fatty acids
-
HSD-PLA2
-
?
phosphatidic acid + H2O
1-acylglycerophosphate + fatty acid
-
-
-
?
phosphatidic acid + H2O
1-acylglycerophosphate + fatty acid
-
-
-
?
phosphatidic acid + H2O
1-acylglycerophosphate + fatty acid
-
-
-
?
phosphatidic acid + H2O
1-acylglycerophosphate + fatty acid
-
-
-
?
phosphatidic acid + H2O
1-acylglycerophosphate + fatty acid
-
-
-
?
phosphatidylcholine + H2O
1-acylglycerophosphocholine + a carboxylate
-
-
-
-
?
phosphatidylcholine + H2O
1-acylglycerophosphocholine + a carboxylate
-
-
-
-
?
phosphatidylcholine + H2O
1-acylglycerophosphocholine + a carboxylate
-
-
-
?
phosphatidylcholine + H2O
1-acylglycerophosphocholine + a carboxylate
-
-
-
-
?
phosphatidylcholine + H2O
1-acylglycerophosphocholine + a carboxylate
-
in the presence of substrate, the enzyme binds to the interface as an active form. This crucial step is mediated by a planar surface region of the protein. The corresponding hydrophobic surface involves hydrophobic residues (Leu2, Trp3, Phe19, Leu20, Leu31, Ile64, Leu65, Tyr69, Ile72, Tyr75, and Leu118), hydrophobic surface involved in lipid binding increases
-
-
?
phosphatidylcholine + H2O
1-acylglycerophosphocholine + a carboxylate
-
-
-
-
?
phosphatidylcholine + H2O
1-acylglycerophosphocholine + a carboxylate
-
the lipoprotein-associated phospholipase A2 is present in vulnerable plaque regions where it acts on LDL phospholipid oxidation products to generate the pro-inflammatory lysophospholipids and oxidized non-esterified fatty acids, it predominantly circulates as a constituent of LDL particles, overview
-
-
?
phosphatidylcholine + H2O
1-acylglycerophosphocholine + a carboxylate
-
substrate is derived from human carotid artery plaques
-
-
?
phosphatidylcholine + H2O
1-acylglycerophosphocholine + a carboxylate
-
-
-
?
phosphatidylcholine + H2O
1-acylglycerophosphocholine + a carboxylate
-
-
-
-
?
phosphatidylcholine + H2O
1-acylglycerophosphocholine + a carboxylate
-
-
-
-
?
phosphatidylcholine + H2O
1-acylglycerophosphocholine + a carboxylate
-
substrate is derived from egg yolk
-
-
?
phosphatidylcholine + H2O
1-acylglycerophosphocholine + a carboxylate
-
-
-
-
?
phosphatidylcholine + H2O
1-acylglycerophosphocholine + fatty acid
-
-
-
?
phosphatidylcholine + H2O
1-acylglycerophosphocholine + fatty acid
-
-
-
?
phosphatidylcholine + H2O
1-acylglycerophosphocholine + fatty acid
-
-
-
?
phosphatidylcholine + H2O
1-acylglycerophosphocholine + fatty acid
-
-
-
-
?
phosphatidylcholine + H2O
1-acylglycerophosphocholine + fatty acid
-
-
-
?
phosphatidylcholine + H2O
1-acylglycerophosphocholine + fatty acid
-
-
-
?
phosphatidylcholine + H2O
1-acylglycerophosphocholine + fatty acid
-
-
-
?
phosphatidylcholine + H2O
1-acylglycerophosphocholine + fatty acid
-
-
-
?
phosphatidylcholine + H2O
1-acylglycerophosphocholine + fatty acid
-
-
-
?
phosphatidylcholine + H2O
1-acylglycerophosphocholine + fatty acid
-
-
-
?
phosphatidylcholine + H2O
1-acylglycerophosphocholine + fatty acid
-
-
-
?
phosphatidylcholine + H2O
1-acylglycerophosphocholine + fatty acid
-
-
-
-
?
phosphatidylcholine + H2O
1-acylglycerophosphocholine + fatty acid
-
-
-
?
phosphatidylcholine + H2O
1-acylglycerophosphocholine + fatty acid
-
-
-
-
?
phosphatidylcholine + H2O
1-acylglycerophosphocholine + fatty acid
-
-
-
?
phosphatidylcholine + H2O
1-acylglycerophosphocholine + fatty acid
-
-
-
?
phosphatidylcholine + H2O
1-acylglycerophosphocholine + fatty acid
-
-
-
?
phosphatidylcholine + H2O
1-acylglycerophosphocholine + fatty acid
-
-
-
-
?
phosphatidylcholine + H2O
1-acylglycerophosphocholine + fatty acid
-
-
-
?
phosphatidylcholine + H2O
1-acylglycerophosphocholine + fatty acid
-
-
-
?
phosphatidylcholine + H2O
1-acylglycerophosphocholine + fatty acid
-
-
-
?
phosphatidylcholine + H2O
1-acylglycerophosphocholine + fatty acid
-
-
-
?
phosphatidylcholine + H2O
1-acylglycerophosphocholine + fatty acid
-
-
-
?
phosphatidylcholine + H2O
1-acylglycerophosphocholine + fatty acid
-
-
-
?
phosphatidylcholine + H2O
1-acylglycerophosphocholine + fatty acid
-
-
-
?
phosphatidylcholine + H2O
1-acylglycerophosphocholine + fatty acid
-
preferred substrate for both isoenzymes, NK-PLA2-I and NK-PLA2-II
-
-
?
phosphatidylcholine + H2O
1-acylglycerophosphocholine + fatty acid
-
-
-
-
?
phosphatidylcholine + H2O
1-acylglycerophosphocholine + fatty acid
-
-
-
?
phosphatidylcholine + H2O
1-acylglycerophosphocholine + fatty acid
-
-
-
?
phosphatidylcholine + H2O
1-acylglycerophosphocholine + fatty acid
-
from egg yolk
-
?
phosphatidylcholine + H2O
1-acylglycerophosphocholine + fatty acid
-
-
-
?
phosphatidylcholine + H2O
1-acylglycerophosphocholine + fatty acid
-
-
?
phosphatidylcholine + H2O
1-acylglycerophosphocholine + fatty acid
-
-
-
?
phosphatidylcholine + H2O
1-acylglycerophosphocholine + fatty acid
-
-
-
?
phosphatidylcholine + H2O
1-acylglycerophosphocholine + fatty acid
-
-
-
?
phosphatidylcholine + H2O
1-acylglycerophosphocholine + fatty acid
-
-
-
?
phosphatidylcholine + H2O
1-acylglycerophosphocholine + fatty acid
-
-
-
?
phosphatidylcholine + H2O
1-acylglycerophosphocholine + fatty acid
-
-
-
?
phosphatidylcholine + H2O
1-acylglycerophosphocholine + fatty acid
-
-
-
?
phosphatidylcholine + H2O
1-acylglycerophosphocholine + fatty acid
-
-
-
?
phosphatidylcholine + H2O
1-acylglycerophosphocholine + fatty acid
-
-
-
?
phosphatidylcholine + H2O
1-acylglycerophosphocholine + fatty acid
-
-
-
?
phosphatidylcholine + H2O
1-acylglycerophosphocholine + fatty acid
-
-
-
?
phosphatidylcholine + H2O
1-acylglycerophosphocholine + fatty acid
-
kinetic investigation of hydrophobic/hydrophilic effect in various W7O microemulsions, using isooctane as main solvents and alcohols from 1-butanol to 1-octanol as co-solvent
-
-
?
phosphatidylcholine + H2O
lysophosphatidylcholine + a fatty acid
-
-
-
-
?
phosphatidylcholine + H2O
lysophosphatidylcholine + a fatty acid
-
-
-
-
?
phosphatidylcholine + H2O
lysophosphatidylcholine + a fatty acid
-
-
-
-
?
phosphatidylcholine + H2O
lysophosphatidylcholine + a fatty acid
-
-
-
-
?
phosphatidylcholine + H2O
lysophosphatidylcholine + a fatty acid
-
-
-
-
?
phosphatidylcholine + H2O
lysophosphatidylcholine + a fatty acid
-
-
-
?
phosphatidylcholine + H2O
lysophosphatidylcholine + a fatty acid
-
-
-
-
?
phosphatidylethanolamine + H2O
1-acylglycerophosphorylethanolamine + fatty acid
-
-
-
?
phosphatidylethanolamine + H2O
1-acylglycerophosphorylethanolamine + fatty acid
-
-
-
?
phosphatidylethanolamine + H2O
1-acylglycerophosphorylethanolamine + fatty acid
-
-
-
?
phosphatidylethanolamine + H2O
1-acylglycerophosphorylethanolamine + fatty acid
-
-
-
?
phosphatidylethanolamine + H2O
1-acylglycerophosphorylethanolamine + fatty acid
-
-
-
-
?
phosphatidylethanolamine + H2O
1-acylglycerophosphorylethanolamine + fatty acid
-
-
-
?
phosphatidylethanolamine + H2O
1-acylglycerophosphorylethanolamine + fatty acid
-
-
-
?
phosphatidylethanolamine + H2O
1-acylglycerophosphorylethanolamine + fatty acid
-
-
-
?
phosphatidylethanolamine + H2O
1-acylglycerophosphorylethanolamine + fatty acid
-
-
-
?
phosphatidylethanolamine + H2O
1-acylglycerophosphorylethanolamine + fatty acid
-
-
-
?
phosphatidylethanolamine + H2O
1-acylglycerophosphorylethanolamine + fatty acid
-
-
-
?
phosphatidylethanolamine + H2O
1-acylglycerophosphorylethanolamine + fatty acid
-
-
-
?
phosphatidylethanolamine + H2O
1-acylglycerophosphorylethanolamine + fatty acid
-
-
-
?
phosphatidylethanolamine + H2O
1-acylglycerophosphorylethanolamine + fatty acid
-
-
-
?
phosphatidylethanolamine + H2O
1-acylglycerophosphorylethanolamine + fatty acid
-
-
-
?
phosphatidylglycerol + H2O
1-acylglycerol + fatty acid
-
-
-
-
?
phosphatidylglycerol + H2O
1-acylglycerol + fatty acid
-
-
-
?
phosphatidylglycerol + H2O
1-acylglycerol + fatty acid
-
-
-
?
phosphatidylglycerol + H2O
1-acylglycerol + fatty acid
-
-
-
?
phosphatidylglycerol + H2O
1-acylglycerol + fatty acid
-
-
-
?
phosphatidylglycerol + H2O
1-acylglycerol + fatty acid
-
-
-
?
phosphatidylglycerol + H2O
1-acylglycerol + fatty acid
-
-
-
?
phosphatidylglycerol + H2O
1-acylglycerol + fatty acid
-
-
-
?
phosphatidylglycerol + H2O
1-acylglycerol + fatty acid
-
-
-
?
phosphatidylglycerol + H2O
1-acylglycerol + fatty acid
-
-
-
?
phosphatidylglycerol + H2O
1-acylglycerol + fatty acid
-
-
-
?
phosphatidylinositol + arachidonic acid
arachidonoyl phosphatidylinositol + fatty acid
-
-
-
?
phosphatidylinositol + arachidonic acid
arachidonoyl phosphatidylinositol + fatty acid
-
-
-
?
phosphatidylserine + H2O
1-acylglycerophosphoserine + fatty acid
-
-
-
-
?
phosphatidylserine + H2O
1-acylglycerophosphoserine + fatty acid
-
-
-
?
phosphatidylserine + H2O
1-acylglycerophosphoserine + fatty acid
-
-
-
?
phospholipid + H2O
lysophospholipid + fatty acid
-
-
-
?
phospholipid + H2O
lysophospholipid + fatty acid
the enzyme is essential for production of two classes of lipid mediators, fatty acid metabolites, and lysophospholipid-related lipids, and is involved in the remodeling of membrane phospholipids, physiologic functions, overview
-
-
?
phospholipids + H2O
?
-
allergenic
-
-
?
phospholipids + H2O
?
-
-
-
-
?
phospholipids + H2O
?
-
influence on platelet aggregation
-
-
?
phospholipids + H2O
?
-
eicosanoids
-
-
?
phospholipids + H2O
?
-
inflammatory diseases
-
-
?
phospholipids + H2O
?
-
release of arachidonic acid: biosynthesis of leucotrienes, thromboxans and prostaglandins
-
-
?
phospholipids + H2O
?
-
presynaptic neurotoxicity of neutral PLA2
-
-
?
phospholipids + H2O
?
-
-
-
-
?
phospholipids + H2O
?
-
-
-
-
?
phospholipids + H2O
?
-
-
-
-
?
phospholipids + H2O
?
-
presynaptic neurotoxicity of neutral PLA2
-
-
?
phospholipids + H2O
?
-
-
-
-
?
phospholipids + H2O
?
-
-
-
-
?
phospholipids + H2O
?
-
myotoxicity
-
-
?
phospholipids + H2O
?
-
presynaptic neurotoxicity of neutral PLA2
-
-
?
phospholipids + H2O
?
-
cardiac toxicity
-
-
?
phospholipids + H2O
?
-
hemolytic activity of basic PLA2
-
-
?
phospholipids + H2O
?
-
influence on platelet aggregation
-
-
?
phospholipids + H2O
?
-
-
-
-
?
phospholipids + H2O
?
-
influence on platelet aggregation
-
-
?
phospholipids + H2O
?
-
signal transduction
-
-
?
phospholipids + H2O
?
-
eicosanoids
-
-
?
phospholipids + H2O
?
-
inflammatory diseases
-
-
?
phospholipids + H2O
?
-
release of arachidonic acid: biosynthesis of leucotrienes, thromboxans and prostaglandins
-
-
?
phospholipids + H2O
?
release of arachidonic acid: biosynthesis of leucotrienes, thromboxans and prostaglandins
-
-
?
phospholipids + H2O
?
-
Lp-PLA2 rapidly degrades oxidatively modified phospholipids in modified low density lipoprotein leading to formation of proinflammatory and cytotoxic products (i.e. lysophosphatidylcholine) and oxidized nonesterified fatty acids
-
-
?
phospholipids + H2O
?
-
-
-
-
?
phospholipids + H2O
?
-
-
-
-
?
phospholipids + H2O
?
-
cardiac contraction and excitation
-
-
?
phospholipids + H2O
?
-
-
-
-
?
phospholipids + H2O
?
-
eicosanoids
-
-
?
phospholipids + H2O
?
-
cancer
-
-
?
phospholipids + H2O
?
-
myotoxicity
-
-
?
phospholipids + H2O
?
-
presynaptic neurotoxicity of neutral PLA2
-
-
?
phospholipids + H2O
?
-
cardiac toxicity
-
-
?
phospholipids + H2O
?
-
hemolytic activity of basic PLA2
-
-
?
phospholipids + H2O
?
-
influence on platelet aggregation
-
-
?
phospholipids + H2O
?
-
-
-
-
?
phospholipids + H2O
?
-
-
-
-
?
phospholipids + H2O
?
-
inflammatory diseases
-
-
?
phospholipids + H2O
?
-
-
-
-
?
phospholipids + H2O
?
-
-
-
-
?
phospholipids + H2O
?
-
-
-
-
?
phospholipids + H2O
?
-
hemolytic activity of basic PLA2
-
-
?
phospholipids + H2O
?
-
myotoxicity
-
-
?
phospholipids + H2O
?
-
presynaptic neurotoxicity of neutral PLA2
-
-
?
phospholipids + H2O
?
-
cardiac toxicity
-
-
?
phospholipids + H2O
?
-
hemolytic activity of basic PLA2
-
-
?
phospholipids + H2O
?
-
influence on platelet aggregation
-
-
?
phospholipids + H2O
?
-
-
-
-
?
phospholipids + H2O
?
-
influence on platelet aggregation
-
-
?
phospholipids + H2O
?
-
eicosanoids
-
-
?
phospholipids + H2O
?
-
inflammatory diseases
-
-
?
phospholipids + H2O
?
-
release of arachidonic acid: biosynthesis of leucotrienes, thromboxans and prostaglandins
-
-
?
phospholipids + H2O
?
-
-
-
-
?
phospholipids + H2O
?
-
-
133874, 133893, 133904, 133905, 133911, 133915, 133922, 133923, 133924, 133925, 133926, 133927, 133928, 133929 -
-
?
phospholipids + H2O
?
-
-
-
?
phospholipids + H2O
?
-
aldosterone-dependent sodium transport
-
-
?
phospholipids + H2O
?
-
cardiac contraction and excitation
-
-
?
phospholipids + H2O
?
-
release of arachidonic acid: biosynthesis of leucotrienes, thromboxans and prostaglandins
-
-
?
phospholipids + H2O
?
-
hemolytic activity of basic PLA2
-
-
?
phospholipids + H2O
?
-
influence on platelet aggregation
-
-
?
platelet activating factor + H2O
?
-
-
-
-
?
platelet activating factor + H2O
?
-
PAF i.e. platelet activating factor, HSD-PLA2
-
-
?
platelet activating factor + H2O
?
-
hGX sPLA2 hydrolyzes platelet activating factor, which is a reaction catalyzed by the platelet activating factor-acetylhydrolase, EC 3.1.1.47
-
-
?
additional information
?
-
-
enzyme causes myotoxicity but no significant neurotoxicity
-
?
additional information
?
-
-
no substrate: p-nitrophenyl palmitate, p-nitrophenyl stearate
-
-
?
additional information
?
-
-
the ability of secretory phospholipase A2 to hydrolyze cell membranes is highly dependent on the physical properties of the membrane, overview
-
-
?
additional information
?
-
-
molecular basis of phospholipase A2 activity toward phospholipids with sn-1 substitutions, molecular dynamics simulations, substrate binding structures comparisons with different compounds using the crystal structures of the enzymes from Apis mellifera and Homo sapiens, overview
-
-
?
additional information
?
-
-
preference of substrates in decreasing order: phosphatidylcholines, phosphatidylglycerols, phosphatidylethanolamines, phosphatidic acids
-
-
?
additional information
?
-
-
the phospholipase A2 superfamily consists of many different groups of enzymes that catalyze the hydrolysis of the sn-2 ester bond in a variety of different phospholipids, products of the hydrolysis of the sn-2 ester bond of phospholipid are a free fatty acid and lysophospholipid
-
-
?
additional information
?
-
-
PLA2 shows low enzymatic activity toward positively charged vesicles due to a long lag period. PLA2 demonstrates a high degree of enzymatic activity toward negatively charged 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine and 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine/1,2-dioleoyl-sn-glycero-3-phosphatidylserine vesicles. Vesicle size distribution of zwitterionic 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine changes faster than that of 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine/1,2-dioleoyl-sn-glycero-3-phosphatidylserine 90:10
-
-
?
additional information
?
-
-
similar activity to phospholipids with different fatty acids in the sn-2 position, but with different preferences for the charge on the lipid surface
-
-
?
additional information
?
-
activity is slightly higher when the acyl group of phosphatidylcholine is a linoleoyl group rather than a palmitoyl group at the sn-2 position
-
?
additional information
?
-
-
substrate specificity, overview, substrate application in micelles, no activity with 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine, AtsPLA2-alpha prefers zwitterionic phospholipids, and shows lower activity toward anionic phospholipids, in substrates with two identical fatty acid chains, AtsPLA2-alpha shows optimum activity toward phospholipids with decanoyl groups, in substrates with palmitoyl groups in sn-1 position, acyl chains with higher degree of unsaturation in sn-2 position are preferred, excluding arachidonic acid, overview
-
-
?
additional information
?
-
-
the phospholipase A2 superfamily consists of many different groups of enzymes that catalyze the hydrolysis of the sn-2 ester bond in a variety of different phospholipids, products of the hydrolysis of the sn-2 ester bond of phospholipid are a free fatty acid and lysophospholipid
-
-
?
additional information
?
-
-
enzyme is responsible for Ca2+-dependent release of arachidonic acid from red blood cells
-
?
additional information
?
-
-
preference of substrates in decreasing order: phosphatidylglycerols, phosphatidylethanolamines, phosphatidylcholines, phosphatidic acids
-
-
?
additional information
?
-
phospholipase A2 hydrolyzes phospholipids at the sn-2 position to cleave the fatty-acid ester bond of L-glycerophospholipids. The catalytic dyad, formed by residues Asp99 and His48, along with a nucleophilic water molecule is responsible for enzyme hydrolysis
-
-
?
additional information
?
-
-
the phospholipase A2 superfamily consists of many different groups of enzymes that catalyze the hydrolysis of the sn-2 ester bond in a variety of different phospholipids, products of the hydrolysis of the sn-2 ester bond of phospholipid are a free fatty acid and lysophospholipid
-
-
?
additional information
?
-
-
the lysosomal isozyme PLA2 contains a Ser-His-Asp catalytic triad
-
-
?
additional information
?
-
the secretory isozyme has a catalytic dyad formed by Asp99 and His48
-
-
?
additional information
?
-
BaTX induces myonecrosis and edema in vivo in mice upon intramuscular or subcutaneous injection, respectively, in vitro, the enzyme rapidly lysed skeletal muscle myoblasts, and causes a potent blockade of neuromuscular transmission in young chicken biventer cervicis preparations, overview
-
-
?
additional information
?
-
-
BaTX induces myonecrosis and edema in vivo in mice upon intramuscular or subcutaneous injection, respectively, in vitro, the enzyme rapidly lysed skeletal muscle myoblasts, and causes a potent blockade of neuromuscular transmission in young chicken biventer cervicis preparations, overview
-
-
?
additional information
?
-
CTX shows myotoxic and neurotoxic activity requiring calcineurin, overview
-
-
?
additional information
?
-
-
CTX shows myotoxic and neurotoxic activity requiring calcineurin, overview
-
-
?
additional information
?
-
-
involved in mast cell degranulation, creatinine kinase release, causes edema and myonecrosis, edema induction is not dependent on the catalytic activity if the enzyme
-
?
additional information
?
-
isozymes BinTx-I and BinTx-II show myotoxic activity in mice skeletal muscle and contribute to the neuromuscular activity of venom, overview
-
-
?
additional information
?
-
-
isozymes BinTx-I and BinTx-II show myotoxic activity in mice skeletal muscle and contribute to the neuromuscular activity of venom, overview
-
-
?
additional information
?
-
-
the enzyme shows myonecrotic activity in rat kidneys causing mild to moderate focal acute tubular necrosis in the convoluted proximal tubules, overview
-
-
?
additional information
?
-
-
enzyme is a D49K variant and lacks hydrolytic activity
-
?
additional information
?
-
-
damages membranes by a noncatalytic Ca2+-independent mechanism
-
?
additional information
?
-
-
SIIISPIIA, SIIISPIIB and SIIISPIIIA show significant anticoagulant activity but no indirect haemolytic activity. SIIISPIIIB shows no anticoagulant activity but presents indirect haemolytic activity. With the exception of SIIISPIIB, which inhibits platelet aggregation, all the others are capable of inducing edema
-
?
additional information
?
-
-
the enzyme is a component of the venom and causes cytotoxic lesions in murine skeletal muscle C2C12 myoblasts and myotubes, overview
-
-
?
additional information
?
-
-
the enzyme has hemolytic activity
-
-
?
additional information
?
-
binding of 4-bromophenacyl bromide and alpha-tocopherol and alpha-tocopherol acetate inhibitors by PrTX-1 involves His48
-
-
?
additional information
?
-
-
binding of 4-bromophenacyl bromide and alpha-tocopherol and alpha-tocopherol acetate inhibitors by PrTX-1 involves His48
-
-
?
additional information
?
-
Bothrops spp.
-
enzyme has indirect haemolytic, anticoagulant, myotoxic and cytotoxic activity
-
?
additional information
?
-
-
Cr-IV 1 shows a rapid cytolytic effect on mouse skeletal muscle myoblasts and myotubes in culture. Cr-IV 1 induces myonecrosis and edema upon intramuscular and intravenous injections, respectively, in mice
-
-
?
additional information
?
-
-
enzyme extracts cause vacuolating and cytolytic effects on Chinese hamster ovary cells in tissue culture
-
-
?
additional information
?
-
-
the enzyme causes endema when applicated to the right footpad of male Swiss mice
-
-
?
additional information
?
-
-
crotoxin, a potent neurotoxin from the venom of the Brazilian rattlesnake, exists as a heterodimer formed between a phospholipase A2 and a catalytically inactive acidic phospholipase A2 analogue crotapotin, overview
-
-
?
additional information
?
-
crotoxin is a heterodimeric molecular complex related to important envenomation effects, as neurological disorders, myotoxicity, and renal failure
-
-
?
additional information
?
-
-
crotoxin is a heterodimeric molecular complex related to important envenomation effects, as neurological disorders, myotoxicity, and renal failure
-
-
?
additional information
?
-
Crotalus sp.
-
the phospholipase A2 superfamily consists of many different groups of enzymes that catalyze the hydrolysis of the sn-2 ester bond in a variety of different phospholipids, products of the hydrolysis of the sn-2 ester bond of phospholipid are a free fatty acid and lysophospholipid
-
-
?
additional information
?
-
-
determination of the cytolytic activity od sPLA2 using oleate-labelled, autoclaved Escherichia coli cells as substrate, overview
-
-
?
additional information
?
-
-
acidic PLA2 non-inhibits the factor Xa in a non-enzymatic mechanism
-
-
?
additional information
?
-
-
the enzyme does not show any proteolytic, ATPase and AchEase activity at a dose of 750 mM
-
-
?
additional information
?
-
-
the PLA2, i.e. RVV-7, is the basic toxin of Russells viper venom, it shows cytotoxic activity with B16F10 melanoma cells, it inhibits trypsin, but not chymotrypsin or bromelain, overview
-
-
?
additional information
?
-
-
the isozymes are neurotoxic and lethal, with the acidic isozyme DrK-aI being the most active toxin, overview
-
-
?
additional information
?
-
the enzyme is able to hydrolyze mainly the sn-2 position of phospholipids
-
-
?
additional information
?
-
-
anticoagulant and haemolytic activity
-
?
additional information
?
-
-
AgkTx-II exerts a potent antibacterial activity against Staphylococcus aureus, Proteus vulgaris, Proteus mirabilis, and Burkholderia pseudomallei. The MIC values of AgkTx-II range between 0.085 and 0.00276 mM. AgkTx-II exhibits no hemolytic action even at high doses in human erythrocytes. AgkTx-II treated mice show severe neurotoxicity, whereas in the skin, no alterations of skin myotoxicity are observed, overview
-
-
?
additional information
?
-
-
enzyme inhibits platelet aggregation which is induced by 1 mmol/l ADP, with IC50 of 6 mmol/l
-
-
?
additional information
?
-
-
despite all features of a class II phospholipase A2, enzyme does not show phospholipase and hemorrhagic activity, but weak toxic and anticoagulant activity
-
-
?
additional information
?
-
-
enzyme has higher phospholipase activity than PLA2 activity, sequentially hydrolyzes fatty acid from the sn-2 and sn-1 positions of phosphatidylcholine
-
?
additional information
?
-
-
enzyme is responsible for Ca2+-dependent release of arachidonic acid from red blood cells
-
?
additional information
?
-
-
role in mediating fatty acid release from intact cells
-
?
additional information
?
-
-
preference of substrates in decreasing order: phosphatidylglycerols, phosphatidylcholines, phosphatidylethanolamines, phosphatidic acids
-
-
?
additional information
?
-
-
PLA2s affect cellular activation, signal transduction, and possibly innate immunity, the specific secretory isozyme sPLA2-X neutralizes human immunodeficiency virus type 1 through degradation of the viral membrane, the catalytic function is required for antiviral activity, the target cells of infection are unaffected, sPLA2-X potently reduces gene transfer of HIV-1 Env-pseudo-typed lentivirus vectors and inhibits the replication of both CCR5- and CXCR4-tropic HIV-1 in human CD4 T cells. Virions resistant to damage by antibody and complement were sensitive to lysis by sPLA2-X, mechanism, overview
-
-
?
additional information
?
-
the lipoprotein-associated PLA2 plays a crucial role in atherosclerosis, and is proposed as a promising target for drug discovery
-
-
?
additional information
?
-
-
hGX sPLA2 prefers phosphatidylcholine 50fold to 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine as substrate, its hydrolyzing activity towards platelet activating factor rises abruptly when the concentration of the substrate passes through its critical micelle concentration, overview
-
-
?
additional information
?
-
-
long chain oxidized phosphatidylcholines represent quantitatively the most abundant phosphatidylcholine products of LDL oxidation, although they are less efficient as substrates for Lp-PLA2 than are the short chain oxidized phosphoatidylcholines
-
-
?
additional information
?
-
-
structural and functional effects of tryptophans inserted into the membrane-binding and substrate-binding sites of human group IIA phospholipase A2, overview
-
-
?
additional information
?
-
-
bile acids are likely to contribute to lung injury, causing surfactant inactivation through the increased sPLA2 activity
-
-
?
additional information
?
-
-
cPLA2alpha interacts with the cPLA2alpha-binding protein p11 via the hydroxyl group of Ser727, binding as annexin A2 complex, mechanism of regulation of group IVA phospholipase A2 activity by Ser727 phosphorylation, surface plasmon resonance analysis, overview
-
-
?
additional information
?
-
-
cPLA2alpha is regulated by phosphorylation at Ser505 and calcium-induced translocation to membranes
-
-
?
additional information
?
-
-
cytosolic phospholipase A2 releases arachidonic acid metabolites from membrane phospholipids, reactive oxygen species are generated from arachidonic acid metabolites by ROS-producing enzymes, e.g. NADPH oxidase. Cyclooxygenase transforms arachidonic acid into prostaglandin H2, the immediate precursor of a variety of prostanoids including prostaglandin and thromboxane A, metabolism, overview
-
-
?
additional information
?
-
-
peroxiredoxin 6 is a bifunctional protein with both GSH peroxidase and phospholipase A2 activities, and is responsible for the metabolism of lung surfactant phospholipids. Prdx6 has a major role in degradation of internalized dipalmitoyl phosphatidylcholine as well as in the remodeling of PC through the deacylation-reacylation pathway by lung granular pneumocytes, i.e. alveolar epithelial type II cells. Mitogen-activated protein kinase-mediated phosphorylation of peroxiredoxin 6 regulates its phospholipase A2 activity, overview
-
-
?
additional information
?
-
-
the phospholipase A2 superfamily consists of many different groups of enzymes that catalyze the hydrolysis of the sn-2 ester bond in a variety of different phospholipids, products of the hydrolysis of the sn-2 ester bond of phospholipid are a free fatty acid and lysophospholipid. GVIA iPLA2 is involved in cell proliferation, mediating cell growth, apoptosis and glucose-induced insulin secretion
-
-
?
additional information
?
-
-
fatty acyl-CoA is a substrate for GVIA iPLA2, The active site serine of the GVIA iPLA2 lies within a lipase consensus sequence Gly-X-Ser519-X-Gly. The group IVA PLA2 isozyme is specific for phospholipids containing arachidonic acid in the sn-2 position, substrate binding involving the C2 domain, the specific site in the C2 domain consists of Arg57, Lys58, and Arg59, structure, overview. The GVIA PLA2 contains multiple ankyrin repeats which may be important in mediating protein-protein interactions
-
-
?
additional information
?
-
inhibitor plus phospholipid vesicles cause a decreases at the C2 domain as well as charged residues on the putative membrane binding surface of the catalytic domain revealing the binding sites of the enzyme to the lipid surface, hypothetical model of initial membrane binding before lid opening, overview
-
-
?
additional information
?
-
-
interfacial binding and kinetics of cPLA2 and its phosphorylated forms in vitro, lipid vesicle formation, overview
-
-
?
additional information
?
-
-
Ser727 is not directly involved in either membrane binding or catalytic steps
-
-
?
additional information
?
-
sPLA2-IIA activity assays using the fluorescent probe ADIFAB, which consists of an acrylodan derivative of rat intestinal fatty acid binding protein that exhibits a shift in fluorescence upon binding to long-chain native fatty acids
-
-
?
additional information
?
-
-
sPLA2-IIA activity assays using the fluorescent probe ADIFAB, which consists of an acrylodan derivative of rat intestinal fatty acid binding protein that exhibits a shift in fluorescence upon binding to long-chain native fatty acids
-
-
?
additional information
?
-
-
14C-oleate radio-labelled Escherichia coli membrane used as substrate
-
-
?
additional information
?
-
-
active splice forms of the enzyme GIVA-1 PLA2 and GIVA-2 PLA2 are composed of 7-8 ankyrin repeats, a linker region and a catalytic domain, uses a serine in the active site to catalyze the cleavage of the sn-2 ester bond
-
-
?
additional information
?
-
-
phosphorylation at Ser505 is key for enzyme activity and lipid droplets formation
-
-
?
additional information
?
-
-
unilamellar liposomes composed of a 9:1 M ratio of dioleoyl phosphatidylcholine and dioleoyl phosphatidylglycerol, release of fatty acid
-
-
?
additional information
?
-
-
isoform cPLA2gamma shows no activity with 1-palmitoyl-2-oleoyl-phosphatidylcholine, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphate, 1-palmitoyl-2-oleoyl-phosphatidylethanolamine, 1-palmitoyl-2-oleoyl-phosphatidylglycerol, and 1-palmitoyl-2-oleoyl-phosphatidylinositol
-
-
?
additional information
?
-
while favorable accommodation of the substrate in the active site greatly contributes to the preferential hydrolysis of arachidonic acid-containing glycerophospholipids by cytosolic phospholipase A2 alphacPLA2alpha also the efflux of the substrate from a bilayer plays a significant role. When the substrate lacks an arachidonic acid residue, efflux from a bilayer appears to be the key rate-limiting step of hydrolysis. Promiscuous binding of the acyl chains of a glycerophospholipid to the active site of cytosolic phospholipase A2 alpha most probably explains why the enzyme has both PLA1 and PLA2 activities
-
-
?
additional information
?
-
-
while favorable accommodation of the substrate in the active site greatly contributes to the preferential hydrolysis of arachidonic acid-containing glycerophospholipids by cytosolic phospholipase A2 alphacPLA2alpha also the efflux of the substrate from a bilayer plays a significant role. When the substrate lacks an arachidonic acid residue, efflux from a bilayer appears to be the key rate-limiting step of hydrolysis. Promiscuous binding of the acyl chains of a glycerophospholipid to the active site of cytosolic phospholipase A2 alpha most probably explains why the enzyme has both PLA1 and PLA2 activities
-
-
?
additional information
?
-
-
inhibits platelet aggregation induced by collagen and ADP
-
?
additional information
?
-
-
enzyme causes a significant concentration-dependent neuromuscular blockade in the chick biventer cervicis preparation
-
-
?
additional information
?
-
-
enzyme induces hemolysis when incubated with exogenous lecithin
-
-
?
additional information
?
-
-
involved in synaptic plasticity, generation of second messengers, axon regeneration and neurodegeneration
-
?
additional information
?
-
-
role in the digestion of prey, neurotoxic, myotoxic, cardiotoxic and cytotoxic activities, can have convulsant, hypotensive and proinflammatory effects, can affect blood coagulation and platelet aggregation, some forms can induce cell proliferation, cell migration and antibacterial activity. Mechanism of action can involve: the intrinsic catalytic activity of vPLA2, i.e. its ability to release potent biologically active fatty acids and lysophospholipids from membrane lipids, the interfacial binding to the membrane lipid bilayer which, without any phospholipid hydrolysis, may affect cellular functions by perturbing cellular membranes, and the binding to specific proteins located at the cell surface
-
?
additional information
?
-
-
substrate: egg yolk emulsion
-
?
additional information
?
-
-
induces pharmacological effects, including myotoxic or anticoagulant effects, and insulin secretion stimulating effects through a non-enzymatic mechanism
-
?
additional information
?
-
-
enzyme produces neuromuscular blockade in vertebrate nerve-muscle preparations without involving cholinergic nicotinic receptors
-
-
?
additional information
?
-
-
enzyme has hemolytic activity with red blood cells, which is greatly inhibited by phosphatidylcholines
-
-
?
additional information
?
-
-
enzyme exhibits lyspohospholipase activity, lysophospholipid transacylase acitivty and phospholipase A2 activity
-
?
additional information
?
-
-
during apoptosis, changes occur in lymphocyte membranes that render them susceptible to hydrolysis by secretory phospholipase A2, mechanism, the membranes of apoptotic cells become susceptible to sPLA2 through a reduction in lipid-neighbor interactions that facilitates migration of phospholipids into the enzyme active site, overview
-
-
?
additional information
?
-
-
substrate specificity, overview, Lpla2 also shows transacylase activity transferring fatty acids from phosphatidylcholine or phosphatidylethanolamine liposomes onto N-acetylsphingosine incorporated into phospholipid liposomes, positional specificity, overview
-
-
?
additional information
?
-
-
prion infection greatly increased both the phosphorylation of cPLA2 and prostaglandin E2 production, the alternatively folded prion protein PrPSc causes a dose-dependent increase in the free cholesterol concentration of cortical neurons, overview
-
-
?
additional information
?
-
-
the phospholipase A2 superfamily consists of many different groups of enzymes that catalyze the hydrolysis of the sn-2 ester bond in a variety of different phospholipids, products of the hydrolysis of the sn-2 ester bond of phospholipid are a free fatty acid and lysophospholipid
-
-
?
additional information
?
-
-
cPLA2 may release fatty acid hydroperoxides from membranes following denervation
-
-
?
additional information
?
-
-
production of lysophosphatidylcholine
-
-
?
additional information
?
-
-
isoform cPLA2beta shows no activity with 1-palmitoyl-2-oleoyl-phosphatidylcholine
-
-
?
additional information
?
-
-
sPLA2-IIE preferentially hydrolyzes the minor lipoprotein phospholipids, phosphatidylethanolamine and phosphatidylserine, with no fatty acid selectivity
-
-
?
additional information
?
-
sPLA2-IIE preferentially hydrolyzes the minor lipoprotein phospholipids, phosphatidylethanolamine and phosphatidylserine, with no fatty acid selectivity
-
-
?
additional information
?
-
-
sPLA2-X secreted from sperm acrosomes selectively hydrolyzes docosahexaenoic acid- or docosapentaenoic acid-containing phosphatidylcholine in the sperm membrane to release docosahexaenoic acid, docosapentaenoic acid, and lysophosphatidylcholine
-
-
?
additional information
?
-
sPLA2-X secreted from sperm acrosomes selectively hydrolyzes docosahexaenoic acid- or docosapentaenoic acid-containing phosphatidylcholine in the sperm membrane to release docosahexaenoic acid, docosapentaenoic acid, and lysophosphatidylcholine
-
-
?
additional information
?
-
native and mutated PLA2s induce apoptotic death of U937 cells
-
-
?
additional information
?
-
-
native and mutated PLA2s induce apoptotic death of U937 cells
-
-
?
additional information
?
-
-
the enzyme in venom effectively inhibits A-type K+ currents in mice and cause alterations of channel gating characters, such as the shifts of steadystate activation and inactivation curves to hyperpolarization direction and changes of V1/2 and slope factor, the effects are independent of the enzymatic activity as phospholipase, overview
-
-
?
additional information
?
-
-
does not hydrolyze either fibrinogen or thrombin
-
-
?
additional information
?
-
-
both isoenzymes NK-PLA2-I and NK-PLA2-II cause significantly more damage to mitochondrial membranes as compared to erythrocyte membranes
-
-
?
additional information
?
-
-
isoenzyme NK-PLA2-I does not discriminate between saturated and unsaturated fatty acids whereas isoenzyme NK-PLA2-II shows a preference for unsaturated fatty acids
-
-
?
additional information
?
-
-
stimulates CD11b translocation from the PMN granule store to the plasma membrane and enhances neutrophil motility on collagen-coated surfaces, first causes a non-enzymatic stimulation of PMN leading to the activation of cytosolic PMN PLA2 production and of arachidonate metabolites involved in stimulation of PMN degranulation and motility
-
?
additional information
?
-
-
preference of substrates in decreasing order: phosphatidylcholines, phosphatidylglycerols, phosphatidylethanolamines, phosphatidic acids
-
-
?
additional information
?
-
-
stimulates CD11b translocation from the polymorph nuclear granule store to the plasma membrane and enhances neutrophil motility on collagen-coated surfaces, first causes a non-enzymatic stimulation of PMN leading to the activation of cytosolic PMN PLA2 production and of arachidonate metabolites involved in stimulation of PMN degranulation and motility
-
?
additional information
?
-
-
enzyme is a class B1 platelet aggregation inhibitor and inhibits platelet aggregation induced by ADP, collagen and epinephrine
-
-
?
additional information
?
-
-
enzyme is toxic to mice with a LD50 value of 0.098 mg/kg body weight, producing acute neurotoxic symptoms. It is weakly coagulant and devoid of cytotoxicity, myotoxicity, hemorrhage, edema inducing, and direct lytic activities
-
-
?
additional information
?
-
-
enzymes show post-synaptic neurotoxicity, they are toxic to mice with LD50 of 1.9-2.1 mg/kg body weight
-
-
?
additional information
?
-
-
the phospholipase A2 superfamily consists of many different groups of enzymes that catalyze the hydrolysis of the sn-2 ester bond in a variety of different phospholipids, products of the hydrolysis of the sn-2 ester bond of phospholipid are a free fatty acid and lysophospholipid
-
-
?
additional information
?
-
-
determination of the cytolytic activity od sPLA2 using oleate-labelled, autoclaved Escherichia coli cells as substrate, overview
-
-
?
additional information
?
-
-
group IA enzyme appears to bind lipid substrate in the active site through the hydrophobic residues lining the active site channel, and binds neutral membrane substrate through interactions with a group of hydrophobic residues on the lipid binding surface of the molecule
-
-
?
additional information
?
-
-
the phospholipase A2 superfamily consists of many different groups of enzymes that catalyze the hydrolysis of the sn-2 ester bond in a variety of different phospholipids, products of the hydrolysis of the sn-2 ester bond of phospholipid are a free fatty acid and lysophospholipid
-
-
?
additional information
?
-
-
enzyme does not show fatty acid specificity, but prefers phosphatidylcholine over phosphatidylethanolamine
-
-
?
additional information
?
-
relationship between polar-group specificity and structure of the pancreatic loop region, overview
-
-
?
additional information
?
-
induces edema, has haemolytic activity and inhibits ADP-induced rabbit platelet aggregation
-
?
additional information
?
-
-
induces edema, has haemolytic activity and inhibits ADP-induced rabbit platelet aggregation
-
?
additional information
?
-
zhaoermiatoxin induces oedema and strong myonecrosis without detectable PLA2 catalytic activity, overview
-
-
?
additional information
?
-
-
zhaoermiatoxin induces oedema and strong myonecrosis without detectable PLA2 catalytic activity, overview
-
-
?
additional information
?
-
zhaoermiatoxin is highly myotoxic and displays high myonecrotic and edema activities
-
-
?
additional information
?
-
-
zhaoermiatoxin is highly myotoxic and displays high myonecrotic and edema activities
-
-
?
additional information
?
-
PEG 400 molecule binding structure, determination and analysis, overview
-
-
?
additional information
?
-
-
PEG 400 molecule binding structure, determination and analysis, overview
-
-
?
additional information
?
-
-
the phospholipase A2 superfamily consists of many different groups of enzymes that catalyze the hydrolysis of the sn-2 ester bond in a variety of different phospholipids, products of the hydrolysis of the sn-2 ester bond of phospholipid are a free fatty acid and lysophospholipid
-
-
?
additional information
?
-
-
ExoU is a potent phospholipase virulence factor that is translocated into the cytosol by type III secretion system
-
-
?
additional information
?
-
-
exoenzyme U, i.e. ExoU, a potent cytotoxin, is delivered via the type III secretion pathway directly into contacting host cells, once inside the mammalian cell, ExoU rapidly lyses the intoxicated cells via its phospholipase A2 activity, overview
-
-
?
additional information
?
-
-
infection by ExoU-producing Pseudomonas aeruginosa induces a rapid release of arachidonic acid as well as a significant release of prostaglandins PGE2 and PGI2 from human endothelial cells of the HMEC-1 line, overview, ExoU may contribute to Pseudomonas aeruginosa pathogenesis by inducing an eicosanoid-mediated inflammatory response of host organisms, overview
-
-
?
additional information
?
-
-
Pseudomonas aeruginosa PLA2 is involved in induction of polymorphonuclear cell migration across lung epithelial barriers in hosts, e.g. A549 alveolar epithelial cells, mediated by epithelial production of the eicosanoid hepoxilin A3, HXA3, in response to Pseudomonas aeruginosa infection, HXA3 is a polymorphonuclear cell, PMN, chemoattractant metabolized from arachidonic acid, overview
-
-
?
additional information
?
-
-
infection by ExoU-producing Pseudomonas aeruginosa induces a rapid release of arachidonic acid as well as a significant release of prostaglandins PGE2 and PGI2 from human endothelial cells of the HMEC-1 line, overview, ExoU may contribute to Pseudomonas aeruginosa pathogenesis by inducing an eicosanoid-mediated inflammatory response of host organisms, overview
-
-
?
additional information
?
-
-
exoenzyme U, i.e. ExoU, a potent cytotoxin, is delivered via the type III secretion pathway directly into contacting host cells, once inside the mammalian cell, ExoU rapidly lyses the intoxicated cells via its phospholipase A2 activity, overview
-
-
?
additional information
?
-
-
no fatty acid is produced by the cell lysate when trimyristin, tristearin, or triolein is incubated at 90°C overnight. Therefore, no thermostable lipase activity is observed in the PLA2 from Pyrococcus horikoshii
-
-
?
additional information
?
-
-
no fatty acid is produced by the cell lysate when trimyristin, tristearin, or triolein is incubated at 90°C overnight. Therefore, no thermostable lipase activity is observed in the PLA2 from Pyrococcus horikoshii
-
-
?
additional information
?
-
-
increased phospholipase A2 activity and inflammatory response but decreased nerve growth factor expression in the olfactory bulbectomized rat model of depression, the effects are associated with increased interleukin-1beta and prostaglandin E2 in the serum and brain, overview
-
-
?
additional information
?
-
-
peroxiredoxin 6 is a bifunctional protein with both GSH peroxidase and phospholipase A2 activities, and is responsible for the metabolism of lung surfactant phospholipids. Prdx6 has a major role in degradation of internalized dipalmitoyl phosphatidylcholine as well as in the remodeling of PC through the deacylation-reacylation pathway by lung granular pneumocytes, i.e. alveolar epithelial type II cells. Mitrogen-activated protein kinase-mediated phosphorylation of peroxiredoxin 6 regulates its phospholipase A2 activity, overview
-
-
?
additional information
?
-
-
phospholipases A2 catalyze hydrolysis of fatty acids from the sn-2 position of phospholipids
-
-
?
additional information
?
-
-
the phospholipase A2 superfamily consists of many different groups of enzymes that catalyze the hydrolysis of the sn-2 ester bond in a variety of different phospholipids, products of the hydrolysis of the sn-2 ester bond of phospholipid are a free fatty acid and lysophospholipid
-
-
?
additional information
?
-
-
AdPLA is most likely a His-Cys PLA2, His23 and Cys113 are critical for activity of AdPLA, catalytic mechanism, overview. AdPLA has phospholipase activity but lacks acyltransferase activity
-
-
?
additional information
?
-
-
enzyme is active towards mono-acyl-glycerolphosphocholines, increasing activity with increasing chain lengths from C12 to C16
-
?
additional information
?
-
-
preference of substrates in decreasing order: phosphatidylcholines, phosphatidylglycerols, phosphatidylethanolamines, phosphatidic acids
-
-
?
additional information
?
-
bile salt regulation of lipid metabolism via both activation and inhibition of PLA2, interaction and binding structure analysis, overview
-
-
?
additional information
?
-
-
the phospholipase A2 superfamily consists of many different groups of enzymes that catalyze the hydrolysis of the sn-2 ester bond in a variety of different phospholipids, products of the hydrolysis of the sn-2 ester bond of phospholipid are a free fatty acid and lysophospholipid
-
-
?
additional information
?
-
-
activity assayed using mixed micelles in a modified Dole assay
-
-
?
additional information
?
-
-
determination of the cytolytic activity od sPLA2 using oleate-labelled, autoclaved Escherichia coli cells as substrate, overview
-
-
?
additional information
?
-
-
cleaves fatty acids at the sn-2 and sn-2 positions of phosphatidylcholine
-
?
additional information
?
-
-
enzyme has cytotoxic activity and can lyse erythrocytes
-
?
additional information
?
-
-
enzyme prefers phosphocholine to ethanolamine and unsaturated fatty acids to saturated fatty acids at sn-2 position of the phospholipids
-
?
additional information
?
-
-
role in the release of linolenic acid
-
?
additional information
?
-
-
the snake phospholipase A2 neurotoxins enter nerve terminals, bind specifically to mitochondria, and open their transition pores, overview. The action of SPANs is very specific for the presynaptic nerve terminals in vivo
-
-
?
additional information
additional information
-
-
Bacillus megaterium 216 produces the bacteriocin megacin A-216, which leads to lysis of the producer cell and kills Bacillus megaterium and a few other bacterial species.
-
?
additional information
additional information
-
-
Bacillus megaterium 216 produces the bacteriocin megacin A-216, which leads to lysis of the producer cell and kills Bacillus megaterium and a few other bacterial species.
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(+-)-3-O-[4-(4,5-dihydro-5-oxo-1,2,4-4H-oxadiazol-3-yl)phenyl]-2-O-tetradecyl-1-O-triphenylmethylglycerol
(2-(2-amino-2-oxoethyl)-5-propyl-1H-indol-7-yl)acetic acid
-
(2-(4-((3-(diphenylmethyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)methyl)phenyl)-1,3-oxazol-4-yl)acetic acid
-
-
(2E,4E,6S)-6-[(2-oxohexadecanoyl)amino]deca-2,4-dienoic acid
-
reduces the cellular release of arachidonic acid by 6%
(2E,4S)-4-[(2-oxohexadecanoyl)amino]oct-2-enoic acid
-
reduces the cellular release of arachidonic acid by 74%
(3-aminooxalyl-1-benzyl-2-ethyl-6-methyl-1H-indol-4-yl)oxyacetic acid methyl ester
-
LY374388, potent sPLA2 inhibitor
(3E)-3-[(3aS,7aS)-3-methyl-2-oxo-6-(propan-2-ylidene)hexahydro-1-benzofuran-7(4H)-ylidene]propanoic acid
-
non-competitive inhibition
(3R,3aS,5aS,8bR)-3,5a,5b-trimethyl-3a,4,5,5a,5b,8b-hexahydro-2H-cyclopenta[2,3]cyclopropa[1,2-g]benzofuran-2,6(3H)-dione
-
non-competitive inhibition
(3R,3aS,5aS,9bR)-3,5a,9-trimethyl-3a,4,5,5a-tetrahydronaphtho[1,2-b]furan-2,8(3H,9bH)-dione
-
non-competitive inhibition
(3R,3aS,6R,8S,9bS)-6,8-dihydroxy-3,6,9-trimethyl-3,3a,4,5,6,6a,7,8-octahydroazuleno[4,5-b]furan-2(9bH)-one
-
non-competitive inhibition
(3R,3aS,6R,8S,9bS)-8-hydroxy-3,6,9-trimethyl-2-oxo-2,3,3a,4,5,6,6a,7,8,9b-decahydroazuleno[4,5-b]furan-6-yl acetate
-
-
(3R,3aS,6R,9bS)-3,6,9-trimethyl-2,8-dioxo-2,3,3a,4,5,6,6a,7,8,9b-decahydroazuleno[4,5-b]furan-6-yl acetate
-
-
(3R,3aS,6R,9bS)-6-hydroxy-3,6,9-trimethyl-3a,4,5,6,6a,7-hexahydroazuleno[4,5-b]furan-2,8(3H,9bH)-dione
-
-
(3S)-4-[(4-benzylphenyl)sulfanyl]-3-[(7-phenylheptanoyl)amino]butane-1-sulfonic acid
bioisosteric replacements, binding energy of -22.05 kJ/mol
(3S)-4-[(4-benzylphenyl)sulfanyl]-3-[(7-phenylheptanoyl)amino]butyl phosphonic acid
bioisosteric replacements, binding energy of -19.76 kJ/mol
(3S)-4-[(4-benzylphenyl)sulfanyl]-3-[[7-(4-hydroxyphenyl)heptanoyl]amino]butane-1-sulfonic acid
bioisosteric replacements, molecular structure is characterized by a chiral centre of absolute (R)-configuration, four carbons in the R1 chain, a hydroxyl group as a substituent in the para-position of the phenyl ring in R1 chain and a sulphonate group instead of the carboxylate group, indicates the highest binding energy (-29.1 kJ/mol) than all the other analogues and the prototype
(3S)-5a-(1-bromo-1-methylethyl)-3-methyl-3,3a,5,5a,8,9b-hexahydro-4H-furo[2,3-f]chromene-2,7-dione
-
non-competitive inhibition
(4-((3-(diphenylmethyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)methyl)phenoxy)acetic acid
-
-
(4-((3-(diphenylmethyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)methyl)phenyl)acetic acid
-
-
(4-((6-bromo-1-(diphenylmethyl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)methyl)phenyl)acetic acid
-
-
(4R)-5-[(4-benzylphenyl)sulfanyl]-4-[(7-phenylheptanoyl)amino]pentanoic acid
(R)-configuration of FPL67047XX, binding energy of -19.5 kJ/mol
(4R)-6-methyl-4-[(2-oxohexadecanoyl)amino]heptanoic acid
-
reduces the cellular release of arachidonic acid by 62%
(4S)-4-[(2-oxododecanoyl)amino]octanoic acid
-
reduces the cellular release of arachidonic acid by 56%
(4S)-4-[(2-oxohexadecanoyl)amino]nonanoic acid
-
-
(4S)-4-[(2-oxohexadecanoyl)amino]octanoic acid
-
reduces the cellular release of arachidonic acid by 79%
(4S)-5-[(4-benzylphenyl)sulfanyl]-4-[(5-phenylpentanoyl)amino]pentanoic acid
decreased carbon chain length between the amide group and the aromatic ring of the R1 chain, binding energy of -22.02 kJ/mol
(4S)-5-[(4-benzylphenyl)sulfanyl]-4-[[7-(4-hydroxyphenyl)heptanoyl]amino]pentanoic acid
substituents in the para-position of the aromatic ring R1, higher binding energy (-27.61 kJ/mol) than the prototype and all the other analogues except structure 9
(4S)-5-[(4-benzylphenyl)sulfanyl]-4-[[7-(4-methoxyphenyl)heptanoyl]amino]pentanoic acid
substituents in the para-position of the aromatic ring R1, binding energy of -22.23 kJ/mol
(4S)-5-[(4-benzylphenyl)sulfanyl]-4-[[7-(4-nitrophenyl)heptanoyl]amino]pentanoic acid
substituents in the para-position of the aromatic ring R1, binding energy of -20.25 kJ/mol
(5S)-5-[(2-oxohexadecanoyl)amino]decanoic acid
-
-
(5S)-5-[(2-oxohexadecanoyl)amino]nonanoic acid
-
reduces the cellular release of arachidonic acid by 59%
(6E)-6-(bromomethylene)-3-(1-naphthyl)tetrahydro-2H-pyran-2-one
-
i.e. BEL, bromoenol lactone suicide inhibitor, alkylates Cys-residues
(6Z,9Z,12Z,15Z)-1,1,1-trifluorohenicosa-6,9,12,15-tetraen-2-one
(9Z)-9-(hydroxyimino)-9H-fluorene-4-carboxamide
-
inhibition of phospholipase A2 activity of cytotoxin ExoU
(E)-6-(bromomethylene)-3-(1-naphthalenyl)-2H-tetrahydropyran-2-one
-
-
(R)-4-(7-phenylheptanamido)octanoic acid
-
-
(R)-gamma-norleucine
-
a highly selective inhibitor of isozyme GV sPLA2
(R)-methyl 6-methyl-4-(2-oxohexadecanamido)heptanoate
-
-
(S)-2-(2-(2-oxohexadecanamido)hexanamido)acetic acid
-
contains a free carboxyl group, inhibits GIVA cPLA2 without affecting the activity of the other intracellular enzyme GVIA iPLA2
(S)-2-(2-(2-oxohexadecanamido)hexyloxy)acetic acid
-
selectively inhibits GIVA cPLA2, due to its free carboxyl group. Most potent inhibitor of GIVA cPLA2. Reduces the cellular release of arachidonic acid by 68%
(S)-2-(3-methyl-2-(2-oxohexadecanamido)butanamido)acetic acid
-
contains a free carboxyl group, inhibits GIVA cPLA2 without affecting the activity of the other intracellular enzyme GVIA iPLA2
(S)-ethyl 2-(2-(2-oxohexadecanamido)hexanamido)acetate
-
ethyl ester based on Nle-Gly dipeptide, potent inhibition of GVIA iPLA2, inhibits GIVA cPLA2 (73%) and GV sPLA2 (63%)
(S)-ethyl 2-(2-(2-oxohexadecanamido)hexyloxy)acetate
-
preferentially inhibits GVIA iPLA2, is a potent inhibitor of GVIA iPLA2, inhibits GIVA cPLA2 by 52% and GV sPLA2 by 81%
(S)-ethyl 6-(2-oxohexadecanamido)decanoate
-
-
(S)-methyl 2-(2-(2-oxohexadecanamido)hexanamido)acetate
-
methyl ester based on dipeptide Nle-Gly, inhibits both GIVA cPLA2 and GVIA iPLA2, showing a small preference for GIVA cPLA2, inhibits GV sPLA2 by 65%
(S)-methyl 2-(3-methyl-2-(2-oxohexadecanamido)butanamido)acetate
-
methyl ester based on dipeptide Val-Gly, inhibits activity of GIVA cPLA2 by 25%
(S)-methyl 4-(2-oxohexadecanamido)octanoate
-
-
(S)-methyl 4-(7-phenylheptanamido)octanoate
-
-
(S)-tert-butyl 2-(2-(2-oxohexadecanamido)hexanamido)acetate
-
tert-butyl ester based on Nle-Gly dipeptide, potent inhibition of GVIA iPLA2, inhibits GIVA cPLA2 (72%) and GV sPLA2 (59%)
(S)-tert-butyl 2-(2-(2-oxohexadecanamido)hexyloxy)acetate
-
preferentially inhibits GVIA iPLA2 (81% inhibition), inhibits GIVA cPLA2 by 44% and GV sPLA2 by 57%
(S)-tert-butyl 2-(3-methyl-2-(2-oxohexadecanamido)butanamido)acetate
-
tert-butyl ester based on dipeptide Val-Gly, inhibits both GIVA cPLA2 and GVIA iPLA2, showing a small preference for GIVA cPLA2, reduces GV sPLA2 activity by 78%. Reduces the cellular release of arachidonic acid by 30%
(S)-tert-butyl 4-(2-oxohexadecanamido)pentanoate
-
-
(S,2E,4E)-6-(2-oxohexadecanamido)deca-2,4-dienoic acid
-
-
(S,2E,4E)-ethyl 6-(2-oxohexadecanamido)deca-2,4-dienoate
-
-
([1-[amino(oxo)acetyl]-3-(biphenyl-2-ylmethyl)-2-(2-methylpropyl)indolizin-8-yl]oxy)acetic acid
([3-[amino(oxo)acetyl]-1-benzyl-2-(2-methylpropyl)-1H-benzo[g]indol-4-yl]oxy)acetic acid
1,1,1,2,2-pentafluoro-5-(4-hexyloxy-phenyl)-pentan-3-one
-
-
1,1,1,2,2-pentafluoro-7-phenyl-heptan-3-one
-
a selective inhibitor of GVIA iPLA2
1,1,1,2,2-pentafluoro-8-phenyl-octan-3-one
-
-
1,1,1,2,2-pentafluoro-9-phenyl-nonan-3-one
-
-
1,1,1,2,2-pentafluoro-octadecan-3-one
-
-
1,1,1,3,3-pentafluoro-6-phenyl-hexane-2,2-diol
-
-
1,1,1,3-tetrafluoro-heptadecan-2-one
-
-
1,1,1-trifluoro-4-(4-hexyloxy-phenyl)-butan-2-one
-
-
1,1,1-trifluoro-6-(4-hexyloxy-phenyl)-hexan-2-one
-
-
1,1,1-trifluoro-6-phenylhexan-2-one
-
-
1,1,1-trifluoro-7-phenylheptan-2-one
-
-
1,1,1-trifluoro-8-phenyloctan-2-one
-
-
1,1,1-trifluoroheptadecan-2-one
-
-
1,2-dipalmitoyl-phosphatidylcholine
-
large unilamellar vesicles, inhibits hydrolysis of 1,2-dipalmitoyl-phosphatidylcholine small unilamellar vesicles
1,3,5-trihydroxybenzene
-
potent inhibition of enzymatic activity and endemic activity of PLA2, binding structure, overview
1,3-dihydroxy benzene
-
potent inhibition of enzymatic activity and endemic activity of PLA2, binding structure, overview
1-(1H-indazol-1-yl)-3-(4-phenoxyphenoxy)propan-2-one
-
-
1-(2-dimethylaminoethyl)-5-[3-(4-octylphenoxy)-2-oxopropoxy]indole-2-carboxylic acid
-
-
1-(4-carboxybenzyl)-5-[3-(4-octylphenoxy)-2-oxopropoxy]indole-2-carboxylic acid
-
-
1-(4-octylphenoxy)-3-[5-(1H-tetrazol-5-yl)indol-1-yl]propan-2-one
-
inhibits isozyme cPLA2alpha
1-(5-nitro-1H-indazol-1-yl)-3-(4-phenoxyphenoxy)propan-2-one
-
-
1-(9H-fluoren-4-ylcarbonyl)piperidine
-
inhibition of phospholipase A2 activity of cytotoxin ExoU
1-(carboxymethyl)-5-[3-(4-octylphenoxy)-2-oxopropoxy]indole-2-carboxylic acid
-
-
1-(carboxypentyl)-5-[3-(4-octylphenoxy)-2-oxopropoxy]indole-2-carboxylic acid
-
-
1-(carboxypropyl)-5-[3-(4-octylphenoxy)-2-oxopropoxy]indole-2-carboxylic acid
-
-
1-benzyl-5-[3-(4-octylphenoxy)-2-oxopropoxy]-indole-2-carboxylic acid
-
-
1-H-indole-3-glyoxamide
-
varespladib methyl, potent sPLA2 inhibitor
1-hexadecyl-3-(trifluoroethyl)-sn-glycero-2-phosphomethanol
i.e. MJ33
1-hexadecyl-3-trifluoroethylglycero-sn-2-phosphomethanol
1-hexyl-5-[3-(4-octylphenoxy)-2-oxopropoxy]indole-2-carboxylic acid
-
-
1-methyl 5-[3-(4-octylphenoxy)-2-oxopropoxy]-indole-2-carboxylic acid
-
-
1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine
-
competitive inhibition of platelet activating factor hydrolysis
1-palmitylthio-2-palmitoylamido-1,2-dideoxy-sn-glycero-3-phosphorylcholine
1-sn-phosphoglycerides
-
-
1-[2-oxo-3-(4-phenoxyphenoxy)propyl]-1H-indazole-5-carboxylic acid
-
-
1-[3-(4-octylphenoxy)-2-oxopropyl]-1H-benzotriazole-5-carboxylic acid
-
43% metabolic stability in an assay with rat liver microsomes. Thermodynamic solubility is less than 1 microg/ml at pH 7.4
1-[3-(4-octylphenoxy)-2-oxopropyl]-1H-benzotriazole-6-carboxylic acid
-
44% metabolic stability in an assay with rat liver microsomes. Thermodynamic solubility is 2 microg/ml at pH 7.4
1-[3-(4-octylphenoxy)-2-oxopropyl]-1H-indole-5-carboxylic acid
-
1-[3-(4-octylphenoxy)-2-oxopropyl]-2,3-dihydro-1H-indole-5-carboxylic acid
-
-
1-[3-(4-octylphenoxy)-2-oxopropyl]benzimidazole-5-carboxylic acid
-
49% metabolic stability in an assay with rat liver microsomes, possesses the best thermodynamic solubility (22 microg/ml at pH 7.4)
1-[3-(4-octylphenoxy)-2-oxopropyl]benzimidazole-6-carboxylic acid
-
40% metabolic stability in an assay with rat liver microsomes. Thermodynamic solubility is 7 microg/ml at pH 7.4
1-[3-(4-octylphenoxy)-2-oxopropyl]indazole-5-carboxylic acid
-
reveals the highest cPLA2a inhibitory potency, is 7fold more active than the lead 1-[3-(4-octylphenoxy)-2-oxopropyl]indole-5-carboxylic acid, is the metabolically most stable compound in an assay with rat liver microsomes (64% stability). Thermodynamic solubility is less than 1 microg/ml at pH 7.4
1-[3-(4-octylphenoxy)-2-oxopropyl]indazole-6-carboxylic acid
-
36% metabolic stability in an assay with rat liver microsomes. Thermodynamic solubility is 5 microg/ml at pH 7.4
1-[3-(4-octylphenoxy)-2-oxopropyl]indole-5-carboxylic acid
-
is 7fold less active than 1-[3-(4-octylphenoxy)-2-oxopropyl]indazole-5-carboxylic acid, is the metabolically most stable compound in an assay with rat liver microsomes (65% stability). Thermodynamic solubility is less than 1 microg/ml at pH 7.4
1-[3-(4-octylphenoxy)-2-oxopropyl]indole-5-sulfonamide
-
inhibits isozyme cPLA2alpha
1-[3-(4-octylphenoxy)-2-oxopropyl]indole-6-carboxylic acid
-
39% metabolic stability in an assay with rat liver microsomes. Thermodynamic solubility is less than 1 microg/ml at pH 7.4
1-[3-[4-(decyloxy)phenoxy]-2-oxopropyl]-3-(methoxycarbonyl)-1H-indole-5-carboxylic acid
-
-
1-[5-(morpholine-4-carbonyl)indol-1-yl]-3-(4-octylphenoxy)propan-2-one
-
inhibits isozyme cPLA2alpha
2,2'-biphenyl-3,4'-diylbis(4H-chromen-4-one)
slight inhibition
2,2'-biphenyl-4,4'-diylbis(4H-chromen-4-one)
slight inhibition
2,2'-diphenyl-4H,4'H-6,6'-bichromene-4,4'-dione
slight inhibition
2,4,6-trihydroxy acetophenone
-
potent inhibition of enzymatic activity and endemic activity of PLA2, binding structure, overview
2,4-dihydroxy acetophenone
-
binding structure, overview
2,6-dihydroxy acetophenone
-
binding structure, overview
2-((6-bromo-1-(diphenylmethyl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)methyl)cyclopropanecarboxylic acid
-
-
2-(1-benzyl-2-ethyl-4-methoxy-1H-benzo[g]indol-3-yl)-2-oxoacetamide
2-(3-(2-amino-2-oxoacetyl)-1-benzyl-2-ethyl-1H-6,7-benzoindol-4-yloxy)acetic acid
2-([3-[amino(oxo)acetyl]-1-benzyl-2-(2-methylpropyl)-1H-benzo[g]indol-4-yl]oxy)-N-(phenylsulfonyl)acetamide
2-([3-[amino(oxo)acetyl]-1-benzyl-2-(2-methylpropyl)-1H-indol-4-yl]oxy)-N-(methylsulfonyl)propanamide
-
-
2-([3-[amino(oxo)acetyl]-1-benzyl-2-(2-methylpropyl)-1H-indol-4-yl]oxy)-N-(phenylsulfonyl)acetamide
2-([3-[amino(oxo)acetyl]-1-benzyl-2-(2-methylpropyl)-1H-indol-4-yl]oxy)-N-(phenylsulfonyl)propanamide
-
-
2-([3-[amino(oxo)acetyl]-1-benzyl-2-(2-methylpropyl)-1H-indol-4-yl]oxy)-N-[(2-chlorophenyl)sulfonyl]propanamide
-
-
2-([3-[amino(oxo)acetyl]-1-benzyl-2-(2-methylpropyl)-1H-indol-4-yl]oxy)-N-[(2-methylphenyl)sulfonyl]propanamide
-
-
2-([3-[amino(oxo)acetyl]-1-benzyl-2-(2-methylpropyl)-1H-indol-4-yl]oxy)-N-[(3-chlorophenyl)sulfonyl]propanamide
-
-
2-([3-[amino(oxo)acetyl]-1-benzyl-2-(2-methylpropyl)-1H-indol-4-yl]oxy)-N-[(4-chlorophenyl)sulfonyl]propanamide
-
-
2-([3-[amino(oxo)acetyl]-1-benzyl-2-(2-methylpropyl)-1H-indol-4-yl]oxy)-N-[(4-methylphenyl)sulfonyl]propanamide
-
-
2-([3-[amino(oxo)acetyl]-1-benzyl-2-(2-methylpropyl)-1H-indol-4-yl]oxy)-N-[(trifluoromethyl)sulfonyl]propanamide
-
-
2-([3-[amino(oxo)acetyl]-1-benzyl-2-(2-methylpropyl)-1H-indol-4-yl]oxy)-N-[[2-(trifluoromethyl)phenyl]sulfonyl]propanamide
-
-
2-([3-[amino(oxo)acetyl]-1-benzyl-2-ethyl-1H-benzo[g]indol-4-yl]oxy)-N-(phenylsulfonyl)acetamide
2-([3-[amino(oxo)acetyl]-1-benzyl-2-ethyl-1H-indol-4-yl]oxy)-N-(phenylsulfonyl)acetamide
2-hydroxy-N-[1-[2-oxo-3-(4-phenoxyphenoxy)propyl]-1H-indazol-5-yl]acetamide
-
-
2-methoxy-N-[1-[2-oxo-3-(4-phenoxyphenoxy)propyl]-1H-indazol-5-yl]acetamide
-
-
2-nitrobenzenesulfonyl fluoride
Bothrops spp.
-
BthTX-I: myotoxic activity reduced to 75% and the cytotoxic activity reduced to 76%
2-oxo-N-(4-oxooctyl)hexadecanamide
-
-
2-tetradecanoylaminohexanol-1-phosphocholine
-
competitive inhibition, R-enantiomer is a more potent inhibitor
2-tetradecanoylaminohexanol-1-phosphoethanolamine
-
competitive inhibition, R-enantiomer is a more potent inhibitor
2-tetradecanoylaminohexanol-1-phosphoglycol
-
competitive inhibition, R-enantiomer is a more potent inhibitor
2-[1-benzyl-2-(2-methylpropyl)-4-(2-oxopropoxy)-1H-indol-3-yl]-2-oxoacetamide
2-[1-benzyl-4-(2-oxopropoxy)-2-propyl-1H-indol-3-yl]-2-oxoacetamide
2-[3-(biphenyl-2-ylmethyl)-2-ethyl-8-(2-oxopropoxy)indolizin-1-yl]-2-oxoacetamide
2-[3-(biphenyl-2-ylmethyl)-2-ethyl-8-methoxyindolizin-1-yl]-2-oxoacetamide
25-O-acetyl-petrosaspongiolide M
an anti-inflammatory marine natural product
3,3'-[[2-(pentyloxy)propane-1,3-diyl]bis(oxybenzene-4,1-diylethane-2,1-diyl)]bis(1,2,4-oxadiazol-5(4H)-one)
3,3'-[[2-(tetradecyloxy)propane-1,3-diyl]bis(oxybenzene-4,1-diylethane-2,1-diyl)]bis(1,2,4-oxadiazol-5(4H)-one)
3,3'-[[2-(tetradecyloxy)propane-1,3-diyl]bis(oxybenzene-4,1-diylmethanediyl)]bis(1,2,4-oxadiazol-5(4H)-one)
3,3'-[[3-(tetradecyloxy)propane-1,2-diyl]bis(oxybenzene-4,1-diylethane-2,1-diyl)]bis(1,2,4-oxadiazol-5(4H)-one)
3,3'-[[3-(tetradecyloxy)propane-1,2-diyl]bis(oxybenzene-4,1-diylmethanediyl)]bis(1,2,4-oxadiazol-5(4H)-one)
3-(((2E)-4-(7-chloro-3-(diphenylmethyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)but-2-en-1-yl)oxy)benzoic acid
-
-
3-(1-benzyl-2,5-dimethylpyrrol-3-yl)-3-(4-fluorophenyl)-3H-isobenzofuran-1-one
-
18% inhibition at 0.033 mM
3-(1-[3-(4-octylphenoxy)-2-oxopropyl]indol-5-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one
-
inhibits isozyme cPLA2alpha
3-(2,5-dimethyl-1-phenylpyrrol-3-yl)-3-(4-fluorophenyl)-3H-isobenzofuran-1-one
-
40% inhibition at 0.033 mM
3-(2,5-dimethylpyrrol-3-yl)-3-(4-fluorophenyl)-3H-isobenzofuran-1-one
-
35% inhibition at 0.033 mM
3-(2-methylpropanoyl)-1-[2-oxo-3-(4-phenoxyphenoxy)propyl]-1H-indole-5-carboxylic acid
-
3-(2-methylpropanoyl)-1-[3-(4-octylphenoxy)-2-oxopropyl]-1H-indole-5-carboxylic acid
-
3-(2-[4-[(4-tetradecylpiperazin-1-yl)carbonyl]phenyl]ethyl)-1,2,4-oxadiazol-5(4H)-one
3-(3-acetamido-2-benzyl-2-ethylindolyl-5-oxy)propane phosphonic acid
-
LY311727, IC50 value of 36 nM, group IIa and V sPLA2
3-(3-carboxypropanoyl)-1-[3-(4-octylphenoxy)-2-oxopropyl]-1H-indole-5-carboxylic acid
-
3-(3-[4-[(4-tetradecylpiperazin-1-yl)carbonyl]phenyl]propyl)-1,2,4-oxadiazol-5(4H)-one
3-(4-fluorophenyl)-3-(1,2,5-trimethylpyrrol-3-yl)-3H-isobenzofuran-1-one
-
36% inhibition at 0.033 mM
3-(4-fluorophenyl)-3-[1-(3-hydroxyphenyl)-2,5-dimethylpyrrol-3-yl]-3H-isobenzofuran-1-one
-
30% inhibition at 0.033 mM
3-(4-fluorophenyl)-3-[1-(4-hydroxyphenyl)-2,5-dimethylpyrrol-3-yl]-3H-isobenzofuran-1-one
-
60% inhibition at 0.033 mM
3-(4-hydroxybutanoyl)-1-[3-(4-octylphenoxy)-2-oxopropyl]-1H-indole-5-carboxylic acid
-
3-(4-methoxybutanoyl)-1-[3-(4-octylphenoxy)-2-oxopropyl]-1H-indole-5-carboxylic acid
-
3-(5-carboxypentanoyl)-1-[3-(4-octylphenoxy)-2-oxopropyl]-1H-indole-5-carboxylic acid
-
3-(6-hydroxyhexanoyl)-1-[3-(4-octylphenoxy)-2-oxopropyl]-1H-indole-5-carboxylic acid
-
3-(6-methoxyhexanoyl)-1-[3-(4-octylphenoxy)-2-oxopropyl]-1H-indole-5-carboxylic acid
-
3-butanoyl-1-[3-(4-octylphenoxy)-2-oxopropyl]-1H-indole-5-carboxylic acid
-
3-hexanoyl-1-[3-(4-octylphenoxy)-2-oxopropyl]-1H-indole-5-carboxylic acid
-
3-pyrrol-3-yl-3H-isobenzofuran-1-one
-
synthesis and inhibitory potency of derivatives, overview
3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonate
-
-
3-[1-(3,4-dihydroxyphenyl)-2,5-dimethylpyrrol-3-yl]-3-(4-fluorophenyl)-3H-isobenzofuran-1-one
-
20% inhibition at 0.033 mM
3-[1-(4-aminophenyl)-2,5-dimethylpyrrol-3-yl]-3-(4-fluorophenyl)-3H-isobenzofuran-1-one
-
55% inhibition at 0.033 mM
3-[1-benzyl-3-(carbamoylmethyl)-2-ethylindol-5-yl]oxypropylphosphonic acid
-
LY311727, potent sPLA2 inhibitor
3-[2,5-dimethyl-1-(4-methylaminophenyl)pyrrol-3-yl]-3-(4-fluorophenyl)-3H-isobenzofuran-1-one
-
36% inhibition at 0.033 mM
3-[2-[2-(2,2-diphenylethyl)-3,5-dioxo-1,2,4-oxadiazolidin-4-yl]ethoxy]benzoate
-
-
3-[4'-(hydroxyimino-p-tolyl-methyl)-phenyl]-4-phenyl-sydnone
3-[4'-(hydroxyimino-p-tolyl-methyl)-phenyl]-sydnone
3-[4'-(hydroxyimino-phenyl-methyl)-phenyl]-4-phenyl-sydnone
3-[4'-(hydroxyimino-phenyl-methyl)-phenyl]-sydnone
3-[4-(4-hexadecylpiperazin-1-yl)benzyl]-1,2,4-oxadiazol-5(4H)-one
3-[4-(4-octadecylpiperazin-1-yl)benzyl]-1,2,4-oxadiazol-5(4H)-one
3-[4-(4-oxo-4H-chromen-2-yl)phenyl]-2-phenyl-4H-chromen-4-one
slight inhibition
3-[4-(4-tetradecylpiperazin-1-yl)benzyl]-1,2,4-oxadiazol-5(4H)-one
3-[4-(tetradecyloxy)benzyl]-1,2,4-oxadiazol-5(4H)-one
3-[4-[(4-docosylpiperazin-1-yl)carbonyl]benzyl]-1,2,4-oxadiazol-5(4H)-one
3-[4-[(4-hexadecylpiperazin-1-yl)carbonyl]benzyl]-1,2,4-oxadiazol-5(4H)-one
3-[4-[(4-hexadecylpiperazin-1-yl)carbonyl]phenyl]-1,2,4-oxadiazol-5(4H)-one
3-[4-[(4-hexadecylpiperazin-1-yl)methyl]benzyl]-1,2,4-oxadiazol-5(4H)-one
3-[4-[(4-hexadecylpiperazin-1-yl)methyl]phenyl]-1,2,4-oxadiazol-5(4H)-one
3-[4-[(4-icosylpiperazin-1-yl)carbonyl]benzyl]-1,2,4-oxadiazol-5(4H)-one
3-[4-[(4-octadecylpiperazin-1-yl)carbonyl]benzyl]-1,2,4-oxadiazol-5(4H)-one
3-[4-[(4-octadecylpiperazin-1-yl)carbonyl]phenyl]-1,2,4-oxadiazol-5(4H)-one
3-[4-[(4-octadecylpiperazin-1-yl)methyl]benzyl]-1,2,4-oxadiazol-5(4H)-one
3-[4-[(4-octadecylpiperazin-1-yl)methyl]phenyl]-1,2,4-oxadiazol-5(4H)-one
3-[4-[(4-tetradecylpiperazin-1-yl)carbonyl]benzyl]-1,2,4-oxadiazol-5(4H)-one
3-[4-[(4-tetradecylpiperazin-1-yl)carbonyl]phenyl]-1,2,4-oxadiazol-5(4H)-one
3-[4-[(4-tetradecylpiperazin-1-yl)methyl]benzyl]-1,2,4-oxadiazol-5(4H)-one
3-[4-[(4-tetradecylpiperazin-1-yl)methyl]phenyl]-1,2,4-oxadiazol-5(4H)-one
3-[4-[3-(4-butylphenoxy)-2-(tetradecyloxy)propoxy]benzyl]-1,2,4-oxadiazol-5(4H)-one
3-[4-[3-(4-methylphenoxy)-2-(tetradecyloxy)propoxy]benzyl]-1,2,4-oxadiazol-5(4H)-one
3-[4-[3-(decyloxy)-2-(tetradecyloxy)propoxy]benzyl]-1,2,4-oxadiazol-5(4H)-one
3-[4-[3-(diphenylmethoxy)-2-(tetradecyloxy)propoxy]benzyl]-1,2,4-oxadiazol-5(4H)-one
3-[4-[3-(pentyloxy)-2-(tetradecyloxy)propoxy]benzyl]-1,2,4-oxadiazol-5(4H)-one
3-[4-[3-ethoxy-2-(tetradecyloxy)propoxy]benzyl]-1,2,4-oxadiazol-5(4H)-one
3-[4-[hydroxyimino-(4'-n-butyl-phenyl)-methyl]-phenyl]-4-phenyl-sydnone
3-[4-[hydroxyimino-(4'-n-butyl-phenyl)-methyl]-phenyl]-sydnone
3-[4-[hydroxyimino-(4'-n-propyl-phenyl)-methyl]-phenyl]-4-phenylsydnone
3-[4-[hydroxyimino-(4'-n-propyl-phenyl)-methyl]-phenyl]-sydnone
4-(((2E)-4-(1-(diphenylmethyl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)but-2-en-1-yl)oxy)benzoic acid
-
-
4-(((2E)-4-(1-(diphenylmethyl)-6-fluoro-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)but-2-en-1-yl)oxy)benzoic acid
-
-
4-(((2E)-4-(3-(diphenylmethyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)but-2-en-1-yl)oxy)benzoic acid
-
-
4-(((2E)-4-(3-(diphenylmethyl)-2,4-dioxo-7-(1H-1,2,4-triazol-1-yl)-3,4-dihydroquinazolin-1(2H)-yl)but-2-en-1-yl)oxy)benzoic acid
-
-
4-(((2E)-4-(3-(diphenylmethyl)-2,4-dioxo-7-(phenylthio)-3,4-dihydroquinazolin-1(2H)-yl)but-2-en-1-yl)oxy)benzoic acid
-
-
4-(((2E)-4-(3-(diphenylmethyl)-2,4-dioxo-7-phenoxy-3,4-dihydroquinazolin-1(2H)-yl)but-2-en-1-yl)oxy)benzoic acid
-
-
4-(((2E)-4-(3-(diphenylmethyl)-2,4-dioxo-7-thiomorpholin-4-yl-3,4-dihydroquinazolin-1(2H)-yl)but-2-en-1-yl)oxy)benzoic acid
-
-
4-(((2E)-4-(3-(diphenylmethyl)-6-fluoro-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)but-2-en-1-yl)oxy)benzoic acid
-
-
4-(((2E)-4-(3-(diphenylmethyl)-7-(4-(methoxycarbonyl)piperidin-1-yl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)but-2-en-1-yl)oxy)benzoic acid
-
-
4-(((2E)-4-(3-(diphenylmethyl)-7-(methylsulfonyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)but-2-en-1-yl)oxy)benzoic acid
-
-
4-(((2E)-4-(3-(diphenylmethyl)-7-(methylthio)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)but-2-en-1-yl)oxy)benzoic acid
-
-
4-(((2E)-4-(3-(diphenylmethyl)-7-fluoro-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)but-2-en-1-yl)oxy)benzoic acid
-
-
4-(((2E)-4-(3-(diphenylmethyl)-7-methoxy-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)but-2-en-1-yl)oxy)benzoic acid
-
-
4-(((2E)-4-(3-(diphenylmethyl)-7-methyl-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)but-2-en-1-yl)oxy)benzoic acid
-
-
4-(((2E)-4-(3-(diphenylmethyl)-7-morpholin-4-yl-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)but-2-en-1-yl)oxy)benzoic acid
-
-
4-(((2E)-4-(3-(diphenylmethyl)-7-nitro-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)but-2-en-1-yl)oxy)benzoic acid
-
-
4-(((2E)-4-(6-chloro-3-(diphenylmethyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)but-2-en-1-yl)oxy)benzoic acid
-
-
4-(((2E)-4-(7-amino-3-(diphenylmethyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)but-2-en-1-yl)oxy)benzoic acid
-
-
4-(((2E)-4-(7-chloro-1-(diphenylmethyl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)but-2-en-1-yl)oxy)benzoic acid
-
-
4-(((2E)-4-(7-chloro-3-(diphenylmethyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)but-2-en-1-yl)oxy)benzoic acid
-
-
4-(((2E)-4-[1-(diphenylmethyl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl]but-2-en-1-yl)oxy)benzoic acid
-
-
4-(((2E)-4-[3-(diphenylmethyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]but-2-en-1-yl)oxy)benzoic acid
-
-
4-(((2E)-4-[3-(diphenylmethyl)-2,4-dioxo-7-(1H-1,2,4-triazol-1-yl)-3,4-dihydroquinazolin-1(2H)-yl]but-2-en-1-yl)oxy)benzoic acid
-
-
4-(((2E)-4-[3-(diphenylmethyl)-7-fluoro-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]but-2-en-1-yl)oxy)benzoic acid
-
-
4-(((2E)-4-[3-(diphenylmethyl)-7-methoxy-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]but-2-en-1-yl)oxy)benzoic acid
-
-
4-(((2E)-4-[3-(diphenylmethyl)-7-nitro-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]but-2-en-1-yl)oxy)benzoic acid
-
-
4-(((2E)-4-[7-chloro-3-(diphenylmethyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]but-2-en-1-yl)oxy)benzoic acid
-
-
4-(((2Z)-4-(1-(diphenylmethyl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)but-2-en-1-yl)oxy)benzoic acid
-
-
4-(((2Z)-4-(3-(diphenylmethyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)but-2-en-1-yl)oxy)benzoic acid
-
-
4-(((2Z)-4-(3-(diphenylmethyl)-6-fluoro-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)but-2-en-1-yl)oxy)benzoic acid
-
-
4-(((2Z)-4-(6-bromo-3-(diphenylmethyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)but-2-en-1-yl)oxy)benzoic acid
-
-
4-(((2Z)-4-(6-chloro-3-(diphenylmethyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)but-2-en-1-yl)oxy)benzoic acid
-
-
4-(((2Z)-4-(7-chloro-1-(diphenylmethyl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)but-2-en-1-yl)oxy)benzoic acid
-
-
4-(((2Z)-4-(7-chloro-3-(diphenylmethyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)but-2-en-1-yl)oxy)benzoic acid
-
-
4-(((E)-4-(3-benzhydryl-6-bromo-2,4-dioxo-3,4-dihydro-1(2H)-quinazolinyl)-2-butenyl)oxy)benzoic acid
-
-
4-((5-(3-(diphenylmethyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)pentyl)oxy)benzoic acid
-
-
4-((6-(3-(diphenylmethyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)hexyl)oxy)benzoic acid
-
-
4-((6-chloro-1-(diphenylmethyl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)methyl)benzoic acid
-
-
4-((7-(3-(diphenylmethyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)heptyl)oxy)benzoic acid
-
-
4-((7-chloro-1-(diphenylmethyl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)methyl)benzoic acid
-
-
4-(2,4-dioxothiazolidin-5-ylidenemethyl)-N-(4-[1-(4-fluorophenyl)-3-one-1H-isobenzofuran-1-yl]-2,5-dimethyl-1-phenylpyrrol-3-ylmethyl)benzamide
-
-
4-(2-(1-(diphenylmethyl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)ethoxy)benzoic acid
-
-
4-(2-(1-benzyl-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)ethoxy)benzoic acid
-
-
4-(2-(7-chloro-1-(diphenylmethyl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)ethoxy)benzoic acid
-
-
4-(2-(7-chloro-3-(diphenylmethyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)ethoxy)benzoic acid
-
-
4-(3-(3-(diphenylmethyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)propoxy)benzoic acid
-
-
4-(3-[1-(4-fluorophenyl)-3-oxo-1,3-dihydroisobenzofuran-1-yl]-2,5-dimethylpyrrol-1-yl)benzamide
-
42% inhibition at 0.033 mM
4-(3-[1-(4-fluorophenyl)-3-oxo-1,3-dihydroisobenzofuran-1-yl]-2,5-dimethylpyrrol-1-yl)benzoic acid
-
51% inhibition at 0.033 mM
4-(4-((3-(diphenylmethyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)methyl)phenoxy)butanoic acid
-
-
4-(4-(7-chloro-3-(diphenylmethyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)butoxy)benzoic acid
-
-
4-(4-benzyloxy-phenyl)-1,1,1-trifluoro-butan-2-one
-
-
4-(4-decyloxy-phenyl)-1,1,1-trifluoro-butan-2-one
-
-
4-([(2E)-4-[2-(2,2-diphenylethyl)-3,5-dioxo-1,2,4-oxadiazolidin-4-yl]but-2-en-1-yl]oxy)benzoate
-
-
4-([(2E)-4-[3-(diphenylmethyl)-2,4,6-trioxo-5-prop-2-en-1-yl-1,3,5-triazinan-1-yl]but-2-en-1-yl]oxy)benzoic acid
-
-
4-([(2E)-4-[3-(diphenylmethyl)-5-ethyl-2,4,6-trioxo-1,3,5-triazinan-1-yl]but-2-en-1-yl]oxy)benzoic acid
-
-
4-([(2E)-4-[3-benzyl-5-(diphenylmethyl)-2,4,6-trioxo-1,3,5-triazinan-1-yl]but-2-en-1-yl]oxy)benzoic acid
-
-
4-([(2E)-4-[3-butyl-5-(diphenylmethyl)-2,4,6-trioxo-1,3,5-triazinan-1-yl]but-2-en-1-yl]oxy)benzoic acid
-
-
4-([4-[2-(2,2-diphenylethyl)-3,5-dioxo-1,2,4-oxadiazolidin-4-yl]but-2-yn-1-yl]oxy)benzoate
-
-
4-[(2-oxohexadecanoyl)amino]butanoic acid
4-[2-aminoethyl]benzensulfonyl fluoride
-
pefabloc, inhibition of activity at 1 mM
4-[2-[2-(1-benzyl-2-phenylethyl)-3,5-dioxo-1,2,4-oxadiazolidin-4-yl]ethoxy]benzoate
-
-
4-[2-[2-(2,2-diphenylethyl)-3,5-dioxo-1,2,4-oxadiazolidin-4-yl]ethoxy]-2-hydroxybenzoate
-
-
4-[2-[2-(2,2-diphenylethyl)-3,5-dioxo-1,2,4-oxadiazolidin-4-yl]ethoxy]benzoate
-
-
4-[2-[2-(diphenylmethyl)-3,5-dioxo-1,2,4-oxadiazolidin-4-yl]ethoxy]benzoate
-
-
4-[2-[3-(2,2-diphenylethyl)-5-ethyl-2,4,6-trioxo-1,3,5-triazinan-1-yl]ethoxy]benzoic acid
-
-
4-[2-[3-(diphenylmethyl)-2,4,6-trioxo-5-phenyl-1,3,5-triazinan-1-yl]ethoxy]benzoic acid
-
-
4-[2-[3-(diphenylmethyl)-2,4,6-trioxo-5-prop-2-en-1-yl-1,3,5-triazinan-1-yl]ethoxy]benzoic acid
-
-
4-[2-[3-(diphenylmethyl)-5-ethyl-2,4,6-trioxo-1,3,5-triazinan-1-yl]ethoxy]benzoic acid
-
-
4-[2-[3-benzyl-5-(diphenylmethyl)-2,4,6-trioxo-1,3,5-triazinan-1-yl]ethoxy]benzoic acid
-
-
4-[2-[3-butyl-5-(diphenylmethyl)-2,4,6-trioxo-1,3,5-triazinan-1-yl]ethoxy]benzoic acid
-
-
4-[2-[5-chloro-1-(diphenylmethyl)-2-methyl-1H-indol-3-yl]ethoxy]benzoic acid
-
-
4-[2-[5-chloro-2-(2-[[(3,4-dichlorobenzyl)sulfonyl]amino]ethyl)-1-(diphenylmethyl)-1H-indol-3-yl]ethoxy]benzoic acid
-
-
4-[3-[2-(2,2-diphenylethyl)-3,5-dioxo-1,2,4-oxadiazolidin-4-yl]propoxy]benzoate
-
-
4-[3-[5-chloro-2-(2-[[(3,4-dichlorobenzyl)sulfonyl]amino]ethyl)-1-(diphenylmethyl)-1H-indol-3-yl]propyl]benzoic acid
-
-
4-[4-[2-(2,2-diphenylethyl)-3,5-dioxo-1,2,4-oxadiazolidin-4-yl]butoxy]benzoate
-
-
4-[4-[2-([2-[bis(4-chlorophenyl)methoxy]ethyl]sulfonyl)ethoxy]phenyl]-1,1,1-trifluorobutan-2-one
-
-
5,5'-dithiobis-(2-nitrobenzoic acid)
-
can be reversed by dithiothreitol
5,8,11,14-Eicosatetraynoic acid
5-(1-[3-(4-octylphenoxy)-2-oxopropyl]indol-5-ylmethylidene)thiazolidine-2,4-dione
-
inhibits isozyme cPLA2alpha
5-(4-[3-(1-[4-fluorophenyl]-3-oxo-1,3-dihydroisobenzofuran-1-yl)-2,5-dimethyl-pyrrol-1-yl]benzylidene)thiazolidine-2,4-dione
-
76% inhibition at 0.033 mM
5-[3-(4-octylphenoxy)-2-oxopropoxy]-1-propylindole-2-carboxylic acid
-
-
5-[3-(4-octylphenoxy)-2-oxopropoxy]indole-2-carboxylic acid
-
-
6-(4-decyloxy-phenyl)-1,1,1-trifluoro-hexan-2-one
-
-
6-[3-(4-oxo-4H-chromen-2-yl)phenyl]-2-phenyl-4H-chromen-4-one
slight inhibition
6-[4-(4-oxo-4H-chromen-2-yl)phenyl]-2-phenyl-4H-chromen-4-one
slight inhibition
7,7-dimethyl-5,8-eicosadienoic acid
-
-
7-chloro-6-[4-(diethylamino)phenyl]-5,8-quinolinedione
-
competitive inhibitor
7-hydroxy-2-oxo-N-[(4Z,7Z,10Z,13Z)-19,19,19-trifluoro-18-oxononadeca-4,7,10,13-tetraen-1-yl]-2H-chromene-3-carboxamide
-
9-oxo-9H-fluorene-3-carboxamide
-
inhibition of phospholipase A2 activity of cytotoxin ExoU
9H-carbazole-4-carboxamide
-
inhibition of phospholipase A2 activity of cytotoxin ExoU
9H-fluoren-4-ol
-
inhibition of phospholipase A2 activity of cytotoxin ExoU
9H-fluorene-4-carboxamide
-
inhibition of phospholipase A2 activity of cytotoxin ExoU
Acetic anhydride
-
loss of both enzymatic and toxic properties
acteoside
-
phenylethanoid glycoside isolated from Clerodendron trichotomum Thunberg, competitive. Acts on cytosolic Ca2+-dependent phospholipase A2 rather than secretory phospholipase A2
Ag+
-
plasmalogen-specific PLA2
AIPLAI
-
PLA2 inhibitor isolated from the methanol extract of Azadirachta indica
-
Al3+
-
can replace Ca2+, decreased activity
allyl 4-(2-oxohexadecanamido)butanoate
-
-
alpha-type phospholipase A2 inhibitor
-
i.e. PLIalpha, an about 75 kDa protein purified from the plasma of the Habu snake Protobothrop flavoviridis, a trimer of two homologous subunits, PLIalpha-A and PLIalpha-B, each of which contains one C-type lectin-like domain, subunit structure and inhibiton specificity, overview. The protein recovers from 6 M guanidine HCl treatment to about 33% inhibition of enzyme activity at 25°C
-
amentoflavone
slight inhibition
ankyrin-iPLA2s
iPLA2-splice variant, contributes to formation of the iPLA2-tetrameric complex but possesses no active site
-
annexin A2
-
phosphorylation of Ser727 disrupts the inhibitory cPLA2alpha-annexin A2-p11 heterotetramer interaction, as annexin A2 complex annexin A2-p11 heterotetramer
-
annexin A2-p11 heterotetramer
-
annexin A2-p11 heterotetramer inhibits cPLA2alpha by interacting with Ser727, phosphorylation of Ser727 disrupts the inhibitory cPLA2alpha-annexin A2-p11 heterotetramer interaction as annexin A2 complex annexin A2-p11 heterotetramer. annexin A2-p11 heterotetramer inhibition of cPLA2alpha is independent of Ser505 phosphorylation
-
arachidonoyl trifluoromethyl ketone
-
-
arachidonoyltrifluoromethyl ketone
-
-
arachidonyl trifluoromethyl ketone
arachidonyl trifluoromethylketone
-
causes inhibition to baseline level of gIVaPLA2 activity caused by IL-8/CXCL8
arachidonyltrifluoromethyl ketone
ATP
-
plasmalogen-specific PLA2
AX006
-
inhibits GIVA cPLA2
AX007
-
interacts with key residues that also exhibit changes in deuterium exchange upon inhibitor binding. Is bound mainly through contacts near the active site. Residues 481-495 and 543-553 exhibit an increase in exchange in the presence of the oxoamide, whereas 393-397 does not show any difference in exchange in the presence of the oxoamide in contrast to the inhibitor pyrrophenone
AX048
-
inhibits GIVA cPLA2 and GVIA iPLA2
AZ-1
cPLA2-alpha inhibitor, causes almost complete suppression of arachidonic acid release induced by various stimuli. Reduces by 70% the generation of platelet activating factor from macrophages
benzyl 4-(2-oxohexadecanamido)butanoate
-
-
Berberine
competitive inhibitor of phospholipase A2
biphenylene-1-carbonyl chloride
-
inhibition of phospholipase A2 activity of cytotoxin ExoU
bromoenollactone
-
is not specific for GVIA PLA2 and actually functions through activation of the inhibitor by GVIA PLA2 followed by nonspecific covalent modification of cysteine residues in all proximally located enzymes
bromophenacyl bromide
specific sPLA2 inhibitor
CaCl2
-
1 mM, residual activity 82.1%
Calmodulin
-
GVIA PLA2 is regulated by calmodulin which negatively regulates GVIA PLA2 through direct binding on the residues 694-705 of GVIA-1 PLA2
catechin
-
reaches 50% inhibition at concentrations of 2.5 mM
Cdcas F3
-
a crotapotin
-
Cdcas F4
-
a crotapotin
-
Cdcoll F3
-
a crotapotin
-
Cdcoll F4
-
a crotapotin
-
cholate
bile salt regulation of lipid metabolism via both activation and inhibition of PLA2, interaction and binding structure analysis, overview
chondroitin sulfate
-
plasmalogen-specific PLA2
citrate
-
plasmalogen-specific PLA2
Co2+
-
can replace Ca2+, decreased activity
Cowper's gland mucin
-
plasmalogen-specific PLA2
-
cyanidin
-
mixed competitive and noncompetitive inhibition, partial hyperbolic type of inhibition
cyproheptadine
-
at a dose of 5 mg inhibits 82% promutoxin elicited microvascular leakage
delphinidin
-
mixed competitive and noncompetitive inhibition, complete inhibition
deoxycholate
-
substrate: phosphatidylcholine
diethyl 4-nitrophenyl phosphate
Diethyl p-nitrophenyl phosphate
diisopropyl fluorophosphate
DNA containing thymine glycol
-
i.e. MAFP, a specific PLA2 inhibitor
-
ethyl (2E,4S)-4-[(2-oxohexadecanoyl)amino]oct-2-enoate
-
reduces the cellular release of arachidonic acid by 16%
ethyl 2-(2-oxohexadecanamido)acetate
-
-
ethyl 3-(2-oxohexadecanamido)propanoate
-
-
ethyl 4-(2-oxohexadecanamido)benzoate
-
-
ethyl 4-[(2-oxohexadecanoyl)amino]butanoate
-
-
ethyl 5-(2-oxohexadecanamido)pentanoate
-
-
Fe3+
-
plasmalogen-specific PLA2
fetuin
-
plasmalogen-specific PLA2
-
FPL67047XX
used as a prototype structure with a binding energy of -18.96 kJ/mol
gallic acid
inhibitory in micromolar concentrations
ganglioside GM1
-
plasmalogen-specific PLA2
ganglioside GM3
-
plasmalogen-specific PLA2
genistein
-
inhibits sPLA(2) enzymes of inflammatory exudates in a concentration dependent manner. Increasing the Ca2+ concentration from 2.5 to 15 mM and substrate concentration up to 0.000120 mM does not alter the level of inhibition
ginkgolide B
-
ginkgolide B at a dose of 5 mg inhibits 31% microvascular leakage induced by promutoxin when they are coinjected
giripladib
i.e. Wyeth-2, the inhibition of phospholipase A2alpha reduces platelet adhesion and accumulation on collagen, it inhibits cPLA2alpha-mediated release of arachidonic acid from glycerophospholipid sources; inhibitor, reduces platelet adhesion and accumulation on collagen. Giripladib differentially affects P-selectin expression and GPIIbIIIa activation depending on the agonist employed. The levels of PAR4- and GPVI-mediated platelet activation are significantly reduced
glycochenodeoxycholate
bile salt regulation of lipid metabolism via both activation and inhibition of PLA2, interaction and binding structure analysis, overview
glycocholate
bile salt regulation of lipid metabolism via both activation and inhibition of PLA2, interaction and binding structure analysis, overview
heparan sulfate
-
plasmalogen-specific PLA2
hexadecyl-3-trifluorethylglycero-sn-2-phospho-methanol
hyaluronic acid
-
plasmalogen-specific PLA2
indole-5-carboxamide
-
inhibits isozyme cPLA2alpha
indole-5-carboxylic acid
-
inhibits isozyme cPLA2alpha
iodoacetate
-
plasmalogen-specific PLA2
lysophosphatidylcholines
-
inhibitory plasma compounds, profile determination by mass spectroscopy, overview
malvidin
-
partial competitive inhibition
methyl 2-(2-oxo-8-phenyloctanamido)acetate
-
-
methyl 2-(2-oxohexadecanamido)acetate
-
-
methyl 2-(7-phenylheptanamido)acetate
-
-
methyl 3-(2-oxohexadecanamido)propanoate
-
-
methyl 5-(2-oxohexadecanamido)pentanoate
-
-
methyl 9H-fluorene-4-carboxylate
-
inhibition of phospholipase A2 activity of cytotoxin ExoU
methyl arachidonyl fluorophosphate
-
i.e. MAFP, an inhibitor of cysteine-dependent phospholipases
methyl arachidonyl fluorophosphonate
methyl arachidonyl-fluorophosphonate
-
-
methyl N-(2-oxohexadecanoyl)glycinate
-
reduces the cellular release of arachidonic acid by 30%
methyl [1-[2-oxo-3-(4-phenoxyphenoxy)propyl]-1H-indazol-5-yl]carbamate
-
-
methyl-4-nitrophenyl-octylphosphonate
-
inactivates at 100fold molar excess
methyl-arachidonyl fluorophosphonate
an irreversible inhibitor
methyl-arachidonylfluorophosphonate
-
irreversible inhibitor of cPLA2 and iPLA2. Ser214 site in microtubule-associated protein Tau is hyperphosphorylated upon inhibitor treatment
methylarachidonyl fluorophosphonate
-
inhibits release of [3H]arachidonic acid by a 0.01 mM concentration
MgCl2
-
1 mM, residual activity 71.6%
minocycline
interferes with the conformation of the active-site Ca2+-binding loop, preventing Ca2+ binding, and shields the active site from substrate entrance, resulting in inhibition of the enzyme. Dissociation constant for PLA2 is Kd = 0.00018 M
MJ33
i.e. 1-hexadecyl-3-(trifluoroethyl)-rac-glycero-2-phosphomethanol, an active-site-directed tetrahedral mimic
mucin
-
plasmalogen-specific PLA2
-
N,N-dimethyl-1-[3-(4-octylphenoxy)-2-oxopropyl]indole-5-carboxamide
-
inhibits isozyme cPLA2alpha
N,N-dimethyl-1-[3-(4-octylphenoxy)-2-oxopropyl]indole-5-sulfonamide
-
inhibits isozyme cPLA2alpha
N,N-dimethyl-9H-fluorene-4-carboxamide
-
inhibition of phospholipase A2 activity of cytotoxin ExoU
N-(2-oxododecanoyl)-L-norleucine
-
reduces the cellular release of arachidonic acid by 21%
N-(4-amylcinnamoyl) anthranilic acid
-
i.e. 12-hydroperoxy-5Z,8Z,10E,14Zeicosatetraenoic acid
N-(4-ethoxybutyl)-2-oxohexadecanamide
-
-
N-(4-[3-(1-(4-fluorophenyl)3-oxo-1,3-dihydroisobenzofuran-1-yl)-2,5-dimethylpyrrol-1-yl]phenyl)acetamide
-
35% inhibition at 0.033 mM
N-(cyclopent-1-en-1-yl)pyrrolidine
ccPLA2-alpha inhibitor, causes almost complete suppression of arachidonic acid release induced by various stimuli. Reduces by 70% the generation of platelet activating factor from macrophages
N-9H-fluoren-2-ylformamide
-
inhibition of phospholipase A2 activity of cytotoxin ExoU
N-9H-fluoren-4-ylacetamide
-
inhibition of phospholipase A2 activity of cytotoxin ExoU
N-acetylneuraminic acid
-
plasmalogen-specific PLA2
N-alpha-p-tosyl-L-lysine chloromethyl ketone
-
-
N-cyclohexyl-N'-[1-[2-oxo-3-(4-phenoxyphenoxy)propyl]-1H-indazol-5-yl]urea
-
-
N-dodecyl-N,N-dimethyl-3-aminopropanesulfonate
-
-
N-ethyl-N'-[1-[2-oxo-3-(4-phenoxyphenoxy)propyl]-1H-indazol-5-yl]urea
-
-
N-methyl-1-[3-(4-octylphenoxy)-2-oxopropyl]indole-5-carboxamide
-
inhibits isozyme cPLA2alpha
N-methyl-1-[3-(4-octylphenoxy)-2-oxopropyl]indole-5-sulfonamide
-
inhibits isozyme cPLA2alpha
N-phenyl-9H-fluorene-4-carboxamide
-
inhibition of phospholipase A2 activity of cytotoxin ExoU
N-tetradecyl-N,N-dimethyl-3-aminopropanesulfonate
-
-
N-tosyl-L-phenylalanyl chloromethyl ketone
-
-
N-[1-[2-oxo-3-(4-phenoxyphenoxy)propyl]-1H-indazol-5-yl]acetamide
-
-
N-[[(2S,4R)-1-([2-[(2,4-difluorophenyl)carbonyl]phenyl]carbonyl)-4-(tritylsulfanyl)pyrrolidin-2-yl]methyl]-4-[(Z)-(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]benzamide
-
-
naringin
-
the enzymatic activity of native secretory phospholipase A2 is virtually abolished by treatment with naringin
nordihydroguaiaretic acid
-
-
o-nitrophenylsulfonyl chloride
Bothrops spp.
-
BthTX-I: myotoxic activity reduced to 65% and the cytotoxic activity reduced to 58%
ochnaflavone
slight inhibition
octylglucoside
-
plasmalogen-specific PLA2
omega-bromo-4-nitroacetophenone
palmitoyl lysophosphatidylcholines
-
competitive product inhibition
-
palmitoyltrifluoromethyl ketone
-
-
pelargonidin
-
mixed competitive and noncompetitive inhibition, complete inhibition
peonidin
-
mixed competitive and noncompetitive inhibition, partial hyperbolic type of inhibition
Peptide inhibitor
-
purified from Habu serum, 100000 Da, heat stable, stable in neutral and basic medium
-
pertussis toxin
-
inhibits dramatically promutoxin-induced histamine release from colon mast cells, but has less effect on promutoxin-induced histamine release from lung cells
-
petrosaspongiolide M
an anti-inflammatory marine natural product, mechanism of sPLA2-IIA inactivation, overview
petunidin
-
mixed competitive and noncompetitive inhibition, partial hyperbolic type of inhibition
phenyl [1-[2-oxo-3-(4-phenoxyphenoxy)propyl]-1H-indazol-5-yl]carbamate
-
-
phenylmethylsulfonyl fluoride
phosphate
-
plasmalogen-specific PLA2
protein p11
-
phosphorylation of Ser727 disrupts the inhibitory cPLA2alpha-annexin A2-p11 heterotetramer interaction as annexin A2 complex annexin A2-p11 heterotetramer
-
pseudolipasin A
-
a specific inhibitor for phospholipase A2 activity of cytotoxin ExoU
pure phospholipid vesicles
-
exception: vesicles composed of phosphatidylcholine or phosphatidylinositol 4,5-bisphosphate
-
pyrroxyphene
-
significantly inhibits both the increase in levels of cPLA2 alpha and eicosanoids as well as the mRNA expression of matrix metalloproteinase-3, -8, -9, -13, and cyclooxygenase-2. Strongly inhibits the incidence of arthritis and bone destruction
quercetin-3-beta-D-glucoside
-
Rose bengal
Bothrops spp.
-
BthTX-I: myotoxic activity reduced to 20% and the cytotoxic activity reduced to 0.5%
SB480848
-
darapladib, completely inhibits lp-PLA2 enzyme activity in the whole culture media of THP-1 cells with 0.0001 mM
sodium 2-(1-benzyl-2-ethyl)-3-oxamoylindol-4-yl oxyacetate
-
varespladib sodium or LY315920, most potent sPLA2 inhibitor
stearoyl lysophosphatidylcholines
-
competitive product inhibition
-
sulfate
-
plasmalogen-specific PLA2
suramin
the C-terminal region of the enzyme is crucial to the stabilization of the complex with suramin and consequently is a major structural determinant of the inhibitory action of suramin
syringic acid
inhibitory in micromolar concentrations
taurochenodeoxycholate
bile salt regulation of lipid metabolism via both activation and inhibition of PLA2, interaction and binding structure analysis, overview
terfenadine
-
at a dose of 5 mg inhibits 67% promutoxin elicited microvascular leakage
tert-butyl ([3-[amino(oxo)acetyl]-1-benzyl-2-(2-methylpropyl)-1H-indol-4-yl]oxy)acetate
tert-butyl 2-(2-oxohexadecanamido)acetate
-
-
tert-butyl 3-(2-oxo-8-phenyloctanamido)propanoate
-
-
tert-butyl 3-(2-oxohexadecanamido)propanoate
-
-
tert-butyl 3-(7-phenylheptanamido)propanoate
-
-
tert-butyl 5-(2-oxohexadecanamido)pentanoate
-
-
tert-butyl 5-[(2-oxohexadecanoyl)amino]pentanoate
-
reduces the cellular release of arachidonic acid by 11%
tetrahydro-3-(1-naphthalenyl)-2H-pyran-2-one
-
-
thioetheramide phosphatidylcholine
-
exhibits complete competitive inhibition
turmerin
-
inhibits the enzymatic activity and neutralises the pharmacological properties, such as cytotoxicity, oedema and myotoxicity of multitoxic phospholipase A2 of cobra venom in a dose-dependent manner, at a 1:2.5 molar ratio of PLA2:turmerin
vanillic acid
inhibitory in micromolar concentrations
Withania somnifera glycoprotein WSG
-
in molar ratio of 1:2, enzyme:WSG, complete inhibition of activity, but not neutralization of toxicity
-
ZnCl2
-
1 mM, no residual activity
(+-)-3-O-[4-(4,5-dihydro-5-oxo-1,2,4-4H-oxadiazol-3-yl)phenyl]-2-O-tetradecyl-1-O-triphenylmethylglycerol
-
-
(+-)-3-O-[4-(4,5-dihydro-5-oxo-1,2,4-4H-oxadiazol-3-yl)phenyl]-2-O-tetradecyl-1-O-triphenylmethylglycerol
-
-
(6Z,9Z,12Z,15Z)-1,1,1-trifluorohenicosa-6,9,12,15-tetraen-2-one
-
(6Z,9Z,12Z,15Z)-1,1,1-trifluorohenicosa-6,9,12,15-tetraen-2-one
-
arachidonic acid with the COOH group replaced by COCF3, i.e. AACOCF3
(6Z,9Z,12Z,15Z)-1,1,1-trifluorohenicosa-6,9,12,15-tetraen-2-one
-
-
([1-[amino(oxo)acetyl]-3-(biphenyl-2-ylmethyl)-2-(2-methylpropyl)indolizin-8-yl]oxy)acetic acid
-
-
([1-[amino(oxo)acetyl]-3-(biphenyl-2-ylmethyl)-2-(2-methylpropyl)indolizin-8-yl]oxy)acetic acid
-
-
([3-[amino(oxo)acetyl]-1-benzyl-2-(2-methylpropyl)-1H-benzo[g]indol-4-yl]oxy)acetic acid
-
-
([3-[amino(oxo)acetyl]-1-benzyl-2-(2-methylpropyl)-1H-benzo[g]indol-4-yl]oxy)acetic acid
-
-
1,2-Didecanoin
-
inhibition below the normal cutoff pressure of PLA2
1,2-Didecanoin
-
inhibition below the normal cutoff pressure of PLA2
1-hexadecyl-3-trifluoroethylglycero-sn-2-phosphomethanol
-
MJ33, competitive inhibitor
1-hexadecyl-3-trifluoroethylglycero-sn-2-phosphomethanol
-
MJ33, competitive inhibitor
1-hexadecyl-3-trifluoroethylglycero-sn-2-phosphomethanol
-
MJ33, competitive inhibitor
1-hexadecyl-3-trifluoroethylglycero-sn-2-phosphomethanol
-
MJ33, competitive inhibitor
1-hexadecyl-3-trifluoroethylglycero-sn-2-phosphomethanol
-
MJ33, competitive inhibitor
1-palmitylthio-2-palmitoylamido-1,2-dideoxy-sn-glycero-3-phosphorylcholine
-
competitive inhibitor toward sPLA2, dose-dependent inhibition
1-palmitylthio-2-palmitoylamido-1,2-dideoxy-sn-glycero-3-phosphorylcholine
-
competitive inhibitor toward recombinant sPLA2, dose-dependent inhibition
2-(1-benzyl-2-ethyl-4-methoxy-1H-benzo[g]indol-3-yl)-2-oxoacetamide
-
-
2-(1-benzyl-2-ethyl-4-methoxy-1H-benzo[g]indol-3-yl)-2-oxoacetamide
-
-
2-(3-(2-amino-2-oxoacetyl)-1-benzyl-2-ethyl-1H-6,7-benzoindol-4-yloxy)acetic acid
-
-
2-(3-(2-amino-2-oxoacetyl)-1-benzyl-2-ethyl-1H-6,7-benzoindol-4-yloxy)acetic acid
-
-
2-([3-[amino(oxo)acetyl]-1-benzyl-2-(2-methylpropyl)-1H-benzo[g]indol-4-yl]oxy)-N-(phenylsulfonyl)acetamide
-
-
2-([3-[amino(oxo)acetyl]-1-benzyl-2-(2-methylpropyl)-1H-benzo[g]indol-4-yl]oxy)-N-(phenylsulfonyl)acetamide
-
-
2-([3-[amino(oxo)acetyl]-1-benzyl-2-(2-methylpropyl)-1H-indol-4-yl]oxy)-N-(phenylsulfonyl)acetamide
-
-
2-([3-[amino(oxo)acetyl]-1-benzyl-2-(2-methylpropyl)-1H-indol-4-yl]oxy)-N-(phenylsulfonyl)acetamide
-
-
2-([3-[amino(oxo)acetyl]-1-benzyl-2-ethyl-1H-benzo[g]indol-4-yl]oxy)-N-(phenylsulfonyl)acetamide
-
-
2-([3-[amino(oxo)acetyl]-1-benzyl-2-ethyl-1H-benzo[g]indol-4-yl]oxy)-N-(phenylsulfonyl)acetamide
-
-
2-([3-[amino(oxo)acetyl]-1-benzyl-2-ethyl-1H-indol-4-yl]oxy)-N-(phenylsulfonyl)acetamide
-
-
2-([3-[amino(oxo)acetyl]-1-benzyl-2-ethyl-1H-indol-4-yl]oxy)-N-(phenylsulfonyl)acetamide
-
-
2-mercaptoethanol
-
-
2-[1-benzyl-2-(2-methylpropyl)-4-(2-oxopropoxy)-1H-indol-3-yl]-2-oxoacetamide
-
-
2-[1-benzyl-2-(2-methylpropyl)-4-(2-oxopropoxy)-1H-indol-3-yl]-2-oxoacetamide
-
-
2-[1-benzyl-4-(2-oxopropoxy)-2-propyl-1H-indol-3-yl]-2-oxoacetamide
-
-
2-[1-benzyl-4-(2-oxopropoxy)-2-propyl-1H-indol-3-yl]-2-oxoacetamide
-
-
2-[3-(biphenyl-2-ylmethyl)-2-ethyl-8-(2-oxopropoxy)indolizin-1-yl]-2-oxoacetamide
-
-
2-[3-(biphenyl-2-ylmethyl)-2-ethyl-8-(2-oxopropoxy)indolizin-1-yl]-2-oxoacetamide
-
-
2-[3-(biphenyl-2-ylmethyl)-2-ethyl-8-methoxyindolizin-1-yl]-2-oxoacetamide
-
-
2-[3-(biphenyl-2-ylmethyl)-2-ethyl-8-methoxyindolizin-1-yl]-2-oxoacetamide
-
-
3,3'-[[2-(pentyloxy)propane-1,3-diyl]bis(oxybenzene-4,1-diylethane-2,1-diyl)]bis(1,2,4-oxadiazol-5(4H)-one)
-
-
3,3'-[[2-(pentyloxy)propane-1,3-diyl]bis(oxybenzene-4,1-diylethane-2,1-diyl)]bis(1,2,4-oxadiazol-5(4H)-one)
-
-
3,3'-[[2-(tetradecyloxy)propane-1,3-diyl]bis(oxybenzene-4,1-diylethane-2,1-diyl)]bis(1,2,4-oxadiazol-5(4H)-one)
-
-
3,3'-[[2-(tetradecyloxy)propane-1,3-diyl]bis(oxybenzene-4,1-diylethane-2,1-diyl)]bis(1,2,4-oxadiazol-5(4H)-one)
-
-
3,3'-[[2-(tetradecyloxy)propane-1,3-diyl]bis(oxybenzene-4,1-diylmethanediyl)]bis(1,2,4-oxadiazol-5(4H)-one)
-
-
3,3'-[[2-(tetradecyloxy)propane-1,3-diyl]bis(oxybenzene-4,1-diylmethanediyl)]bis(1,2,4-oxadiazol-5(4H)-one)
-
-
3,3'-[[3-(tetradecyloxy)propane-1,2-diyl]bis(oxybenzene-4,1-diylethane-2,1-diyl)]bis(1,2,4-oxadiazol-5(4H)-one)
-
-
3,3'-[[3-(tetradecyloxy)propane-1,2-diyl]bis(oxybenzene-4,1-diylethane-2,1-diyl)]bis(1,2,4-oxadiazol-5(4H)-one)
-
-
3,3'-[[3-(tetradecyloxy)propane-1,2-diyl]bis(oxybenzene-4,1-diylmethanediyl)]bis(1,2,4-oxadiazol-5(4H)-one)
-
-
3,3'-[[3-(tetradecyloxy)propane-1,2-diyl]bis(oxybenzene-4,1-diylmethanediyl)]bis(1,2,4-oxadiazol-5(4H)-one)
-
-
3,4-dichloroisocoumarin
-
-
3,4-dichloroisocoumarin
-
-
3,5-Dibromosalicylate
-
inhibition below the normal cutoff pressure of PLA2
3,5-Dibromosalicylate
-
inhibition below the normal cutoff pressure of PLA2
3,5-diiodosalicylate
-
inhibition below the normal cutoff pressure of PLA2
3,5-diiodosalicylate
-
inhibition below the normal cutoff pressure of PLA2
3-(2-[4-[(4-tetradecylpiperazin-1-yl)carbonyl]phenyl]ethyl)-1,2,4-oxadiazol-5(4H)-one
-
-
3-(2-[4-[(4-tetradecylpiperazin-1-yl)carbonyl]phenyl]ethyl)-1,2,4-oxadiazol-5(4H)-one
-
-
3-(3-[4-[(4-tetradecylpiperazin-1-yl)carbonyl]phenyl]propyl)-1,2,4-oxadiazol-5(4H)-one
-
-
3-(3-[4-[(4-tetradecylpiperazin-1-yl)carbonyl]phenyl]propyl)-1,2,4-oxadiazol-5(4H)-one
-
-
3-[4'-(hydroxyimino-p-tolyl-methyl)-phenyl]-4-phenyl-sydnone
-
in vivo edema inducing activity, overview
3-[4'-(hydroxyimino-p-tolyl-methyl)-phenyl]-4-phenyl-sydnone
-
in vivo edema inducing activity, overview
3-[4'-(hydroxyimino-p-tolyl-methyl)-phenyl]-4-phenyl-sydnone
-
in vivo edema inducing activity, overview
3-[4'-(hydroxyimino-p-tolyl-methyl)-phenyl]-sydnone
-
in vivo edema inducing activity, overview
3-[4'-(hydroxyimino-p-tolyl-methyl)-phenyl]-sydnone
-
in vivo edema inducing activity, overview
3-[4'-(hydroxyimino-p-tolyl-methyl)-phenyl]-sydnone
-
in vivo edema inducing activity, overview
3-[4'-(hydroxyimino-phenyl-methyl)-phenyl]-4-phenyl-sydnone
-
in vivo edema inducing activity, overview
3-[4'-(hydroxyimino-phenyl-methyl)-phenyl]-4-phenyl-sydnone
-
in vivo edema inducing activity, overview
3-[4'-(hydroxyimino-phenyl-methyl)-phenyl]-4-phenyl-sydnone
-
in vivo edema inducing activity, overview
3-[4'-(hydroxyimino-phenyl-methyl)-phenyl]-sydnone
-
in vivo edema inducing activity, overview
3-[4'-(hydroxyimino-phenyl-methyl)-phenyl]-sydnone
-
in vivo edema inducing activity, overview
3-[4'-(hydroxyimino-phenyl-methyl)-phenyl]-sydnone
-
in vivo edema inducing activity, overview
3-[4-(4-hexadecylpiperazin-1-yl)benzyl]-1,2,4-oxadiazol-5(4H)-one
-
-
3-[4-(4-hexadecylpiperazin-1-yl)benzyl]-1,2,4-oxadiazol-5(4H)-one
-
-
3-[4-(4-octadecylpiperazin-1-yl)benzyl]-1,2,4-oxadiazol-5(4H)-one
-
-
3-[4-(4-octadecylpiperazin-1-yl)benzyl]-1,2,4-oxadiazol-5(4H)-one
-
-
3-[4-(4-tetradecylpiperazin-1-yl)benzyl]-1,2,4-oxadiazol-5(4H)-one
-
-
3-[4-(4-tetradecylpiperazin-1-yl)benzyl]-1,2,4-oxadiazol-5(4H)-one
-
-
3-[4-(tetradecyloxy)benzyl]-1,2,4-oxadiazol-5(4H)-one
-
-
3-[4-(tetradecyloxy)benzyl]-1,2,4-oxadiazol-5(4H)-one
-
-
3-[4-[(4-docosylpiperazin-1-yl)carbonyl]benzyl]-1,2,4-oxadiazol-5(4H)-one
-
-
3-[4-[(4-docosylpiperazin-1-yl)carbonyl]benzyl]-1,2,4-oxadiazol-5(4H)-one
-
-
3-[4-[(4-hexadecylpiperazin-1-yl)carbonyl]benzyl]-1,2,4-oxadiazol-5(4H)-one
-
-
3-[4-[(4-hexadecylpiperazin-1-yl)carbonyl]benzyl]-1,2,4-oxadiazol-5(4H)-one
-
-
3-[4-[(4-hexadecylpiperazin-1-yl)carbonyl]phenyl]-1,2,4-oxadiazol-5(4H)-one
-
-
3-[4-[(4-hexadecylpiperazin-1-yl)carbonyl]phenyl]-1,2,4-oxadiazol-5(4H)-one
-
-
3-[4-[(4-hexadecylpiperazin-1-yl)methyl]benzyl]-1,2,4-oxadiazol-5(4H)-one
-
-
3-[4-[(4-hexadecylpiperazin-1-yl)methyl]benzyl]-1,2,4-oxadiazol-5(4H)-one
-
-
3-[4-[(4-hexadecylpiperazin-1-yl)methyl]phenyl]-1,2,4-oxadiazol-5(4H)-one
-
-
3-[4-[(4-hexadecylpiperazin-1-yl)methyl]phenyl]-1,2,4-oxadiazol-5(4H)-one
-
-
3-[4-[(4-icosylpiperazin-1-yl)carbonyl]benzyl]-1,2,4-oxadiazol-5(4H)-one
-
-
3-[4-[(4-icosylpiperazin-1-yl)carbonyl]benzyl]-1,2,4-oxadiazol-5(4H)-one
-
-
3-[4-[(4-octadecylpiperazin-1-yl)carbonyl]benzyl]-1,2,4-oxadiazol-5(4H)-one
-
-
3-[4-[(4-octadecylpiperazin-1-yl)carbonyl]benzyl]-1,2,4-oxadiazol-5(4H)-one
-
-
3-[4-[(4-octadecylpiperazin-1-yl)carbonyl]phenyl]-1,2,4-oxadiazol-5(4H)-one
-
-
3-[4-[(4-octadecylpiperazin-1-yl)carbonyl]phenyl]-1,2,4-oxadiazol-5(4H)-one
-
-
3-[4-[(4-octadecylpiperazin-1-yl)methyl]benzyl]-1,2,4-oxadiazol-5(4H)-one
-
-
3-[4-[(4-octadecylpiperazin-1-yl)methyl]benzyl]-1,2,4-oxadiazol-5(4H)-one
-
-
3-[4-[(4-octadecylpiperazin-1-yl)methyl]phenyl]-1,2,4-oxadiazol-5(4H)-one
-
-
3-[4-[(4-octadecylpiperazin-1-yl)methyl]phenyl]-1,2,4-oxadiazol-5(4H)-one
-
-
3-[4-[(4-tetradecylpiperazin-1-yl)carbonyl]benzyl]-1,2,4-oxadiazol-5(4H)-one
-
-
3-[4-[(4-tetradecylpiperazin-1-yl)carbonyl]benzyl]-1,2,4-oxadiazol-5(4H)-one
-
-
3-[4-[(4-tetradecylpiperazin-1-yl)carbonyl]phenyl]-1,2,4-oxadiazol-5(4H)-one
-
-
3-[4-[(4-tetradecylpiperazin-1-yl)carbonyl]phenyl]-1,2,4-oxadiazol-5(4H)-one
-
-
3-[4-[(4-tetradecylpiperazin-1-yl)methyl]benzyl]-1,2,4-oxadiazol-5(4H)-one
-
-
3-[4-[(4-tetradecylpiperazin-1-yl)methyl]benzyl]-1,2,4-oxadiazol-5(4H)-one
-
-
3-[4-[(4-tetradecylpiperazin-1-yl)methyl]phenyl]-1,2,4-oxadiazol-5(4H)-one
-
-
3-[4-[(4-tetradecylpiperazin-1-yl)methyl]phenyl]-1,2,4-oxadiazol-5(4H)-one
-
-
3-[4-[3-(4-butylphenoxy)-2-(tetradecyloxy)propoxy]benzyl]-1,2,4-oxadiazol-5(4H)-one
-
-
3-[4-[3-(4-butylphenoxy)-2-(tetradecyloxy)propoxy]benzyl]-1,2,4-oxadiazol-5(4H)-one
-
-
3-[4-[3-(4-methylphenoxy)-2-(tetradecyloxy)propoxy]benzyl]-1,2,4-oxadiazol-5(4H)-one
-
-
3-[4-[3-(4-methylphenoxy)-2-(tetradecyloxy)propoxy]benzyl]-1,2,4-oxadiazol-5(4H)-one
-
-
3-[4-[3-(decyloxy)-2-(tetradecyloxy)propoxy]benzyl]-1,2,4-oxadiazol-5(4H)-one
-
-
3-[4-[3-(decyloxy)-2-(tetradecyloxy)propoxy]benzyl]-1,2,4-oxadiazol-5(4H)-one
-
-
3-[4-[3-(diphenylmethoxy)-2-(tetradecyloxy)propoxy]benzyl]-1,2,4-oxadiazol-5(4H)-one
-
-
3-[4-[3-(diphenylmethoxy)-2-(tetradecyloxy)propoxy]benzyl]-1,2,4-oxadiazol-5(4H)-one
-
-
3-[4-[3-(pentyloxy)-2-(tetradecyloxy)propoxy]benzyl]-1,2,4-oxadiazol-5(4H)-one
-
-
3-[4-[3-(pentyloxy)-2-(tetradecyloxy)propoxy]benzyl]-1,2,4-oxadiazol-5(4H)-one
-
-
3-[4-[3-ethoxy-2-(tetradecyloxy)propoxy]benzyl]-1,2,4-oxadiazol-5(4H)-one
-
-
3-[4-[3-ethoxy-2-(tetradecyloxy)propoxy]benzyl]-1,2,4-oxadiazol-5(4H)-one
-
-
3-[4-[hydroxyimino-(4'-n-butyl-phenyl)-methyl]-phenyl]-4-phenyl-sydnone
-
in vivo edema inducing activity, overview
3-[4-[hydroxyimino-(4'-n-butyl-phenyl)-methyl]-phenyl]-4-phenyl-sydnone
-
in vivo edema inducing activity, overview
3-[4-[hydroxyimino-(4'-n-butyl-phenyl)-methyl]-phenyl]-4-phenyl-sydnone
-
in vivo edema inducing activity, overview
3-[4-[hydroxyimino-(4'-n-butyl-phenyl)-methyl]-phenyl]-sydnone
-
in vivo edema inducing activity, overview
3-[4-[hydroxyimino-(4'-n-butyl-phenyl)-methyl]-phenyl]-sydnone
-
in vivo edema inducing activity, overview
3-[4-[hydroxyimino-(4'-n-butyl-phenyl)-methyl]-phenyl]-sydnone
-
in vivo edema inducing activity, overview
3-[4-[hydroxyimino-(4'-n-propyl-phenyl)-methyl]-phenyl]-4-phenylsydnone
-
in vivo edema inducing activity, overview
3-[4-[hydroxyimino-(4'-n-propyl-phenyl)-methyl]-phenyl]-4-phenylsydnone
-
in vivo edema inducing activity, overview
3-[4-[hydroxyimino-(4'-n-propyl-phenyl)-methyl]-phenyl]-4-phenylsydnone
-
in vivo edema inducing activity, overview
3-[4-[hydroxyimino-(4'-n-propyl-phenyl)-methyl]-phenyl]-sydnone
-
in vivo edema inducing activity, overview
3-[4-[hydroxyimino-(4'-n-propyl-phenyl)-methyl]-phenyl]-sydnone
-
in vivo edema inducing activity, overview
3-[4-[hydroxyimino-(4'-n-propyl-phenyl)-methyl]-phenyl]-sydnone
-
in vivo edema inducing activity, overview
4-bromophenacyl bromide
-
1.8 mM, prevents myotoxicity caused by the enzyme
4-bromophenacyl bromide
-
suppresses anticoagulant activity, indirect haemolytic activity and inhibition of platelet aggregation, does not inhibit the induction of edema
4-bromophenacyl bromide
Bothrops spp.
-
BthTX-II: loses most of its catalytic, indirect haemolytic, anticoagulant, myotoxic and cytotoxic activity, BthTX-I: myotoxic activity reduced to 50% and the cytotoxic activity reduced to 13%
4-bromophenacyl bromide
-
4-bromophenacyl bromide treatment irreversibly abolishes the neurotoxic effect induced by secretory phospholipase A2
4-bromophenacyl bromide
-
-
4-bromophenacyl bromide
alkylation with 4-bromophenacyl bromide leads to the complete loss of its enzymatic activity signifying the crucial role of histidine residue in catalysis
4-bromophenacyl bromide
-
inhibits activity
4-bromophenacyl bromide
-
abolishes inhibitory effect upon collagen- and ADP-induced platelet aggregation and the edematogenic effect
4-bromophenacyl bromide
-
enzymatic activity of bromophenacylated PLA2 is approximate 0.06% of that of PLA2
4-bromophenacyl bromide
selectively and irreversibly modifies the His48 residue in the active site
4-bromophenacyl bromide
complete inactivation
4-[(2-oxohexadecanoyl)amino]butanoic acid
-
-
4-[(2-oxohexadecanoyl)amino]butanoic acid
-
reduces the cellular release of arachidonic acid by 52%
5,8,11,14-Eicosatetraynoic acid
-
-
5,8,11,14-Eicosatetraynoic acid
-
-
AACOCF3
-
significantly inhibits IL-1beta-stimulated prostaglandin E2 synthesis
AACOCF3
-
PLA2 inhibitor, does not affect basal Mn2+ entry, but strongly reduces the enhanced Mn2+ entry of thapsigargin-treated fibers
acalyphin
from Acalypha indica, shows interaction with the amino acids at the active site of PLA2, interacts also with the Ca2+ ion in the active site of PLA2
acalyphin
from Acalypha indica, shows interaction with the amino acids (Asp-49, Lys-69 and Gly-30) at the active site of PLA2
Acetyl salicylate
-
inhibition below the normal cutoff pressure of PLA2
Acetyl salicylate
-
inhibition below the normal cutoff pressure of PLA2
Anisic acid
-
-
AnMIP
a PLA2 inhibitor isolated from Atropoides nummifer plasma, inhibitor protein DNA and amino acid sequence determination and phylogenetic analysis, 22247-22301 Da, pI 4.1-4.7, trimeric structure, inhibitory profile, overview
-
AnMIP
-
a PLA2 inhibitor isolated from Atropoides nummifer plasma, inhibitor protein DNA and amino acid sequence determination and phylogenetic analysis, 22247-22301 Da, pI 4.1-4.7, trimeric structure, inhibitory profile, overview
-
AnMIP
-
a PLA2 inhibitor isolated from Atropoides nummifer plasma, inhibitor protein DNA and amino acid sequence determination and phylogenetic analysis, 22247-22301 Da, pI 4.1-4.7, trimeric structure, inhibitory profile, overview
-
anti-peptide antibody
-
-
-
anti-peptide antibody
-
-
-
anti-peptide antibody
-
-
-
anti-peptide antibody
-
-
-
anti-peptide antibody
-
group II PLA2-antibody
-
aplysulphurin A
from Aplysilla sp., shows interaction with the amino acids at the active site of PLA2, interacts also with the Ca2+ ion in the active site of PLA2
aplysulphurin A
from Aplysilla sp., shows interaction with the amino acids at the active site of PLA2
arachidonyl trifluoromethyl ketone
inhibits dose-dependently
arachidonyl trifluoromethyl ketone
-
AACOCF3, inhibits release of [3H]arachidonic acid by a 0.01 mM concentration
arachidonyl trifluoromethyl ketone
-
AACOCF3, both de novo lysophosphatidic acid production and neuropathic pain-like behaviors are substantially abolished by intrathecal injection of arachidonyl trifluoromethyl ketone, a mixed inhibitor of cPLA2 and iPLA2, at 1 h after injury
arachidonyl trifluoromethyl ketone
-
AACOCF3, highly selective cPLA2 inhibitor, inhibits the Amplex Red signal in mitochondria from denervated muscle and from Sod1-/- mice
arachidonyl trifluoromethyl ketone
-
-
arachidonyl trifluoromethyl ketone
-
i.e. AACOCF3
arachidonyl trifluoromethyl ketone
-
i.e. AACOCF3, a cPLA2-specific inhibitor
arachidonyltrifluoromethyl ketone
-
-
arachidonyltrifluoromethyl ketone
-
-
arachidonyltrifluoromethyl ketone
-
-
aristolochic acid
-
aristolochic acid
-
partial inhibition
aristolochic acid
-
partial inhibition
aristolochic acid
-
partial inhibition of catalytic activity
Ba2+
-
-
Ba2+
-
competitive inhibition
bromoenol lactone
-
strong inhibition
bromoenol lactone
-
plasmalogen-specific PLA2, suicide inhibitor, IC50 30nM
bromoenol lactone
-
40% inhibition at 0.05 mM
bromoenol lactone
-
specific iPLA2 inhibitor, which completely suppresses fMLP-induced generation of superoxide. Completely blocks superoxide generation in neutrophils from healthy and diabetic subjects. Exogeneous arachidonic acid rescues neutrophil superoxide inhibition by partly restoring NADPH oxidase activity, resulting in superoxide generation
bromoenol lactone
-
inhibits at 0.025 mM
bromoenol lactone
-
both de novo lysophosphatidic acid production and neuropathic pain-like behaviors are substantially abolished by intrathecal injection of bromoenol lactone, an iPLA2 inhibitor, at 1 h after injury
bromoenol lactone
-
specific suicide substrate of PLA2, does not affect basal Mn2+ entry, but strongly reduces the enhanced Mn2+ entry of thapsigargin-treated fibers
bromoenol lactone
-
iPLA2 inhibitor, does not inhibit the Amplex Red signal
Ca2+
-
-
Ca2+
-
activity is unaffected by the addition of 0.0001-1 mM calcium, but is inhibited slightly by the addition of 2-10 mM calcium
Ca2+
-
30% decrease of activity at 5-10 mM
Ca2+
-
partial inhibition, isoform PLA2-H
Cd2+
-
-
Cd2+
10 mM, notable inhibition even in the presence of 10 mM Ca2+
chlorogenic acid
from Achillea millefolium, shows interaction with the amino acids at the active site of PLA2
chlorogenic acid
from Achillea millefolium, shows interaction with the amino acids (Asp-49, Lys-69, Trp-31 and Trp-A31) at the active site of PLA2
crotapotin
-
-
-
crotapotin
-
PLA2-like protein from Crotalus durissus terrificus snake venom, 23% inhibition of the edema induced by isoenzyme BthTX-I on the mouse paw, 27% inhibition of the edema induced by isoenzyme BthTX-II. Reduction of their membrane damaging activity, very little inhibition of catalytic enzyme activity
-
crotapotin
-
PLA2-like protein from Crotalus durissus terrificus snake venom, 10% inhibition of the edema induced by enzyme on the mouse paw. Reduction of their membrane damaging activity, very little inhibition of catalytic enzyme activity
-
crotapotin
-
PLA2-like protein from Crotalus durissus terrificus snake venom, 25% inhibition of the edema induced by isoenzyme BthTX-I on the mouse paw, 35% inhibition of the edema induced by isoenzyme BthTX-II. Reduction of their membrane damaging activity, very little inhibition of catalytic enzyme activity
-
crotapotin
-
allosteric inhibitor, 50% inhibition at 0.001 mg/ml, maximal inhibition at 0.002 mg/ml
-
crotapotin
-
inhibitory to isoform LmTX-I
-
Cu2+
-
10 mM
Cu2+
-
at 10 mM, diminishes activation in presence of 1 mM Ca2+, slight activation in absence of Ca2+
Cu2+
10 mM, 10% residual activity
curcumin
from Curcuma longa, shows interaction with the amino acids at the active site of PLA2
curcumin
from Curcuma longa, shows interaction with the amino acids (Asp-49 and Gly-30) at the active site of PLA2
darapladib
-
inhibits Lp-PLA2 activity by 59%
darapladib
-
reduces development of advanced coronary atherosclerosis in diabetic and hypercholesterolemic swine, specifically reduces plaque area and necrotic core area and medial destruction, resulting in fewer lesions with an unstable phenotype
dexamethasone
complete inactivation
dexamethasone
-
inhibitor of PLA2, phagocytosis of hemocyte monolayers is significantly reduced in cells provided by insects treated with dexamethasone (0.125 mM), when compared to untreated controls or hemocytes taken from insects treated with dexamethasone but that receive inoculation of arachidonic acid or platelet activating factor. Inhibits total PLA2 activity in lysates from hemocytes by 42%. Cell-free hemolymph PLA2 activity is not affected by dexamethasone treatment (slight but not significant inhibition)
dexamethasone
-
specific phopholipase A2, blocks phagocytosis of yeast cells by bloodsucking bug hemocytes
Dicetyl phosphate
-
inhibition below the normal cutoff pressure of PLA2
Dicetyl phosphate
-
inhibition below the normal cutoff pressure of PLA2
diethyl 4-nitrophenyl phosphate
-
diethyl 4-nitrophenyl phosphate
-
diethyl 4-nitrophenyl phosphate
-
diethyl 4-nitrophenyl phosphate
-
diethyl 4-nitrophenyl phosphate
-
diethyl 4-nitrophenyl phosphate
-
diethyl 4-nitrophenyl phosphate
-
-
diethyl 4-nitrophenyl phosphate
-
Diethyl p-nitrophenyl phosphate
-
-
Diethyl p-nitrophenyl phosphate
-
-
diisopropyl fluorophosphate
-
-
diisopropyl fluorophosphate
-
-
diisopropyl fluorophosphate
-
-
dithiothreitol
-
DTNB
-
plasmalogen-specific PLA2
DTNB
-
plasmalogen-specific PLA2
EDTA
-
-
EDTA
-
10 mM, complete inhibition
EDTA
-
95% inhibition at 5 mM
EDTA
-
0.2 mM, 35% inhibition
EDTA
1 mM, complete inhibition
EDTA
-
complete inhibition at 1 mM
EDTA
-
complete inhibition above 0.05 mM
EGTA
-
-
EGTA
-
10 mM, complete inhibition
EGTA
-
loss of hydrolytic activity
EGTA
-
complete inhibition at 1 mM
EGTA
almost complete inhibition at 0.06 mM EGTA
Fe2+
-
-
gracilin A
from Aplysilla sp., shows interaction with the amino acids at the active site of PLA2, interacts also with the Ca2+ ion in the active site of PLA2
gracilin A
from Aplysilla sp., shows interaction with the amino acids (Asp-49, His-48, Trp-31 and Gly-30) at the active site of PLA2
heparin
-
plasmalogen-specific PLA2
heparin
-
allosteric inhibitor
heparin
-
at a dose of 5 mg inhibits 49% promutoxin elicited microvascular leakage. At 10 and 100 microg/ml diminishes promutoxin-induced histamine release from lung mast cells by 56% and 53%, has little effect on promutoxin-induced histamine release from colon mast cells. At a concentration of 100 microg/ml, heparin inhibits promutoxin-induced histamine release from tonsil mast cells
hexadecyl-3-trifluorethylglycero-sn-2-phospho-methanol
-
i.e. MJ33
hexadecyl-3-trifluorethylglycero-sn-2-phospho-methanol
-
i.e. MJ33
Hg2+
-
plasmalogen-specific PLA2
indoxam
-
-
indoxam
-
most potent sPLA2 inhibitor
iodoacetamide
-
can be reversed by dithiothreitol
iodoacetamide
-
weak inhibitor
KCl
-
1 mM, residual activity 78.9%
koninginin E
-
KonE, isolated from Trichoderma koningii, inhibits edema-inducing, myotoxic and enzymatic activities of PLA2. Action mode in comparison to vitmain E inhibition
koninginin E
-
KonE, isolated from Trichoderma koningii, inhibits edema-inducing, myotoxic and enzymatic activities of PLA2
koninginin F
-
KonF, isolated from Trichoderma koningii, inhibits edema-inducing, myotoxic and enzymatic activities of PLA2. Action mode in comparison to vitmain E inhibition
koninginin F
-
KonF, isolated from Trichoderma koningii, inhibits edema-inducing, myotoxic and enzymatic activities of PLA2
luffariellin B
-
-
LY 329722
-
i.e. 3-(3-aminooxalyl-1-benzyl-2-ethyl-6-methyl-1H-indol-4-yl)propionic acid
LY 329722
-
specific inhibitor of secreted phospholipase A2
LY311727
-
-
LY315920
-
-
LY315920
-
i.e. [[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetate
manoalogue
-
synthetic analogue of the sea sponge-derived manoalide, time dependent irreversible loss of activity: modification of lysine residues
manoalogue
-
synthetic analogue of the sea sponge-derived manoalide, time dependent irreversible loss of activity: modification of lysine residues
manoalogue
-
synthetic analogue of the sea sponge-derived manoalide, time dependent irreversible loss of activity: modification of lysine residues
Me-Indoxam
-
-
Me-Indoxam
sPLA2 inhibitor, has no effect on arachidonic acid release and platelet activating factor synthesis
Me-Indoxam
-
most potent sPLA2 inhibitor
methyl arachidonyl fluorophosphonate
-
-
methyl arachidonyl fluorophosphonate
-
80% inhibition at 0.001 mM
methyl arachidonyl fluorophosphonate
-
50% inhibition at 0.0005 mM
methyl arachidonyl fluorophosphonate
-
-
methyl arachidonyl fluorophosphonate
-
induces hepatitis C viral replication deficiency, not reversible by arachidonic acid in vivo
methyl arachidonyl fluorophosphonate
-
almost complete inhibition
methyl arachidonyl fluorophosphonate
-
almost complete inhibition
Mg2+
-
-
Mg2+
-
at 10 mM, diminishes activation in presence of 1 mM Ca2+, poor activation in absence of Ca2+
N-ethylmaleimide
-
plasmalogen-specific PLA2
N-ethylmaleimide
-
weak inhibitor
NaCl
-
1 mM, residual activity 58.5%
omega-bromo-4-nitroacetophenone
-
-
omega-bromo-4-nitroacetophenone
-
-
omega-bromo-4-nitroacetophenone
-
-
ONO-RS-082
-
reversible PLA2 antagonist, treatment for 45 min causes the intact Golgi ribbon to break up into fragments of disconnected mini-stacks
p-bromophenacyl bromide
-
-
p-bromophenacyl bromide
-
inhibits both the catalytic and anticoagulant activities. Inhibition of catalytic activity is approximately 6fold higher compared with inhibition of anticoagulant activity
p-bromophenacyl bromide
-
-
p-bromophenacyl bromide
abolishes the enzymatic activity of PLA2 without affecting its anti-tumor effect, suggesting the presence of pharmacological sites distinct from the catalytic site
p-bromophenacyl bromide
-
-
p-bromophenacyl bromide
-
complete loss of both catalytic activity and platelet aggregation inhibitory activity
p-bromophenacyl bromide
-
loss of both catalytic activity and neurotoxicity
p-bromophenacyl bromide
-
loss of both enzymatic and toxic properties
p-bromophenacyl bromide
-
Oh-DE-2
p-bromophenacyl bromide
-
-
p-bromophenacyl bromide
-
-
p-bromophenacyl bromide
-
-
p-bromophenacyl bromide
-
-
p-bromophenacylbromide
-
i.e. pBpb, 0.1 mM, 60% inhibition
p-bromophenacylbromide
-
i.e. pBPB, 3.3 mM, 95% inhibition of isoenzyme NK-PLA2-I, 89% inhibition of isoenzyme NK-PLA2-II
p-hydroxymercuribenzoate
-
weak inhibitor
p-hydroxymercuribenzoate
-
-
phenylmethylsulfonyl fluoride
-
-
phenylmethylsulfonyl fluoride
-
-
protocatechuic acid
-
reaches 50% inhibition at concentrations of 3.3 mM
protocatechuic acid
inhibitory in micromolar concentrations
pyrrolidine-1
-
specific cPLA2 inhibitor, does not inhibit the superoxide generation in healthy neutrophils
pyrrolidine-1
-
isoform cPLA2alpha inhibitor
pyrrolidine-1
-
isoform cPLA2alpha inhibitor
pyrrolidine-2
-
inhibits release of [3H]AA by a 0.001 mM concentration
pyrrolidine-2
-
isoform cPLA2alpha inhibitor
pyrrolidine-2
-
isoform cPLA2alpha inhibitor
pyrrophenone
-
potent gIVaPLA2 inhibitor, attenuates gIVaPLA2 activity in concentration-dependent manner
pyrrophenone
-
pretreatment of cells with pyrrophenone reduces Kdo2-lipid A stimulated arachidonic acid release to background levels
pyrrophenone
-
interacts with key residues that also exhibit changes in deuterium exchange upon inhibitor binding. Is bound to the protein through numerous hydrophobic residues located distal from the active site. Residues 393-397, 481-495, and 543-553 exhibit increased rates of exchange in the presence of pyrrophenone
salicylic acid
-
inhibition below the normal cutoff pressure of PLA2
salicylic acid
-
inhibition below the normal cutoff pressure of PLA2
SB435495
specific inhibition of isozyme Lp-PLA2, used for inhibitor screening
SB435495
-
SB435495-treated oxidized low density lipoprotein has nearly undetectable lp-PLA2 activity. Completely inhibits lp-PLA2 enzyme activity in the whole culture media of THP-1 cells with 0.0001 mM
sodium deoxycholate
-
plasmalogen-specific PLA2
sodium deoxycholate
-
inhibitory at higher concentrations
Sodium dodecyl sulfate
-
-
Sodium dodecyl sulfate
-
-
sphingomyelin
-
-
sphingomyelin
-
suppresses the activating effect of oxidized palmitoyl arachidonyl phosphatidylcholine in a dose-dependent manner, abolishing it almost completely at a concentration 8times as high as that of oxidized palmitoyl arachidonyl phosphatidylcholine. Oxidized palmitoyl arachidonyl phosphatidylcholine completely abolishes the inhibitory effect of low density lipoprotein-incorporated sphingomyelin on the enzyme activity at the oxidized palmitoyl arachidonyl phosphatidylcholine/sphingomyelin concentration ratio 1:2
Sr2+
-
competitive inhibition
Sr2+
-
competitive inhibition
stigmasterol
from Achillea millefolium, shows interaction with the amino acids at the active site of PLA2
stigmasterol
from Achillea millefolium, shows interaction with the amino acids (His-48) at the active site of PLA2
surfactant protein A
-
-
-
surfactant protein A
-
-
-
taurocholate
-
plasmalogen-specific PLA2
taurocholate
bile salt regulation of lipid metabolism via both activation and inhibition of PLA2, interaction and binding structure analysis, overview
tectoridin
from Belamcanda chinensis, shows interaction with the amino acids at the active site of PLA2
tectoridin
from Belamcanda chinensis, shows interaction with the amino acids (Asp-49 and Lys-69) at the active site of PLA2
tert-butyl ([3-[amino(oxo)acetyl]-1-benzyl-2-(2-methylpropyl)-1H-indol-4-yl]oxy)acetate
-
-
tert-butyl ([3-[amino(oxo)acetyl]-1-benzyl-2-(2-methylpropyl)-1H-indol-4-yl]oxy)acetate
-
-
Triton X-100
-
plasmalogen-specific PLA2
Zn2+
-
-
Zn2+
-
at 10 mM, diminishes activation in presence of 1 mM Ca2+, no activation in absence of Ca2+
Zn2+
10 mM, notable inhibition even in the presence of 10 mM Ca2+
Zn2+
-
inhibits in the presence of Ca2+, inactivates in the absence of Ca2+
Zn2+
10 mM, 38% residual activity
additional information
-
not inhibitory: EDTA
-
additional information
no inhibition by bromoenol lactone
-
additional information
no inhibition by bromoenol lactone
-
additional information
-
no inhibition by koninginin A, KonA, isolated from Trichoderma koningii
-
additional information
binding of 4-bromophenacyl bromide and alpha-tocopherol and alpha-tocopherol acetate inhibitors by PrTX-1 involves His48
-
additional information
-
binding of 4-bromophenacyl bromide and alpha-tocopherol and alpha-tocopherol acetate inhibitors by PrTX-1 involves His48
-
additional information
-
molecular modeling of the inhibition mechanism of polyhydroxylated phenols
-
additional information
no inhibition by bromoenol lactone
-
additional information
-
no inhibition of isozyme cPLA2alpha by 1-[5-(3-benzyl-1,2,4-oxadiazol-5-yl)indol-1-yl]-3-(4-octylphenoxy)propan-2-one and 1-[5-(3-ethyl-1,2,4-oxadiazol-5-yl)indol-1-yl]-3-(4-octylphenoxy)propan-2-one
-
additional information
-
inhibitor synthesis and screening, overview, inhibitory potency of 3-[4-[3-ethoxy-2-(tetradecyloxy)propoxy]benzyl]-1,2,4-oxadiazol-5(4H)-one derivatives with the different isozymes, overview
-
additional information
-
SB202190 and PD98059 abolish the enzyme activation by phosphorylation through protein kinase C by specific inhibition of PKC
-
additional information
-
relative inhibition rates of isozymes GIVA cPLA2, GVIA iPLA2, GVsPLA2, with 2-oxoamide compounds, structure-activity relationships, overview
-
additional information
structural analysis of PLA2-inhibitor complexes, computational and mass spectrometry analysis, molecular dynamics simulations, overview
-
additional information
-
structural analysis of PLA2-inhibitor complexes, computational and mass spectrometry analysis, molecular dynamics simulations, overview
-
additional information
-
p11 overexpression inhibits the Ca2+-induced perinuclear translocation of and amino acid release by cPLA2alpha wild type, S727E, and S727T but not by S727A
-
additional information
-
structure-activity relationship, overview
-
additional information
-
substituted indole and 6,7-benzoindole inhibitor binding, molecular modeling, overview
-
additional information
-
synthesis of fluoroketone inhibitors and inhibitory effects against isozymes group IVA cytosolic phospholipase A2, , group V secreted phospholipase A2, and group VIA calcium-independent phospholipase A2, overview. Trifluoromethyl ketone analogues of arachidonic and palmitic acids also inhibit GVIA iPLA2
-
additional information
-
no inhibition by koninginin A, KonA, isolated from Trichoderma koningii
-
additional information
-
novel potent piperazinic derivatives that show improved anti-PLA2 activity with a high selectivity for human GIIA versus porcine GIB PLA2s compared to the reference compound of LY311727 and that are more active than reference compound II
-
additional information
-
replacement of the amino acid unit of a 2-oxoamide inhibitor by a dipeptide unit may shift the selectivity in favour of GVIA iPLA2
-
additional information
-
is not inhibited by bromoenol lactone or AACOCF3 (arachidonyl trifluoromethyl ketone)
-
additional information
-
substituted indoles and indolizines are the most potent sPLA2 inhibitors
-
additional information
-
bromoenol lactone does not inhibit release of [3H]arachidonic acid by a 0.01 mM concentration
-
additional information
the (R)-enantiomer presents higher binding energy than the (S)-FPL67047XX inhibitor. The decrease of the number of carbon atoms of the R1 chain increases the binding energy. The insertion of a hydroxyl group in the para-position of the aromatic ring of R1 chain increases the binding energy. The optimum number of carbon atoms in the amino acid part of the ligand is three. The sulphonate group presents the most favourable interactions in comparison with carboxylate and phosphonate groups and the aromatic chains are essential for the binding activity because the phenyl rings participate in tilted-T aromatic (PiPi) stacking and aromatic/aliphatic interactions
-
additional information
-
inhibition of JNK activity inhibits the translocation of cPLA2alpha to phagosomal membranes
-
additional information
-
inhibition of gIVaPLA2 blocks the deformability and subsequent migration of polymophonuclear leukocytes caused by IL-8/CXCL8
-
additional information
-
anthocyanidins exhibit the best inhibitory effects on PLA2, whereas inhibitory properties of anthocyanins are less pronounced
-
additional information
no inhibition by bromoenol lactone
-
additional information
-
indazole-5-carboxylic acids with 3-aryloxy-2-oxopropyl residues in position 1 are reported to be potent dual inhibitors of cytosolic phospholipase A2alpha and fatty acid amide hydrolase. The carboxylic acid functionality of the lead compounds is of special importance for a pronounced inhibition of cytosolic phospholipase A2alpha and fatty acid amide hydrolase
-
additional information
-
neither PAP-1 nor PKC inhibition reduces GIVA PLA2 synergistic activation by stimulation with Kdo2-Lipid A and ATP. Neither EDTA nor EGTA reduce the arachidonic acid release
-
additional information
-
substituted indole and 6,7-benzoindole inhibitor binding, molecular modeling, overview
-
additional information
-
recombinant sPLA2 is not inhibited by bromoenol lactone or AACOCF3 (arachidonyl trifluoromethyl ketone)
-
additional information
-
during low density lipoprotein oxidation with 0.005 mM CuSO4, the remaining Lp-PLA2 activity after 6h is approximately 40-50% while after 24h only 10-15% of the initial activity is preserved
-
additional information
no inhibition by bromoenol lactone
-
additional information
-
4-bromophenacyl bromide does not modify the enzyme, no incorporation of the 4-bromophenacyl group into the enzyme
-
additional information
-
not inhibitory to both isoenzymes: p-methylsulfonylfluoride, tosyl-L-phenylalaninchlormethylketon, N-bromosuccinamide, tosyl-L-lysinechlormethylketon
-
additional information
-
promutoxin induced histamine release from colon, lung and tonsil mast cells is inhibited by up to 89%, 99% and 90%, respectively when cells are pretreated with metabolic inhibitors for 40 min. Quinacrine at the dose of 5 mg has little effect on promutoxin provoked microvascular leakage in rat skin
-
additional information
-
phospholipase A2 inhibitors may represent a novel mode of treatment for acute infection of Pseudomonas aeruginosa
-
additional information
-
high-throughput inhibitor screening, overview
-
additional information
-
activity is unaffected by the addition of 1-5 mM EDTA or 0.01-20 mM dithiothreitol
-
additional information
-
inhibition mechanisms of 1,2,4-oxadiazolidin-3,5-diones and 1,3,5-triazin-2,4,6-triones, overview
-
additional information
-
SB202190 and PD98059 abolish the enzyme activation by phosphorylation through protein kinase C by specific inhibition of PKC
-
additional information
-
no inhibition of AdPLA and sPLA2 by bromoenolactone
-
additional information
-
no inhibition by decanoyl lysophosphatidylcholine in vitro
-
additional information
no inhibition by bromoenol lactone
-
additional information
epigallocatechin is a poor inhibitor
-
additional information
-
inhibitor screening, overview, inhibitory potency of 3-[4-[3-ethoxy-2-(tetradecyloxy)propoxy]benzyl]-1,2,4-oxadiazol-5(4H)-one derivatives, overview
-
additional information
-
novel potent piperazinic derivatives that show improved anti-PLA2 activity with a high selectivity for human GIIA versus porcine GIB PLA2s compared to the reference compound of LY311727 and that are more active than reference compound II
-
additional information
-
no inhibition by bromoenol lactone
-
additional information
sPLA2 is not inhibited by methylarachidonyl fluorophosphonate
-
additional information
-
sPLA2 is not inhibited by methylarachidonyl fluorophosphonate
-
additional information
no inhibition by bromoenol lactone
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.0007 - 0.0058
(+-)-3-O-[4-(4,5-dihydro-5-oxo-1,2,4-4H-oxadiazol-3-yl)phenyl]-2-O-tetradecyl-1-O-triphenylmethylglycerol
0.14
(2-(4-((3-(diphenylmethyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)methyl)phenyl)-1,3-oxazol-4-yl)acetic acid
synthetic construct
-
7-hydroxycoumarinyl-gamma-linoleolate micelle assay
0.025
(2E,4S)-4-[(2-oxohexadecanoyl)amino]oct-2-enoic acid
Homo sapiens
-
at 37°C, pH not specified in the publication
0.36
(4-((3-(diphenylmethyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)methyl)phenoxy)acetic acid
synthetic construct
-
7-hydroxycoumarinyl-gamma-linoleolate micelle assay
0.26
(4-((3-(diphenylmethyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)methyl)phenyl)acetic acid
synthetic construct
-
7-hydroxycoumarinyl-gamma-linoleolate micelle assay
0.012
(4-((6-bromo-1-(diphenylmethyl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)methyl)phenyl)acetic acid
synthetic construct
-
7-hydroxycoumarinyl-gamma-linoleolate micelle assay
0.025
(4R)-6-methyl-4-[(2-oxohexadecanoyl)amino]heptanoic acid
Homo sapiens
-
at 37°C, pH not specified in the publication
0.01
(4S)-4-[(2-oxododecanoyl)amino]octanoic acid
Homo sapiens
-
at 37°C, pH not specified in the publication
0.025
(4S)-4-[(2-oxohexadecanoyl)amino]octanoic acid
Homo sapiens
-
at 37°C, pH not specified in the publication
0.007
(5S)-5-[(2-oxohexadecanoyl)amino]nonanoic acid
Homo sapiens
-
at 37°C, pH not specified in the publication
0.0023 - 0.0165
(6Z,9Z,12Z,15Z)-1,1,1-trifluorohenicosa-6,9,12,15-tetraen-2-one
0.002
(S)-2-(2-(2-oxohexadecanamido)hexyloxy)acetic acid
Homo sapiens
-
at 37°C, pH not specified in the publication
0.00097 - 0.0011
([1-[amino(oxo)acetyl]-3-(biphenyl-2-ylmethyl)-2-(2-methylpropyl)indolizin-8-yl]oxy)acetic acid
0.00001 - 0.00013
([3-[amino(oxo)acetyl]-1-benzyl-2-(2-methylpropyl)-1H-benzo[g]indol-4-yl]oxy)acetic acid
0.0063
1-(1H-indazol-1-yl)-3-(4-phenoxyphenoxy)propan-2-one
Homo sapiens
-
37°C, pH 8.0, substrate 1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine
0.01
1-(2-dimethylaminoethyl)-5-[3-(4-octylphenoxy)-2-oxopropoxy]indole-2-carboxylic acid
Homo sapiens
-
above, pH 7.4
0.0015
1-(4-carboxybenzyl)-5-[3-(4-octylphenoxy)-2-oxopropoxy]indole-2-carboxylic acid
Homo sapiens
-
pH 7.4
0.0011
1-(4-octylphenoxy)-3-[5-(1H-tetrazol-5-yl)indol-1-yl]propan-2-one
Homo sapiens
-
-
0.0016
1-(5-nitro-1H-indazol-1-yl)-3-(4-phenoxyphenoxy)propan-2-one
Homo sapiens
-
37°C, pH 8.0, substrate 1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine
0.3
1-(carboxymethyl)-5-[3-(4-octylphenoxy)-2-oxopropoxy]indole-2-carboxylic acid
Homo sapiens
-
pH 7.4
0.6
1-(carboxypentyl)-5-[3-(4-octylphenoxy)-2-oxopropoxy]indole-2-carboxylic acid
Homo sapiens
-
pH 7.4
0.4
1-(carboxypropyl)-5-[3-(4-octylphenoxy)-2-oxopropoxy]indole-2-carboxylic acid
Homo sapiens
-
pH 7.4
0.01
1-benzyl-5-[3-(4-octylphenoxy)-2-oxopropoxy]-indole-2-carboxylic acid
Homo sapiens
-
pH 7.4
0.01
1-hexyl-5-[3-(4-octylphenoxy)-2-oxopropoxy]indole-2-carboxylic acid
Homo sapiens
-
above, pH 7.4
0.0012
1-methyl 5-[3-(4-octylphenoxy)-2-oxopropoxy]-indole-2-carboxylic acid
Homo sapiens
-
pH 7.4
0.000005
1-[2-oxo-3-(4-phenoxyphenoxy)propyl]-1H-indazole-5-carboxylic acid
Homo sapiens
-
37°C, pH 8.0, substrate 1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine
0.000026
1-[3-(4-octylphenoxy)-2-oxopropyl]-1H-benzotriazole-5-carboxylic acid
Homo sapiens
-
-
0.000016
1-[3-(4-octylphenoxy)-2-oxopropyl]-1H-benzotriazole-6-carboxylic acid
Homo sapiens
-
-
0.00035
1-[3-(4-octylphenoxy)-2-oxopropyl]-1H-indole-5-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication
0.000035
1-[3-(4-octylphenoxy)-2-oxopropyl]-2,3-dihydro-1H-indole-5-carboxylic acid
Homo sapiens
-
pH 7.4
0.00015
1-[3-(4-octylphenoxy)-2-oxopropyl]benzimidazole-5-carboxylic acid
Homo sapiens
-
-
0.000085
1-[3-(4-octylphenoxy)-2-oxopropyl]benzimidazole-6-carboxylic acid
Homo sapiens
-
-
0.000005
1-[3-(4-octylphenoxy)-2-oxopropyl]indazole-5-carboxylic acid
Homo sapiens
-
-
0.000026
1-[3-(4-octylphenoxy)-2-oxopropyl]indazole-6-carboxylic acid
Homo sapiens
-
-
0.000035
1-[3-(4-octylphenoxy)-2-oxopropyl]indole-5-carboxylic acid
Homo sapiens
-
-
0.00039
1-[3-(4-octylphenoxy)-2-oxopropyl]indole-5-sulfonamide
Homo sapiens
-
-
0.0011
1-[3-(4-octylphenoxy)-2-oxopropyl]indole-6-carboxylic acid
Homo sapiens
-
-
0.0005
1-[5-(morpholine-4-carbonyl)indol-1-yl]-3-(4-octylphenoxy)propan-2-one
Homo sapiens
-
-
0.013 - 0.1
2,2'-biphenyl-3,4'-diylbis(4H-chromen-4-one)
0.011 - 0.1
2,2'-biphenyl-4,4'-diylbis(4H-chromen-4-one)
0.024 - 0.1
2,2'-diphenyl-4H,4'H-6,6'-bichromene-4,4'-dione
0.12
2-((6-bromo-1-(diphenylmethyl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)methyl)cyclopropanecarboxylic acid
synthetic construct
-
7-hydroxycoumarinyl-gamma-linoleolate micelle assay
0.000014 - 0.000034
2-(1-benzyl-2-ethyl-4-methoxy-1H-benzo[g]indol-3-yl)-2-oxoacetamide
0.000006 - 0.000007
2-(3-(2-amino-2-oxoacetyl)-1-benzyl-2-ethyl-1H-6,7-benzoindol-4-yloxy)acetic acid
0.00003 - 0.00045
2-([3-[amino(oxo)acetyl]-1-benzyl-2-(2-methylpropyl)-1H-benzo[g]indol-4-yl]oxy)-N-(phenylsulfonyl)acetamide
0.000007
2-([3-[amino(oxo)acetyl]-1-benzyl-2-(2-methylpropyl)-1H-indol-4-yl]oxy)-N-(methylsulfonyl)propanamide
Homo sapiens
-
isozyme sPLA2 group IIX
0.000021 - 0.0016
2-([3-[amino(oxo)acetyl]-1-benzyl-2-(2-methylpropyl)-1H-indol-4-yl]oxy)-N-(phenylsulfonyl)acetamide
0.00008
2-([3-[amino(oxo)acetyl]-1-benzyl-2-(2-methylpropyl)-1H-indol-4-yl]oxy)-N-(phenylsulfonyl)propanamide
Homo sapiens
-
isozyme sPLA2 group IIX
0.000014
2-([3-[amino(oxo)acetyl]-1-benzyl-2-(2-methylpropyl)-1H-indol-4-yl]oxy)-N-[(2-chlorophenyl)sulfonyl]propanamide
Homo sapiens
-
isozyme sPLA2 group IIX
0.000011
2-([3-[amino(oxo)acetyl]-1-benzyl-2-(2-methylpropyl)-1H-indol-4-yl]oxy)-N-[(2-methylphenyl)sulfonyl]propanamide
Homo sapiens
-
isozyme sPLA2 group IIX
0.00014
2-([3-[amino(oxo)acetyl]-1-benzyl-2-(2-methylpropyl)-1H-indol-4-yl]oxy)-N-[(3-chlorophenyl)sulfonyl]propanamide
Homo sapiens
-
isozyme sPLA2 group IIX
0.00054
2-([3-[amino(oxo)acetyl]-1-benzyl-2-(2-methylpropyl)-1H-indol-4-yl]oxy)-N-[(4-chlorophenyl)sulfonyl]propanamide
Homo sapiens
-
isozyme sPLA2 group IIX
0.00032
2-([3-[amino(oxo)acetyl]-1-benzyl-2-(2-methylpropyl)-1H-indol-4-yl]oxy)-N-[(4-methylphenyl)sulfonyl]propanamide
Homo sapiens
-
isozyme sPLA2 group IIX
0.00003
2-([3-[amino(oxo)acetyl]-1-benzyl-2-(2-methylpropyl)-1H-indol-4-yl]oxy)-N-[(trifluoromethyl)sulfonyl]propanamide
Homo sapiens
-
isozyme sPLA2 group IIX
0.00007
2-([3-[amino(oxo)acetyl]-1-benzyl-2-(2-methylpropyl)-1H-indol-4-yl]oxy)-N-[[2-(trifluoromethyl)phenyl]sulfonyl]propanamide
Homo sapiens
-
isozyme sPLA2 group IIX
0.000016 - 0.000035
2-([3-[amino(oxo)acetyl]-1-benzyl-2-ethyl-1H-benzo[g]indol-4-yl]oxy)-N-(phenylsulfonyl)acetamide
0.000007 - 0.000012
2-([3-[amino(oxo)acetyl]-1-benzyl-2-ethyl-1H-indol-4-yl]oxy)-N-(phenylsulfonyl)acetamide
0.00066
2-hydroxy-N-[1-[2-oxo-3-(4-phenoxyphenoxy)propyl]-1H-indazol-5-yl]acetamide
Homo sapiens
-
37°C, pH 8.0, substrate 1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine
0.00059
2-methoxy-N-[1-[2-oxo-3-(4-phenoxyphenoxy)propyl]-1H-indazol-5-yl]acetamide
Homo sapiens
-
37°C, pH 8.0, substrate 1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine
0.00005 - 0.00058
2-[1-benzyl-2-(2-methylpropyl)-4-(2-oxopropoxy)-1H-indol-3-yl]-2-oxoacetamide
0.000009 - 0.00002
2-[1-benzyl-4-(2-oxopropoxy)-2-propyl-1H-indol-3-yl]-2-oxoacetamide
0.00041 - 0.009
2-[3-(biphenyl-2-ylmethyl)-2-ethyl-8-(2-oxopropoxy)indolizin-1-yl]-2-oxoacetamide
0.000035 - 0.00023
2-[3-(biphenyl-2-ylmethyl)-2-ethyl-8-methoxyindolizin-1-yl]-2-oxoacetamide
0.0305 - 0.1
3,3'-[[2-(pentyloxy)propane-1,3-diyl]bis(oxybenzene-4,1-diylethane-2,1-diyl)]bis(1,2,4-oxadiazol-5(4H)-one)
0.0021 - 0.0399
3,3'-[[2-(tetradecyloxy)propane-1,3-diyl]bis(oxybenzene-4,1-diylethane-2,1-diyl)]bis(1,2,4-oxadiazol-5(4H)-one)
0.0477 - 0.1
3,3'-[[2-(tetradecyloxy)propane-1,3-diyl]bis(oxybenzene-4,1-diylmethanediyl)]bis(1,2,4-oxadiazol-5(4H)-one)
0.0031 - 0.0578
3,3'-[[3-(tetradecyloxy)propane-1,2-diyl]bis(oxybenzene-4,1-diylethane-2,1-diyl)]bis(1,2,4-oxadiazol-5(4H)-one)
0.021 - 0.0636
3,3'-[[3-(tetradecyloxy)propane-1,2-diyl]bis(oxybenzene-4,1-diylmethanediyl)]bis(1,2,4-oxadiazol-5(4H)-one)
0.1
3-(((2E)-4-(7-chloro-3-(diphenylmethyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)but-2-en-1-yl)oxy)benzoic acid
synthetic construct
-
7-hydroxycoumarinyl-gamma-linoleolate micelle assay
0.0035
3-(1-[3-(4-octylphenoxy)-2-oxopropyl]indol-5-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one
Homo sapiens
-
-
0.000012
3-(2-methylpropanoyl)-1-[2-oxo-3-(4-phenoxyphenoxy)propyl]-1H-indole-5-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication
0.00001
3-(2-methylpropanoyl)-1-[3-(4-octylphenoxy)-2-oxopropyl]-1H-indole-5-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication
0.0187 - 0.1
3-(2-[4-[(4-tetradecylpiperazin-1-yl)carbonyl]phenyl]ethyl)-1,2,4-oxadiazol-5(4H)-one
0.000036
3-(3-acetamido-2-benzyl-2-ethylindolyl-5-oxy)propane phosphonic acid
Homo sapiens
-
LY311727, IC50 value of 36 nM, group IIa and V sPLA2
0.00021
3-(3-carboxypropanoyl)-1-[3-(4-octylphenoxy)-2-oxopropyl]-1H-indole-5-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication
0.0053 - 0.1
3-(3-[4-[(4-tetradecylpiperazin-1-yl)carbonyl]phenyl]propyl)-1,2,4-oxadiazol-5(4H)-one
0.000023
3-(4-hydroxybutanoyl)-1-[3-(4-octylphenoxy)-2-oxopropyl]-1H-indole-5-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication
0.000015
3-(4-methoxybutanoyl)-1-[3-(4-octylphenoxy)-2-oxopropyl]-1H-indole-5-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication
0.000022
3-(5-carboxypentanoyl)-1-[3-(4-octylphenoxy)-2-oxopropyl]-1H-indole-5-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication
0.000031
3-(6-hydroxyhexanoyl)-1-[3-(4-octylphenoxy)-2-oxopropyl]-1H-indole-5-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication
0.000049
3-(6-methoxyhexanoyl)-1-[3-(4-octylphenoxy)-2-oxopropyl]-1H-indole-5-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication
0.00001
3-butanoyl-1-[3-(4-octylphenoxy)-2-oxopropyl]-1H-indole-5-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication
0.000071
3-hexanoyl-1-[3-(4-octylphenoxy)-2-oxopropyl]-1H-indole-5-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication
0.05
3-O-[4-(4,5-dihydro-5-oxo-1,2,4-4H-oxadiazol-3-yl)phenyl]-2-O-tetradecyl-1-O-triphenylmethylglycerol
Sus scrofa
-
pH 7.5, isozyme hGIB sPLA2
0.05
3-[2-[2-(2,2-diphenylethyl)-3,5-dioxo-1,2,4-oxadiazolidin-4-yl]ethoxy]benzoate
Rattus norvegicus
-
above
0.0035 - 0.1
3-[4-(4-hexadecylpiperazin-1-yl)benzyl]-1,2,4-oxadiazol-5(4H)-one
0.00271 - 0.1
3-[4-(4-octadecylpiperazin-1-yl)benzyl]-1,2,4-oxadiazol-5(4H)-one
0.0035 - 0.1
3-[4-(4-oxo-4H-chromen-2-yl)phenyl]-2-phenyl-4H-chromen-4-one
0.0045 - 0.1
3-[4-(4-tetradecylpiperazin-1-yl)benzyl]-1,2,4-oxadiazol-5(4H)-one
0.004 - 0.1
3-[4-(tetradecyloxy)benzyl]-1,2,4-oxadiazol-5(4H)-one
0.1
3-[4-[(4-docosylpiperazin-1-yl)carbonyl]benzyl]-1,2,4-oxadiazol-5(4H)-one
0.004 - 0.1
3-[4-[(4-hexadecylpiperazin-1-yl)carbonyl]benzyl]-1,2,4-oxadiazol-5(4H)-one
0.1
3-[4-[(4-hexadecylpiperazin-1-yl)carbonyl]phenyl]-1,2,4-oxadiazol-5(4H)-one
0.1
3-[4-[(4-hexadecylpiperazin-1-yl)methyl]benzyl]-1,2,4-oxadiazol-5(4H)-one
0.1
3-[4-[(4-hexadecylpiperazin-1-yl)methyl]phenyl]-1,2,4-oxadiazol-5(4H)-one
0.1
3-[4-[(4-icosylpiperazin-1-yl)carbonyl]benzyl]-1,2,4-oxadiazol-5(4H)-one
0.0008 - 0.1
3-[4-[(4-octadecylpiperazin-1-yl)carbonyl]benzyl]-1,2,4-oxadiazol-5(4H)-one
0.0011 - 0.1
3-[4-[(4-octadecylpiperazin-1-yl)carbonyl]phenyl]-1,2,4-oxadiazol-5(4H)-one
0.0022 - 0.1
3-[4-[(4-octadecylpiperazin-1-yl)methyl]benzyl]-1,2,4-oxadiazol-5(4H)-one
0.00508 - 0.1
3-[4-[(4-octadecylpiperazin-1-yl)methyl]phenyl]-1,2,4-oxadiazol-5(4H)-one
0.009 - 0.1
3-[4-[(4-tetradecylpiperazin-1-yl)carbonyl]benzyl]-1,2,4-oxadiazol-5(4H)-one
0.1
3-[4-[(4-tetradecylpiperazin-1-yl)carbonyl]phenyl]-1,2,4-oxadiazol-5(4H)-one
0.1
3-[4-[(4-tetradecylpiperazin-1-yl)methyl]benzyl]-1,2,4-oxadiazol-5(4H)-one
0.1
3-[4-[(4-tetradecylpiperazin-1-yl)methyl]phenyl]-1,2,4-oxadiazol-5(4H)-one
0.00029 - 0.022
3-[4-[3-(4-butylphenoxy)-2-(tetradecyloxy)propoxy]benzyl]-1,2,4-oxadiazol-5(4H)-one
0.014 - 0.1
3-[4-[3-(4-methylphenoxy)-2-(tetradecyloxy)propoxy]benzyl]-1,2,4-oxadiazol-5(4H)-one
0.00028 - 0.1
3-[4-[3-(decyloxy)-2-(tetradecyloxy)propoxy]benzyl]-1,2,4-oxadiazol-5(4H)-one
0.00028 - 0.018
3-[4-[3-(diphenylmethoxy)-2-(tetradecyloxy)propoxy]benzyl]-1,2,4-oxadiazol-5(4H)-one
0.0083 - 0.1
3-[4-[3-(pentyloxy)-2-(tetradecyloxy)propoxy]benzyl]-1,2,4-oxadiazol-5(4H)-one
0.0298 - 0.04
3-[4-[3-ethoxy-2-(tetradecyloxy)propoxy]benzyl]-1,2,4-oxadiazol-5(4H)-one
0.002
4-(((2E)-4-(1-(diphenylmethyl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)but-2-en-1-yl)oxy)benzoic acid
synthetic construct
-
7-hydroxycoumarinyl-gamma-linoleolate micelle assay
0.0056
4-(((2E)-4-(1-(diphenylmethyl)-6-fluoro-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)but-2-en-1-yl)oxy)benzoic acid
synthetic construct
-
7-hydroxycoumarinyl-gamma-linoleolate micelle assay
0.003
4-(((2E)-4-(3-(diphenylmethyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)but-2-en-1-yl)oxy)benzoic acid
synthetic construct
-
7-hydroxycoumarinyl-gamma-linoleolate micelle assay
0.0011
4-(((2E)-4-(3-(diphenylmethyl)-2,4-dioxo-7-(1H-1,2,4-triazol-1-yl)-3,4-dihydroquinazolin-1(2H)-yl)but-2-en-1-yl)oxy)benzoic acid
synthetic construct
-
7-hydroxycoumarinyl-gamma-linoleolate micelle assay
0.0021
4-(((2E)-4-(3-(diphenylmethyl)-2,4-dioxo-7-(phenylthio)-3,4-dihydroquinazolin-1(2H)-yl)but-2-en-1-yl)oxy)benzoic acid
synthetic construct
-
7-hydroxycoumarinyl-gamma-linoleolate micelle assay
0.0016
4-(((2E)-4-(3-(diphenylmethyl)-2,4-dioxo-7-phenoxy-3,4-dihydroquinazolin-1(2H)-yl)but-2-en-1-yl)oxy)benzoic acid
synthetic construct
-
7-hydroxycoumarinyl-gamma-linoleolate micelle assay
0.0024
4-(((2E)-4-(3-(diphenylmethyl)-2,4-dioxo-7-thiomorpholin-4-yl-3,4-dihydroquinazolin-1(2H)-yl)but-2-en-1-yl)oxy)benzoic acid
synthetic construct
-
7-hydroxycoumarinyl-gamma-linoleolate micelle assay
0.006
4-(((2E)-4-(3-(diphenylmethyl)-6-fluoro-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)but-2-en-1-yl)oxy)benzoic acid
synthetic construct
-
7-hydroxycoumarinyl-gamma-linoleolate micelle assay
0.0018
4-(((2E)-4-(3-(diphenylmethyl)-7-(4-(methoxycarbonyl)piperidin-1-yl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)but-2-en-1-yl)oxy)benzoic acid
synthetic construct
-
7-hydroxycoumarinyl-gamma-linoleolate micelle assay
0.015
4-(((2E)-4-(3-(diphenylmethyl)-7-(methylsulfonyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)but-2-en-1-yl)oxy)benzoic acid
synthetic construct
-
7-hydroxycoumarinyl-gamma-linoleolate micelle assay
0.002
4-(((2E)-4-(3-(diphenylmethyl)-7-(methylthio)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)but-2-en-1-yl)oxy)benzoic acid
synthetic construct
-
7-hydroxycoumarinyl-gamma-linoleolate micelle assay
0.0014
4-(((2E)-4-(3-(diphenylmethyl)-7-fluoro-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)but-2-en-1-yl)oxy)benzoic acid
synthetic construct
-
7-hydroxycoumarinyl-gamma-linoleolate micelle assay
0.003
4-(((2E)-4-(3-(diphenylmethyl)-7-methoxy-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)but-2-en-1-yl)oxy)benzoic acid
synthetic construct
-
7-hydroxycoumarinyl-gamma-linoleolate micelle assay
0.0028
4-(((2E)-4-(3-(diphenylmethyl)-7-methyl-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)but-2-en-1-yl)oxy)benzoic acid
synthetic construct
-
7-hydroxycoumarinyl-gamma-linoleolate micelle assay
0.0022
4-(((2E)-4-(3-(diphenylmethyl)-7-morpholin-4-yl-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)but-2-en-1-yl)oxy)benzoic acid
synthetic construct
-
7-hydroxycoumarinyl-gamma-linoleolate micelle assay
0.001
4-(((2E)-4-(3-(diphenylmethyl)-7-nitro-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)but-2-en-1-yl)oxy)benzoic acid
synthetic construct
-
7-hydroxycoumarinyl-gamma-linoleolate micelle assay
0.01
4-(((2E)-4-(6-chloro-3-(diphenylmethyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)but-2-en-1-yl)oxy)benzoic acid
synthetic construct
-
7-hydroxycoumarinyl-gamma-linoleolate micelle assay
0.009
4-(((2E)-4-(7-amino-3-(diphenylmethyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)but-2-en-1-yl)oxy)benzoic acid
synthetic construct
-
7-hydroxycoumarinyl-gamma-linoleolate micelle assay
0.0045
4-(((2E)-4-(7-chloro-1-(diphenylmethyl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)but-2-en-1-yl)oxy)benzoic acid
synthetic construct
-
7-hydroxycoumarinyl-gamma-linoleolate micelle assay
0.001
4-(((2E)-4-(7-chloro-3-(diphenylmethyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)but-2-en-1-yl)oxy)benzoic acid
synthetic construct
-
7-hydroxycoumarinyl-gamma-linoleolate micelle assay
0.012
4-(((2E)-4-[1-(diphenylmethyl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl]but-2-en-1-yl)oxy)benzoic acid
Rattus norvegicus
-
whole blood assay
0.014
4-(((2E)-4-[3-(diphenylmethyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]but-2-en-1-yl)oxy)benzoic acid
Rattus norvegicus
-
whole blood assay
0.011
4-(((2E)-4-[3-(diphenylmethyl)-2,4-dioxo-7-(1H-1,2,4-triazol-1-yl)-3,4-dihydroquinazolin-1(2H)-yl]but-2-en-1-yl)oxy)benzoic acid
Rattus norvegicus
-
whole blood assay
0.006
4-(((2E)-4-[3-(diphenylmethyl)-7-fluoro-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]but-2-en-1-yl)oxy)benzoic acid
Rattus norvegicus
-
whole blood assay
0.009
4-(((2E)-4-[3-(diphenylmethyl)-7-methoxy-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]but-2-en-1-yl)oxy)benzoic acid
Rattus norvegicus
-
whole blood assay
0.013
4-(((2E)-4-[3-(diphenylmethyl)-7-nitro-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]but-2-en-1-yl)oxy)benzoic acid
Rattus norvegicus
-
whole blood assay
0.011
4-(((2E)-4-[7-chloro-3-(diphenylmethyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]but-2-en-1-yl)oxy)benzoic acid
Rattus norvegicus
-
whole blood assay
0.025
4-(((2Z)-4-(1-(diphenylmethyl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)but-2-en-1-yl)oxy)benzoic acid
synthetic construct
-
7-hydroxycoumarinyl-gamma-linoleolate micelle assay
0.044
4-(((2Z)-4-(3-(diphenylmethyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)but-2-en-1-yl)oxy)benzoic acid
synthetic construct
-
7-hydroxycoumarinyl-gamma-linoleolate micelle assay
0.04
4-(((2Z)-4-(3-(diphenylmethyl)-6-fluoro-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)but-2-en-1-yl)oxy)benzoic acid
synthetic construct
-
7-hydroxycoumarinyl-gamma-linoleolate micelle assay
0.03
4-(((2Z)-4-(6-bromo-3-(diphenylmethyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)but-2-en-1-yl)oxy)benzoic acid
synthetic construct
-
7-hydroxycoumarinyl-gamma-linoleolate micelle assay
0.04
4-(((2Z)-4-(6-chloro-3-(diphenylmethyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)but-2-en-1-yl)oxy)benzoic acid
synthetic construct
-
7-hydroxycoumarinyl-gamma-linoleolate micelle assay
0.06
4-(((2Z)-4-(7-chloro-1-(diphenylmethyl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)but-2-en-1-yl)oxy)benzoic acid
synthetic construct
-
7-hydroxycoumarinyl-gamma-linoleolate micelle assay
0.03
4-(((2Z)-4-(7-chloro-3-(diphenylmethyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)but-2-en-1-yl)oxy)benzoic acid
synthetic construct
-
7-hydroxycoumarinyl-gamma-linoleolate micelle assay
0.009
4-(((E)-4-(3-benzhydryl-6-bromo-2,4-dioxo-3,4-dihydro-1(2H)-quinazolinyl)-2-butenyl)oxy)benzoic acid
synthetic construct
-
7-hydroxycoumarinyl-gamma-linoleolate micelle assay
0.03
4-((5-(3-(diphenylmethyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)pentyl)oxy)benzoic acid
synthetic construct
-
7-hydroxycoumarinyl-gamma-linoleolate micelle assay
0.047
4-((6-(3-(diphenylmethyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)hexyl)oxy)benzoic acid
synthetic construct
-
7-hydroxycoumarinyl-gamma-linoleolate micelle assay
0.09
4-((6-chloro-1-(diphenylmethyl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)methyl)benzoic acid
synthetic construct
-
7-hydroxycoumarinyl-gamma-linoleolate micelle assay
0.071
4-((7-(3-(diphenylmethyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)heptyl)oxy)benzoic acid
synthetic construct
-
7-hydroxycoumarinyl-gamma-linoleolate micelle assay
0.08
4-((7-chloro-1-(diphenylmethyl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)methyl)benzoic acid
synthetic construct
-
7-hydroxycoumarinyl-gamma-linoleolate micelle assay
0.01
4-(2-(1-(diphenylmethyl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)ethoxy)benzoic acid
synthetic construct
-
7-hydroxycoumarinyl-gamma-linoleolate micelle assay
0.1
4-(2-(1-benzyl-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)ethoxy)benzoic acid
synthetic construct
-
7-hydroxycoumarinyl-gamma-linoleolate micelle assay
0.004
4-(2-(7-chloro-1-(diphenylmethyl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)ethoxy)benzoic acid
synthetic construct
-
7-hydroxycoumarinyl-gamma-linoleolate micelle assay
0.01
4-(2-(7-chloro-3-(diphenylmethyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)ethoxy)benzoic acid
synthetic construct
-
7-hydroxycoumarinyl-gamma-linoleolate micelle assay
0.05
4-(3-(3-(diphenylmethyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)propoxy)benzoic acid
synthetic construct
-
7-hydroxycoumarinyl-gamma-linoleolate micelle assay
0.04
4-(4-((3-(diphenylmethyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)methyl)phenoxy)butanoic acid
synthetic construct
-
7-hydroxycoumarinyl-gamma-linoleolate micelle assay
0.0025
4-(4-(7-chloro-3-(diphenylmethyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)butoxy)benzoic acid
synthetic construct
-
7-hydroxycoumarinyl-gamma-linoleolate micelle assay
0.05
4-([(2E)-4-[2-(2,2-diphenylethyl)-3,5-dioxo-1,2,4-oxadiazolidin-4-yl]but-2-en-1-yl]oxy)benzoate
Rattus norvegicus
-
above
0.0013
4-([(2E)-4-[3-(diphenylmethyl)-2,4,6-trioxo-5-prop-2-en-1-yl-1,3,5-triazinan-1-yl]but-2-en-1-yl]oxy)benzoic acid
Rattus norvegicus
-
-
0.0016
4-([(2E)-4-[3-(diphenylmethyl)-5-ethyl-2,4,6-trioxo-1,3,5-triazinan-1-yl]but-2-en-1-yl]oxy)benzoic acid
Rattus norvegicus
-
-
0.0013
4-([(2E)-4-[3-benzyl-5-(diphenylmethyl)-2,4,6-trioxo-1,3,5-triazinan-1-yl]but-2-en-1-yl]oxy)benzoic acid
Rattus norvegicus
-
-
0.0024
4-([(2E)-4-[3-butyl-5-(diphenylmethyl)-2,4,6-trioxo-1,3,5-triazinan-1-yl]but-2-en-1-yl]oxy)benzoic acid
Rattus norvegicus
-
-
0.023
4-([4-[2-(2,2-diphenylethyl)-3,5-dioxo-1,2,4-oxadiazolidin-4-yl]but-2-yn-1-yl]oxy)benzoate
Rattus norvegicus
-
-
0.025
4-[(2-oxohexadecanoyl)amino]butanoic acid
Homo sapiens
-
at 37°C, pH not specified in the publication
0.05
4-[2-[2-(1-benzyl-2-phenylethyl)-3,5-dioxo-1,2,4-oxadiazolidin-4-yl]ethoxy]benzoate
Rattus norvegicus
-
above
0.027
4-[2-[2-(2,2-diphenylethyl)-3,5-dioxo-1,2,4-oxadiazolidin-4-yl]ethoxy]-2-hydroxybenzoate
Rattus norvegicus
-
-
0.0067
4-[2-[2-(2,2-diphenylethyl)-3,5-dioxo-1,2,4-oxadiazolidin-4-yl]ethoxy]benzoate
Rattus norvegicus
-
-
0.05
4-[2-[2-(diphenylmethyl)-3,5-dioxo-1,2,4-oxadiazolidin-4-yl]ethoxy]benzoate
Rattus norvegicus
-
above
0.03
4-[2-[3-(2,2-diphenylethyl)-5-ethyl-2,4,6-trioxo-1,3,5-triazinan-1-yl]ethoxy]benzoic acid
Rattus norvegicus
-
-
0.05
4-[2-[3-(diphenylmethyl)-2,4,6-trioxo-5-phenyl-1,3,5-triazinan-1-yl]ethoxy]benzoic acid
Rattus norvegicus
-
above
0.005
4-[2-[3-(diphenylmethyl)-2,4,6-trioxo-5-prop-2-en-1-yl-1,3,5-triazinan-1-yl]ethoxy]benzoic acid
Rattus norvegicus
-
-
0.0075
4-[2-[3-(diphenylmethyl)-5-ethyl-2,4,6-trioxo-1,3,5-triazinan-1-yl]ethoxy]benzoic acid
Rattus norvegicus
-
-
0.0035
4-[2-[3-benzyl-5-(diphenylmethyl)-2,4,6-trioxo-1,3,5-triazinan-1-yl]ethoxy]benzoic acid
Rattus norvegicus
-
-
0.0056
4-[2-[3-butyl-5-(diphenylmethyl)-2,4,6-trioxo-1,3,5-triazinan-1-yl]ethoxy]benzoic acid
Rattus norvegicus
-
-
0.003
4-[2-[5-chloro-1-(diphenylmethyl)-2-methyl-1H-indol-3-yl]ethoxy]benzoic acid
Rattus norvegicus
-
-
0.0124
4-[3-[2-(2,2-diphenylethyl)-3,5-dioxo-1,2,4-oxadiazolidin-4-yl]propoxy]benzoate
Rattus norvegicus
-
-
0.05
4-[4-[2-(2,2-diphenylethyl)-3,5-dioxo-1,2,4-oxadiazolidin-4-yl]butoxy]benzoate
Rattus norvegicus
-
above
0.01
5-(1-[3-(4-octylphenoxy)-2-oxopropyl]indol-5-ylmethylidene)thiazolidine-2,4-dione
Homo sapiens
-
above
0.0021
5-[3-(4-octylphenoxy)-2-oxopropoxy]-1-propylindole-2-carboxylic acid
Homo sapiens
-
pH 7.4
0.0033
5-[3-(4-octylphenoxy)-2-oxopropoxy]indole-2-carboxylic acid
Homo sapiens
-
pH 7.4
0.0065 - 0.1
6-[3-(4-oxo-4H-chromen-2-yl)phenyl]-2-phenyl-4H-chromen-4-one
0.048 - 0.1
6-[4-(4-oxo-4H-chromen-2-yl)phenyl]-2-phenyl-4H-chromen-4-one
0.0125
7-hydroxy-2-oxo-N-[(4Z,7Z,10Z,13Z)-19,19,19-trifluoro-18-oxononadeca-4,7,10,13-tetraen-1-yl]-2H-chromene-3-carboxamide
Apis mellifera
pH and temperature not specified in the publication
0.016 - 0.1
amentoflavone
0.0001
annexin A2-p11 heterotetramer
Homo sapiens
-
pH 7.4, 37°C, recombinant enzyme
-
0.01
aristolochic acid
Sus scrofa
pH 7.4, 37°C, isozyme sPLA2 IB
0.008742
aspirin
Sus scrofa
pH 8.5, 37°C
0.087
Berberine
Daboia russelii russelii
at pH 8.9, temperature not specified in the publication
0.00003
bromoenol lactone
Homo sapiens
-
plasmalogen-specific PLA2, suicide inhibitor, IC50 30nM
0.000013
FPL67047XX
Homo sapiens
-
0.001
gallic acid
Sus scrofa
pH 8.5, 37°C
0.00012
indole-5-carboxamide
Homo sapiens
-
-
0.000035
indole-5-carboxylic acid
Homo sapiens
-
-
0.00001 - 0.000035
indoxam
0.00005 - 0.00007
LY315920
0.0021
methyl [1-[2-oxo-3-(4-phenoxyphenoxy)propyl]-1H-indazol-5-yl]carbamate
Homo sapiens
-
37°C, pH 8.0, substrate 1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine
0.00084
N,N-dimethyl-1-[3-(4-octylphenoxy)-2-oxopropyl]indole-5-carboxamide
Homo sapiens
-
-
0.0005
N,N-dimethyl-1-[3-(4-octylphenoxy)-2-oxopropyl]indole-5-sulfonamide
Homo sapiens
-
-
0.00029
N-cyclohexyl-N'-[1-[2-oxo-3-(4-phenoxyphenoxy)propyl]-1H-indazol-5-yl]urea
Homo sapiens
-
37°C, pH 8.0, substrate 1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine
0.0019
N-ethyl-N'-[1-[2-oxo-3-(4-phenoxyphenoxy)propyl]-1H-indazol-5-yl]urea
Homo sapiens
-
37°C, pH 8.0, substrate 1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine
0.00037
N-methyl-1-[3-(4-octylphenoxy)-2-oxopropyl]indole-5-carboxamide
Homo sapiens
-
-
0.00031
N-methyl-1-[3-(4-octylphenoxy)-2-oxopropyl]indole-5-sulfonamide
Homo sapiens
-
-
0.00013
N-[1-[2-oxo-3-(4-phenoxyphenoxy)propyl]-1H-indazol-5-yl]acetamide
Homo sapiens
-
37°C, pH 8.0, substrate 1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine
0.00055
phenyl [1-[2-oxo-3-(4-phenoxyphenoxy)propyl]-1H-indazol-5-yl]carbamate
Homo sapiens
-
37°C, pH 8.0, substrate 1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine
0.00134
protocatechuic acid
Sus scrofa
pH 8.5, 37°C
0.01
quercetin
Sus scrofa
pH 7.4, 37°C, isozyme sPLA2 IB
0.02
quercetin-3-beta-D-glucoside
Sus scrofa
pH 7.4, 37°C, isozyme sPLA2 IB
0.00181
syringic acid
Sus scrofa
pH 8.5, 37°C
0.00245
vanillic acid
Sus scrofa
pH 8.5, 37°C
additional information
additional information
-
0.0007
(+-)-3-O-[4-(4,5-dihydro-5-oxo-1,2,4-4H-oxadiazol-3-yl)phenyl]-2-O-tetradecyl-1-O-triphenylmethylglycerol
Homo sapiens
-
pH 7.5, isozyme hGV sPLA2
0.0009
(+-)-3-O-[4-(4,5-dihydro-5-oxo-1,2,4-4H-oxadiazol-3-yl)phenyl]-2-O-tetradecyl-1-O-triphenylmethylglycerol
Homo sapiens
-
pH 7.5, isozyme hGIIA sPLA2
0.0013
(+-)-3-O-[4-(4,5-dihydro-5-oxo-1,2,4-4H-oxadiazol-3-yl)phenyl]-2-O-tetradecyl-1-O-triphenylmethylglycerol
Homo sapiens
-
pH 7.5, isozyme hGX sPLA2
0.0058
(+-)-3-O-[4-(4,5-dihydro-5-oxo-1,2,4-4H-oxadiazol-3-yl)phenyl]-2-O-tetradecyl-1-O-triphenylmethylglycerol
Homo sapiens
-
pH 7.5, isozyme hGIB sPLA2
0.0023
(6Z,9Z,12Z,15Z)-1,1,1-trifluorohenicosa-6,9,12,15-tetraen-2-one
Homo sapiens
-
pH 7.4
0.0165
(6Z,9Z,12Z,15Z)-1,1,1-trifluorohenicosa-6,9,12,15-tetraen-2-one
Apis mellifera
pH and temperature not specified in the publication
0.00097
([1-[amino(oxo)acetyl]-3-(biphenyl-2-ylmethyl)-2-(2-methylpropyl)indolizin-8-yl]oxy)acetic acid
Homo sapiens
-
isozyme sPLA2 group IIF
0.0011
([1-[amino(oxo)acetyl]-3-(biphenyl-2-ylmethyl)-2-(2-methylpropyl)indolizin-8-yl]oxy)acetic acid
Mus musculus
-
isozyme sPLA2 group IIF
0.00001
([3-[amino(oxo)acetyl]-1-benzyl-2-(2-methylpropyl)-1H-benzo[g]indol-4-yl]oxy)acetic acid
Homo sapiens
-
isozyme sPLA2 group IIX
0.00013
([3-[amino(oxo)acetyl]-1-benzyl-2-(2-methylpropyl)-1H-benzo[g]indol-4-yl]oxy)acetic acid
Mus musculus
-
isozyme sPLA2 group IIF
0.013
2,2'-biphenyl-3,4'-diylbis(4H-chromen-4-one)
Homo sapiens
pH 9.0, 37°C, isozyme sPLA2-V
0.017
2,2'-biphenyl-3,4'-diylbis(4H-chromen-4-one)
Homo sapiens
pH 9.0, 37°C, isozyme cPLA2
0.02
2,2'-biphenyl-3,4'-diylbis(4H-chromen-4-one)
Homo sapiens
pH 9.0, 37°C, isozyme sPLA2-IIA
0.1
2,2'-biphenyl-3,4'-diylbis(4H-chromen-4-one)
Homo sapiens
above, pH 9.0, 37°C, isozyme sPLA2-V
0.1
2,2'-biphenyl-3,4'-diylbis(4H-chromen-4-one)
Homo sapiens
above, pH 9.0, 37°C, isozyme sPLA2IB2
0.011
2,2'-biphenyl-4,4'-diylbis(4H-chromen-4-one)
Homo sapiens
pH 9.0, 37°C, isozyme sPLA2-V
0.012
2,2'-biphenyl-4,4'-diylbis(4H-chromen-4-one)
Homo sapiens
pH 9.0, 37°C, isozyme cPLA2
0.064
2,2'-biphenyl-4,4'-diylbis(4H-chromen-4-one)
Homo sapiens
pH 9.0, 37°C, isozyme sPLA2-IIA
0.1
2,2'-biphenyl-4,4'-diylbis(4H-chromen-4-one)
Homo sapiens
above, pH 9.0, 37°C, isozyme sPLA2-X
0.1
2,2'-biphenyl-4,4'-diylbis(4H-chromen-4-one)
Homo sapiens
above, pH 9.0, 37°C, isozyme sPLA2IB2
0.024
2,2'-diphenyl-4H,4'H-6,6'-bichromene-4,4'-dione
Homo sapiens
pH 9.0, 37°C, isozyme sPLA2-IIA
0.042
2,2'-diphenyl-4H,4'H-6,6'-bichromene-4,4'-dione
Homo sapiens
pH 9.0, 37°C, isozyme sPLA2-V
0.1
2,2'-diphenyl-4H,4'H-6,6'-bichromene-4,4'-dione
Homo sapiens
above, pH 9.0, 37°C, isozyme cPLA2
0.1
2,2'-diphenyl-4H,4'H-6,6'-bichromene-4,4'-dione
Homo sapiens
above, pH 9.0, 37°C, isozyme sPLA2-X
0.1
2,2'-diphenyl-4H,4'H-6,6'-bichromene-4,4'-dione
Homo sapiens
above, pH 9.0, 37°C, isozyme sPLA2IB2
0.000014
2-(1-benzyl-2-ethyl-4-methoxy-1H-benzo[g]indol-3-yl)-2-oxoacetamide
Homo sapiens
-
isozyme sPLA2 group IIA
0.000034
2-(1-benzyl-2-ethyl-4-methoxy-1H-benzo[g]indol-3-yl)-2-oxoacetamide
Mus musculus
-
isozyme sPLA2 group IIA
0.000006
2-(3-(2-amino-2-oxoacetyl)-1-benzyl-2-ethyl-1H-6,7-benzoindol-4-yloxy)acetic acid
Mus musculus
-
isozyme sPLA2 group IIX
0.000007
2-(3-(2-amino-2-oxoacetyl)-1-benzyl-2-ethyl-1H-6,7-benzoindol-4-yloxy)acetic acid
Homo sapiens
-
isozymes sPLA2 group IIE and IID
0.00003
2-([3-[amino(oxo)acetyl]-1-benzyl-2-(2-methylpropyl)-1H-benzo[g]indol-4-yl]oxy)-N-(phenylsulfonyl)acetamide
Homo sapiens
-
isozyme sPLA2 group IIX
0.00045
2-([3-[amino(oxo)acetyl]-1-benzyl-2-(2-methylpropyl)-1H-benzo[g]indol-4-yl]oxy)-N-(phenylsulfonyl)acetamide
Mus musculus
-
isozyme sPLA2 group IIF
0.000021
2-([3-[amino(oxo)acetyl]-1-benzyl-2-(2-methylpropyl)-1H-indol-4-yl]oxy)-N-(phenylsulfonyl)acetamide
Homo sapiens
-
isozyme sPLA2 group IIX
0.0016
2-([3-[amino(oxo)acetyl]-1-benzyl-2-(2-methylpropyl)-1H-indol-4-yl]oxy)-N-(phenylsulfonyl)acetamide
Mus musculus
-
above, isozyme sPLA2 group IIA-IIX
0.000016
2-([3-[amino(oxo)acetyl]-1-benzyl-2-ethyl-1H-benzo[g]indol-4-yl]oxy)-N-(phenylsulfonyl)acetamide
Homo sapiens
-
isozyme sPLA2 group IIE
0.000035
2-([3-[amino(oxo)acetyl]-1-benzyl-2-ethyl-1H-benzo[g]indol-4-yl]oxy)-N-(phenylsulfonyl)acetamide
Mus musculus
-
isozyme sPLA2 group IIX
0.000007
2-([3-[amino(oxo)acetyl]-1-benzyl-2-ethyl-1H-indol-4-yl]oxy)-N-(phenylsulfonyl)acetamide
Homo sapiens
-
isozyme sPLA2 group IIE
0.000012
2-([3-[amino(oxo)acetyl]-1-benzyl-2-ethyl-1H-indol-4-yl]oxy)-N-(phenylsulfonyl)acetamide
Mus musculus
-
isozyme sPLA2 group IIE
0.00005
2-[1-benzyl-2-(2-methylpropyl)-4-(2-oxopropoxy)-1H-indol-3-yl]-2-oxoacetamide
Homo sapiens
-
isozyme sPLA2 group IIX
0.00058
2-[1-benzyl-2-(2-methylpropyl)-4-(2-oxopropoxy)-1H-indol-3-yl]-2-oxoacetamide
Mus musculus
-
isozyme sPLA2 group IIB
0.000009
2-[1-benzyl-4-(2-oxopropoxy)-2-propyl-1H-indol-3-yl]-2-oxoacetamide
Homo sapiens
-
isozyme sPLA2 group IIE
0.00002
2-[1-benzyl-4-(2-oxopropoxy)-2-propyl-1H-indol-3-yl]-2-oxoacetamide
Mus musculus
-
isozyme sPLA2 group IIX
0.00041
2-[3-(biphenyl-2-ylmethyl)-2-ethyl-8-(2-oxopropoxy)indolizin-1-yl]-2-oxoacetamide
Mus musculus
-
isozyme sPLA2 group IIE
0.009
2-[3-(biphenyl-2-ylmethyl)-2-ethyl-8-(2-oxopropoxy)indolizin-1-yl]-2-oxoacetamide
Homo sapiens
-
isozyme sPLA2 group IIE
0.000035
2-[3-(biphenyl-2-ylmethyl)-2-ethyl-8-methoxyindolizin-1-yl]-2-oxoacetamide
Homo sapiens
-
isozyme sPLA2 group IIA
0.00023
2-[3-(biphenyl-2-ylmethyl)-2-ethyl-8-methoxyindolizin-1-yl]-2-oxoacetamide
Mus musculus
-
isozyme sPLA2 group IIE
0.0305
3,3'-[[2-(pentyloxy)propane-1,3-diyl]bis(oxybenzene-4,1-diylethane-2,1-diyl)]bis(1,2,4-oxadiazol-5(4H)-one)
Homo sapiens
-
above, pH 7.5, isozyme hGIIA sPLA2
0.1
3,3'-[[2-(pentyloxy)propane-1,3-diyl]bis(oxybenzene-4,1-diylethane-2,1-diyl)]bis(1,2,4-oxadiazol-5(4H)-one)
Sus scrofa
-
above, pH 7.5, isozyme hGIB sPLA2
0.0021
3,3'-[[2-(tetradecyloxy)propane-1,3-diyl]bis(oxybenzene-4,1-diylethane-2,1-diyl)]bis(1,2,4-oxadiazol-5(4H)-one)
Homo sapiens
-
pH 7.5, isozyme hGIIA sPLA2
0.0399
3,3'-[[2-(tetradecyloxy)propane-1,3-diyl]bis(oxybenzene-4,1-diylethane-2,1-diyl)]bis(1,2,4-oxadiazol-5(4H)-one)
Sus scrofa
-
pH 7.5, isozyme hGIB sPLA2
0.0477
3,3'-[[2-(tetradecyloxy)propane-1,3-diyl]bis(oxybenzene-4,1-diylmethanediyl)]bis(1,2,4-oxadiazol-5(4H)-one)
Homo sapiens
-
above, pH 7.5, isozyme hGIIA sPLA2
0.1
3,3'-[[2-(tetradecyloxy)propane-1,3-diyl]bis(oxybenzene-4,1-diylmethanediyl)]bis(1,2,4-oxadiazol-5(4H)-one)
Sus scrofa
-
above, pH 7.5, isozyme hGIB sPLA2
0.0031
3,3'-[[3-(tetradecyloxy)propane-1,2-diyl]bis(oxybenzene-4,1-diylethane-2,1-diyl)]bis(1,2,4-oxadiazol-5(4H)-one)
Homo sapiens
-
pH 7.5, isozyme hGIIA sPLA2
0.0578
3,3'-[[3-(tetradecyloxy)propane-1,2-diyl]bis(oxybenzene-4,1-diylethane-2,1-diyl)]bis(1,2,4-oxadiazol-5(4H)-one)
Sus scrofa
-
pH 7.5, isozyme hGIB sPLA2
0.021
3,3'-[[3-(tetradecyloxy)propane-1,2-diyl]bis(oxybenzene-4,1-diylmethanediyl)]bis(1,2,4-oxadiazol-5(4H)-one)
Homo sapiens
-
pH 7.5, isozyme hGIIA sPLA2
0.0636
3,3'-[[3-(tetradecyloxy)propane-1,2-diyl]bis(oxybenzene-4,1-diylmethanediyl)]bis(1,2,4-oxadiazol-5(4H)-one)
Sus scrofa
-
pH 7.5, isozyme hGIB sPLA2
0.0187
3-(2-[4-[(4-tetradecylpiperazin-1-yl)carbonyl]phenyl]ethyl)-1,2,4-oxadiazol-5(4H)-one
Homo sapiens
-
-
0.1
3-(2-[4-[(4-tetradecylpiperazin-1-yl)carbonyl]phenyl]ethyl)-1,2,4-oxadiazol-5(4H)-one
Sus scrofa
-
-
0.0053
3-(3-[4-[(4-tetradecylpiperazin-1-yl)carbonyl]phenyl]propyl)-1,2,4-oxadiazol-5(4H)-one
Homo sapiens
-
-
0.1
3-(3-[4-[(4-tetradecylpiperazin-1-yl)carbonyl]phenyl]propyl)-1,2,4-oxadiazol-5(4H)-one
Sus scrofa
-
-
0.0035
3-[4-(4-hexadecylpiperazin-1-yl)benzyl]-1,2,4-oxadiazol-5(4H)-one
Homo sapiens
-
-
0.1
3-[4-(4-hexadecylpiperazin-1-yl)benzyl]-1,2,4-oxadiazol-5(4H)-one
Sus scrofa
-
-
0.00271
3-[4-(4-octadecylpiperazin-1-yl)benzyl]-1,2,4-oxadiazol-5(4H)-one
Homo sapiens
-
-
0.1
3-[4-(4-octadecylpiperazin-1-yl)benzyl]-1,2,4-oxadiazol-5(4H)-one
Sus scrofa
-
-
0.0035
3-[4-(4-oxo-4H-chromen-2-yl)phenyl]-2-phenyl-4H-chromen-4-one
Homo sapiens
pH 9.0, 37°C, isozyme sPLA2-IIA
0.018
3-[4-(4-oxo-4H-chromen-2-yl)phenyl]-2-phenyl-4H-chromen-4-one
Homo sapiens
pH 9.0, 37°C, isozyme sPLA2-V
0.1
3-[4-(4-oxo-4H-chromen-2-yl)phenyl]-2-phenyl-4H-chromen-4-one
Homo sapiens
above, pH 9.0, 37°C, isozyme cPLA2
0.1
3-[4-(4-oxo-4H-chromen-2-yl)phenyl]-2-phenyl-4H-chromen-4-one
Homo sapiens
above, pH 9.0, 37°C, isozyme sPLA2-X
0.1
3-[4-(4-oxo-4H-chromen-2-yl)phenyl]-2-phenyl-4H-chromen-4-one
Homo sapiens
above, pH 9.0, 37°C, isozyme sPLA2IB2
0.0045
3-[4-(4-tetradecylpiperazin-1-yl)benzyl]-1,2,4-oxadiazol-5(4H)-one
Homo sapiens
-
-
0.1
3-[4-(4-tetradecylpiperazin-1-yl)benzyl]-1,2,4-oxadiazol-5(4H)-one
Sus scrofa
-
-
0.004
3-[4-(tetradecyloxy)benzyl]-1,2,4-oxadiazol-5(4H)-one
Homo sapiens
-
-
0.1
3-[4-(tetradecyloxy)benzyl]-1,2,4-oxadiazol-5(4H)-one
Sus scrofa
-
-
0.1
3-[4-[(4-docosylpiperazin-1-yl)carbonyl]benzyl]-1,2,4-oxadiazol-5(4H)-one
Homo sapiens
-
-
0.1
3-[4-[(4-docosylpiperazin-1-yl)carbonyl]benzyl]-1,2,4-oxadiazol-5(4H)-one
Sus scrofa
-
-
0.004
3-[4-[(4-hexadecylpiperazin-1-yl)carbonyl]benzyl]-1,2,4-oxadiazol-5(4H)-one
Homo sapiens
-
-
0.1
3-[4-[(4-hexadecylpiperazin-1-yl)carbonyl]benzyl]-1,2,4-oxadiazol-5(4H)-one
Sus scrofa
-
-
0.1
3-[4-[(4-hexadecylpiperazin-1-yl)carbonyl]phenyl]-1,2,4-oxadiazol-5(4H)-one
Homo sapiens
-
-
0.1
3-[4-[(4-hexadecylpiperazin-1-yl)carbonyl]phenyl]-1,2,4-oxadiazol-5(4H)-one
Sus scrofa
-
-
0.1
3-[4-[(4-hexadecylpiperazin-1-yl)methyl]benzyl]-1,2,4-oxadiazol-5(4H)-one
Homo sapiens
-
-
0.1
3-[4-[(4-hexadecylpiperazin-1-yl)methyl]benzyl]-1,2,4-oxadiazol-5(4H)-one
Sus scrofa
-
-
0.1
3-[4-[(4-hexadecylpiperazin-1-yl)methyl]phenyl]-1,2,4-oxadiazol-5(4H)-one
Homo sapiens
-
-
0.1
3-[4-[(4-hexadecylpiperazin-1-yl)methyl]phenyl]-1,2,4-oxadiazol-5(4H)-one
Sus scrofa
-
-
0.1
3-[4-[(4-icosylpiperazin-1-yl)carbonyl]benzyl]-1,2,4-oxadiazol-5(4H)-one
Homo sapiens
-
-
0.1
3-[4-[(4-icosylpiperazin-1-yl)carbonyl]benzyl]-1,2,4-oxadiazol-5(4H)-one
Sus scrofa
-
-
0.0008
3-[4-[(4-octadecylpiperazin-1-yl)carbonyl]benzyl]-1,2,4-oxadiazol-5(4H)-one
Homo sapiens
-
-
0.1
3-[4-[(4-octadecylpiperazin-1-yl)carbonyl]benzyl]-1,2,4-oxadiazol-5(4H)-one
Sus scrofa
-
-
0.0011
3-[4-[(4-octadecylpiperazin-1-yl)carbonyl]phenyl]-1,2,4-oxadiazol-5(4H)-one
Homo sapiens
-
-
0.1
3-[4-[(4-octadecylpiperazin-1-yl)carbonyl]phenyl]-1,2,4-oxadiazol-5(4H)-one
Sus scrofa
-
-
0.0022
3-[4-[(4-octadecylpiperazin-1-yl)methyl]benzyl]-1,2,4-oxadiazol-5(4H)-one
Homo sapiens
-
-
0.1
3-[4-[(4-octadecylpiperazin-1-yl)methyl]benzyl]-1,2,4-oxadiazol-5(4H)-one
Sus scrofa
-
-
0.00508
3-[4-[(4-octadecylpiperazin-1-yl)methyl]phenyl]-1,2,4-oxadiazol-5(4H)-one
Homo sapiens
-
-
0.1
3-[4-[(4-octadecylpiperazin-1-yl)methyl]phenyl]-1,2,4-oxadiazol-5(4H)-one
Sus scrofa
-
-
0.009
3-[4-[(4-tetradecylpiperazin-1-yl)carbonyl]benzyl]-1,2,4-oxadiazol-5(4H)-one
Homo sapiens
-
-
0.1
3-[4-[(4-tetradecylpiperazin-1-yl)carbonyl]benzyl]-1,2,4-oxadiazol-5(4H)-one
Sus scrofa
-
-
0.1
3-[4-[(4-tetradecylpiperazin-1-yl)carbonyl]phenyl]-1,2,4-oxadiazol-5(4H)-one
Homo sapiens
-
-
0.1
3-[4-[(4-tetradecylpiperazin-1-yl)carbonyl]phenyl]-1,2,4-oxadiazol-5(4H)-one
Sus scrofa
-
-
0.1
3-[4-[(4-tetradecylpiperazin-1-yl)methyl]benzyl]-1,2,4-oxadiazol-5(4H)-one
Homo sapiens
-
-
0.1
3-[4-[(4-tetradecylpiperazin-1-yl)methyl]benzyl]-1,2,4-oxadiazol-5(4H)-one
Sus scrofa
-
-
0.1
3-[4-[(4-tetradecylpiperazin-1-yl)methyl]phenyl]-1,2,4-oxadiazol-5(4H)-one
Homo sapiens
-
-
0.1
3-[4-[(4-tetradecylpiperazin-1-yl)methyl]phenyl]-1,2,4-oxadiazol-5(4H)-one
Sus scrofa
-
-
0.00029
3-[4-[3-(4-butylphenoxy)-2-(tetradecyloxy)propoxy]benzyl]-1,2,4-oxadiazol-5(4H)-one
Homo sapiens
-
pH 7.5, isozyme hGIIA sPLA2
0.0022
3-[4-[3-(4-butylphenoxy)-2-(tetradecyloxy)propoxy]benzyl]-1,2,4-oxadiazol-5(4H)-one
Sus scrofa
-
pH 7.5, isozyme hGIB sPLA2
0.012
3-[4-[3-(4-butylphenoxy)-2-(tetradecyloxy)propoxy]benzyl]-1,2,4-oxadiazol-5(4H)-one
Homo sapiens
-
pH 7.5, isozyme hGX sPLA2
0.015
3-[4-[3-(4-butylphenoxy)-2-(tetradecyloxy)propoxy]benzyl]-1,2,4-oxadiazol-5(4H)-one
Homo sapiens
-
pH 7.5, isozyme hGIB sPLA2
0.022
3-[4-[3-(4-butylphenoxy)-2-(tetradecyloxy)propoxy]benzyl]-1,2,4-oxadiazol-5(4H)-one
Homo sapiens
-
pH 7.5, isozyme hGV sPLA2
0.014
3-[4-[3-(4-methylphenoxy)-2-(tetradecyloxy)propoxy]benzyl]-1,2,4-oxadiazol-5(4H)-one
Homo sapiens
-
pH 7.5, isozyme hGX sPLA2
0.0148
3-[4-[3-(4-methylphenoxy)-2-(tetradecyloxy)propoxy]benzyl]-1,2,4-oxadiazol-5(4H)-one
Homo sapiens
-
pH 7.5, isozyme hGIIA sPLA2
0.025
3-[4-[3-(4-methylphenoxy)-2-(tetradecyloxy)propoxy]benzyl]-1,2,4-oxadiazol-5(4H)-one
Sus scrofa
-
pH 7.5, isozyme hGIB sPLA2
0.1
3-[4-[3-(4-methylphenoxy)-2-(tetradecyloxy)propoxy]benzyl]-1,2,4-oxadiazol-5(4H)-one
Homo sapiens
-
pH 7.5, isozyme hGIB sPLA2
0.1
3-[4-[3-(4-methylphenoxy)-2-(tetradecyloxy)propoxy]benzyl]-1,2,4-oxadiazol-5(4H)-one
Homo sapiens
-
pH 7.5, isozyme hGV sPLA2
0.00028
3-[4-[3-(decyloxy)-2-(tetradecyloxy)propoxy]benzyl]-1,2,4-oxadiazol-5(4H)-one
Homo sapiens
-
pH 7.5, isozyme hGIIA sPLA2
0.00055
3-[4-[3-(decyloxy)-2-(tetradecyloxy)propoxy]benzyl]-1,2,4-oxadiazol-5(4H)-one
Homo sapiens
-
pH 7.5, isozyme hGV sPLA2
0.001
3-[4-[3-(decyloxy)-2-(tetradecyloxy)propoxy]benzyl]-1,2,4-oxadiazol-5(4H)-one
Homo sapiens
-
pH 7.5, isozyme hGX sPLA2
0.01
3-[4-[3-(decyloxy)-2-(tetradecyloxy)propoxy]benzyl]-1,2,4-oxadiazol-5(4H)-one
Homo sapiens
-
pH 7.5, isozyme hGIB sPLA2
0.1
3-[4-[3-(decyloxy)-2-(tetradecyloxy)propoxy]benzyl]-1,2,4-oxadiazol-5(4H)-one
Sus scrofa
-
pH 7.5, isozyme hGIB sPLA2
0.00028
3-[4-[3-(diphenylmethoxy)-2-(tetradecyloxy)propoxy]benzyl]-1,2,4-oxadiazol-5(4H)-one
Homo sapiens
-
pH 7.5, isozyme hGIIA sPLA2
0.002
3-[4-[3-(diphenylmethoxy)-2-(tetradecyloxy)propoxy]benzyl]-1,2,4-oxadiazol-5(4H)-one
Homo sapiens
-
pH 7.5, isozyme hGV sPLA2
0.0053
3-[4-[3-(diphenylmethoxy)-2-(tetradecyloxy)propoxy]benzyl]-1,2,4-oxadiazol-5(4H)-one
Homo sapiens
-
pH 7.5, isozyme hGX sPLA2
0.0056
3-[4-[3-(diphenylmethoxy)-2-(tetradecyloxy)propoxy]benzyl]-1,2,4-oxadiazol-5(4H)-one
Sus scrofa
-
pH 7.5, isozyme hGIB sPLA2
0.018
3-[4-[3-(diphenylmethoxy)-2-(tetradecyloxy)propoxy]benzyl]-1,2,4-oxadiazol-5(4H)-one
Homo sapiens
-
pH 7.5, isozyme hGIB sPLA2
0.0083
3-[4-[3-(pentyloxy)-2-(tetradecyloxy)propoxy]benzyl]-1,2,4-oxadiazol-5(4H)-one
Homo sapiens
-
pH 7.5, isozyme hGIIA sPLA2
0.1
3-[4-[3-(pentyloxy)-2-(tetradecyloxy)propoxy]benzyl]-1,2,4-oxadiazol-5(4H)-one
Sus scrofa
-
pH 7.5, isozyme hGIB sPLA2
0.0298
3-[4-[3-ethoxy-2-(tetradecyloxy)propoxy]benzyl]-1,2,4-oxadiazol-5(4H)-one
Homo sapiens
-
pH 7.5, isozyme hGIIA sPLA2
0.04
3-[4-[3-ethoxy-2-(tetradecyloxy)propoxy]benzyl]-1,2,4-oxadiazol-5(4H)-one
Sus scrofa
-
pH 7.5, isozyme hGIB sPLA2
0.0065
6-[3-(4-oxo-4H-chromen-2-yl)phenyl]-2-phenyl-4H-chromen-4-one
Homo sapiens
pH 9.0, 37°C, isozyme sPLA2-V
0.009
6-[3-(4-oxo-4H-chromen-2-yl)phenyl]-2-phenyl-4H-chromen-4-one
Homo sapiens
pH 9.0, 37°C, isozyme cPLA2
0.023
6-[3-(4-oxo-4H-chromen-2-yl)phenyl]-2-phenyl-4H-chromen-4-one
Homo sapiens
pH 9.0, 37°C, isozyme sPLA2-IIA
0.028
6-[3-(4-oxo-4H-chromen-2-yl)phenyl]-2-phenyl-4H-chromen-4-one
Homo sapiens
pH 9.0, 37°C, isozyme sPLA2-X
0.1
6-[3-(4-oxo-4H-chromen-2-yl)phenyl]-2-phenyl-4H-chromen-4-one
Homo sapiens
above, pH 9.0, 37°C, isozyme sPLA2IB2
0.048
6-[4-(4-oxo-4H-chromen-2-yl)phenyl]-2-phenyl-4H-chromen-4-one
Homo sapiens
pH 9.0, 37°C, isozyme cPLA2
0.05
6-[4-(4-oxo-4H-chromen-2-yl)phenyl]-2-phenyl-4H-chromen-4-one
Homo sapiens
pH 9.0, 37°C, isozyme sPLA2-V
0.069
6-[4-(4-oxo-4H-chromen-2-yl)phenyl]-2-phenyl-4H-chromen-4-one
Homo sapiens
pH 9.0, 37°C, isozyme sPLA2-IIA
0.1
6-[4-(4-oxo-4H-chromen-2-yl)phenyl]-2-phenyl-4H-chromen-4-one
Homo sapiens
above, pH 9.0, 37°C, isozyme sPLA2-X
0.1
6-[4-(4-oxo-4H-chromen-2-yl)phenyl]-2-phenyl-4H-chromen-4-one
Homo sapiens
above, pH 9.0, 37°C, isozyme sPLA2IB2
0.016
amentoflavone
Homo sapiens
pH 9.0, 37°C, isozyme sPLA2-IIA
0.024
amentoflavone
Homo sapiens
pH 9.0, 37°C, isozyme sPLA2-V
0.039
amentoflavone
Homo sapiens
pH 9.0, 37°C, isozyme cPLA2
0.1
amentoflavone
Homo sapiens
above, pH 9.0, 37°C, isozyme sPLA2IB2
0.1
amentoflavone
Homo sapiens
pH 9.0, 37°C, isozyme sPLA2-X
0.00001
indoxam
Homo sapiens
-
isozyme sPLA2 group IIE
0.000035
indoxam
Mus musculus
-
isozyme sPLA2 group IIE
0.00047
LY311727
Homo sapiens
-
-
0.008
LY311727
Sus scrofa
-
-
0.00005
LY315920
Homo sapiens
-
isozyme sPLA2 group IIE
0.00007
LY315920
Mus musculus
-
isozyme sPLA2 group IIA
0.003
ochnaflavone
Homo sapiens
pH 9.0, 37°C, isozyme sPLA2-IIA
0.006
ochnaflavone
Homo sapiens
pH 9.0, 37°C, isozyme cPLA2
0.0087
ochnaflavone
Homo sapiens
pH 9.0, 37°C, isozyme sPLA2-V
0.1
ochnaflavone
Homo sapiens
above, pH 9.0, 37°C, isozyme sPLA2IB2
0.1
ochnaflavone
Homo sapiens
pH 9.0, 37°C, isozyme sPLA2-X
additional information
additional information
Homo sapiens
-
-
-
additional information
additional information
Mus musculus
-
IC50 values of diverse isozymes, overview
-
additional information
additional information
Homo sapiens
-
IC50 values of diverse isozymes, overview
-
additional information
additional information
Homo sapiens
-
inhibition of cPLA2a activity in the isolated enzyme assay and in the cellular assay, overview
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.000006
-
isoform cPLA2delta, using 1-palmitoyl-2-arachidonyl-sn-glycerol-3-phosphocholine as substrate, in 10 mM MOPS, pH 7.2, 0.5 mM EGTA, 100 mM KCl, 0.5 mg/ml bovine serum albumin, 0.02 mM Ca2+, at 37°C
0.00001
-
cytosolic colon mucosa PLA2, substrate: 1-palmitoyl-2-oleolylphosphatidylcholine
0.0000115
-
particulate associated hormonally regulated PLA2, substrate: 1-palmitoyl-2-arachidonylphosphatidylcholine, mixed micelles with Triton X-100
0.000019
-
cytosolic colon mucosa PLA2, substrate: 1-palmitoyl-2-arachidonylphosphatidylcholine
0.00002
-
microsomal colon mucosa PLA2, substrate: 1-palmitoyl-2-arachidonylphosphatidylcholine
0.000021
-
isoform cPLA2epsilon, using 1-palmitoyl-sn-glycero-3-phosphocholine as substrate, in 10 mM MOPS, pH 7.2, 0.5 mM EGTA, 100 mM KCl, 0.5 mg/ml bovine serum albumin, in the absence of Ca2+, at 37°C
0.00004
-
isoform cPLA2epsilon, using 1-palmitoyl-2-arachidonyl-sn-glycerol-3-phosphocholine as substrate, in 10 mM MOPS, pH 7.2, 0.5 mM EGTA, 100 mM KCl, 0.5 mg/ml bovine serum albumin, 0.02 mM Ca2+, at 37°C
0.0000538
-
particulate associated hormonally regulated PLA2, substrate: micellar 1-palmitoyl-2-arachidonylphosphatidylcholine
0.00006
-
isoform cPLA2delta, using 1-palmitoyl-2-arachidonyl-sn-glycerol-3-phosphocholine as substrate, in 10 mM MOPS, pH 7.2, 0.5 mM EGTA, 100 mM KCl, 0.5 mg/ml bovine serum albumin, in the absence of Ca2+, at 37°C
0.000145
-
isoform cPLA2epsilon, using 1-palmitoyl-sn-glycero-3-phosphocholine as substrate, in 10 mM MOPS, pH 7.2, 0.5 mM EGTA, 100 mM KCl, 0.5 mg/ml bovine serum albumin, 0.02 mM Ca2+, at 37°C
0.00021
-
isoform cPLA2delta, using 1-palmitoyl-sn-glycero-3-phosphocholine as substrate, in 10 mM MOPS, pH 7.2, 0.5 mM EGTA, 100 mM KCl, 0.5 mg/ml bovine serum albumin, 0.02 mM Ca2+, at 37°C
0.000245
-
isoform cPLA2beta, using 1-palmitoyl-2-arachidonyl-sn-glycerol-3-phosphocholine as substrate, in 10 mM MOPS, pH 7.2, 0.5 mM EGTA, 100 mM KCl, 0.5 mg/ml bovine serum albumin, in the absence of Ca2+, at 37°C
0.000295
-
isoform cPLA2beta, using 1-palmitoyl-2-arachidonyl-sn-glycerol-3-phosphocholine as substrate, in 10 mM MOPS, pH 7.2, 0.5 mM EGTA, 100 mM KCl, 0.5 mg/ml bovine serum albumin, 0.02 mM Ca2+, at 37°C
0.0011
-
isoform cPLA2alpha, using 1-palmitoyl-2-arachidonyl-sn-glycerol-3-phosphocholine as substrate, in 10 mM MOPS, pH 7.2, 0.5 mM EGTA, 100 mM KCl, 0.5 mg/ml bovine serum albumin, in the absence of Ca2+, at 37°C
0.0014
-
oleate labelled Escherichia coli membrane
0.0016
-
arachidonate labelled Escherichia coli membrane
0.0021
-
arachidonate labelled Escherichia coli membrane
0.0023
-
oleate labelled Escherichia coli membrane
0.00245
-
isoform cPLA2zeta, using 1-palmitoyl-2-arachidonyl-sn-glycerol-3-phosphocholine as substrate, in 10 mM MOPS, pH 7.2, 0.5 mM EGTA, 100 mM KCl, 0.5 mg/ml bovine serum albumin, in the absence of Ca2+, at 37°C
0.0062
-
sigmoid colon mucosa, substrate: 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol
0.0071
-
cecal mucosa, substrate: 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol
0.0072
-
ascending colon mucosa, substrate: 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol
0.0078
-
transverse colon mucosa, substrate: 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol
0.0092
-
descending colon mucosa, substrate: 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol
0.0106
1-palmitoyl-2-arachidonylphosphocholine as substrate
0.0156
1-stearoyl-2-arachidonylphosphocholine as substrate
0.0172
-
substrate: 1-acyl-arachidonoyl-sn-glycero-3-phosphoethanolamine
0.0192
-
substrate: phosphatidylcholine
0.027
-
acidic iPLA2, substrate: 1-O-hexadecyl-2-arachidonoyl-glycero-3-phosphocholine
0.0379
-
substrate: phosphatidylethanolamine
0.04
-
renatured enzyme, substrate: 1,2-dipalmitoyl-phosphatidylcholine
0.05
-
isoform cPLA2gamma, using 1-palmitoyl-sn-glycero-3-phosphocholine as substrate, in 10 mM MOPS, pH 7.2, 0.5 mM EGTA, 100 mM KCl, 0.5 mg/ml bovine serum albumin, 0.02 mM Ca2+, at 37°C
0.0509
-
ileal mucosa, substrate: 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol
0.058
-
isoform cPLA2gamma, using 1-palmitoyl-sn-glycero-3-phosphocholine as substrate, in 10 mM MOPS, pH 7.2, 0.5 mM EGTA, 100 mM KCl, 0.5 mg/ml bovine serum albumin, in the absence of Ca2+, at 37°C
0.06
-
isoform cPLA2zeta, using 1-palmitoyl-2-arachidonyl-sn-glycerol-3-phosphocholine as substrate, in 10 mM MOPS, pH 7.2, 0.5 mM EGTA, 100 mM KCl, 0.5 mg/ml bovine serum albumin, 0.02 mM Ca2+, at 37°C
0.0609
-
substrate: 1-palmitoyl-2-arachidonylphosphatidylcholine
0.064
-
acidic iPLA2, substrate: 1-palmitoyl-2-arachidonylphosphatidylcholine or 1,2-dipalmitoyl-phosphatidylcholine
0.065
-
acidic iPLA2, substrate: oxidized 1-palmitoyl-2-arachidonylphosphatidylcholine
0.08
-
acidic iPLA2, pH 4.0, Ca2+-free medium, substrate: 1,2-dipalmitoyl-phosphatidylcholine
0.12
-
pancreas, substrate: mixed micelles of 1-palmitoyl-2-oleolyl-sn-glycero-3-phosphoethanolamine and deoxycholate
0.126
-
isoform cPLA2alpha, using 1-palmitoyl-sn-glycero-3-phosphocholine as substrate, in 10 mM MOPS, pH 7.2, 0.5 mM EGTA, 100 mM KCl, 0.5 mg/ml bovine serum albumin, 0.02 mM Ca2+, at 37°C
0.14
-
substrate 1-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine
0.145
-
isoform cPLA2alpha, using 1-palmitoyl-sn-glycero-3-phosphocholine as substrate, in 10 mM MOPS, pH 7.2, 0.5 mM EGTA, 100 mM KCl, 0.5 mg/ml bovine serum albumin, in the absence of Ca2+, at 37°C
0.2
-
extraction at pH 8.5, in 10 mM Tris/HCl buffer, 10 mM CaCl2, 0.15 M NaCl
0.211
-
pancreas, substrate: 1-O-hexadecyl-oleolyl-sn-glycero-3-phosphocholine
0.23
-
isoform cPLA2alpha, using 1-palmitoyl-2-arachidonyl-sn-glycerol-3-phosphocholine as substrate, in 10 mM MOPS, pH 7.2, 0.5 mM EGTA, 100 mM KCl, 0.5 mg/ml bovine serum albumin, 0.02 mM Ca2+, at 37°C
0.259
-
substrate: 1-acyl-2-arachidonoyl-glycerophosphocholine
0.3
-
crude enzyme, in 10 mM Tris-HCl, 10 mM CaCl2 and 100 mM NaCl, pH 8.0, at 37°C
0.347
-
crude venom preparation
0.365
-
isoform cPLA2beta, using 1-palmitoyl-sn-glycero-3-phosphocholine as substrate, in 10 mM MOPS, pH 7.2, 0.5 mM EGTA, 100 mM KCl, 0.5 mg/ml bovine serum albumin, 0.02 mM Ca2+, at 37°C
0.3695
-
isoform cPLA2zeta, using 1-palmitoyl-sn-glycero-3-phosphocholine as substrate, in 10 mM MOPS, pH 7.2, 0.5 mM EGTA, 100 mM KCl, 0.5 mg/ml bovine serum albumin, 0.02 mM Ca2+, at 37°C
0.372
-
isoform cPLA2zeta, using 1-palmitoyl-sn-glycero-3-phosphocholine as substrate, in 10 mM MOPS, pH 7.2, 0.5 mM EGTA, 100 mM KCl, 0.5 mg/ml bovine serum albumin, in the absence of Ca2+, at 37°C
0.381
-
isoform cPLA2beta, using 1-palmitoyl-sn-glycero-3-phosphocholine as substrate, in 10 mM MOPS, pH 7.2, 0.5 mM EGTA, 100 mM KCl, 0.5 mg/ml bovine serum albumin, in the absence of Ca2+, at 37°C
0.4
-
substrate: phosphatidylcholine
0.45
-
antrum, substrate: mixed micelles of 1-palmitoyl-2-oleolyl-sn-glycero-3-phosphoethanolamine and deoxycholate
0.51
-
substrate: standardized commercial phospholipid emulsion
0.56
-
native enzyme, substrate: 1,2-dipalmitoyl-phosphatidylcholine
0.6
-
iPLA2 in a 30000fold purification, substrate: 1-stearoyl-2-arachidonoylphosphatidylcholine
0.72
-
crude extract, at 50°C and pH 8.5, with phosphatidylcholine liposomes as a substrate in the presence of 4 mM sodium taurodeoxycholate and 6 mM CaCl2
1 - 10
-
phospholipid/Triton X-100: 1/2,1/3,und 1/4, phospholipid concentration up to 30 mM
1.05
-
substrate: phosphatidylcholine
1.1
-
isoform Tpu-E6b, presence of Triton X-100, 37°C, pH 7.4
1.6
-
PLA2 zymogen, substrate: egg yolk emulsion
1.8
-
substrate: 1-palmitoyl-2-linoleoylphosphatidylcholine
101.2
-
isoenzyme NK-PLA2-I, substrate phosphatidylserine, sn-2 fatty acid C18:1, 25°C
1030
-
gastric mucosa, substrate: 1-palmitoyl-2-oleolyl-sn-glycero-3-phosphoethanolamine
1034
-
crude venom, pH and temperature not specified in the publication
1050
-
10 mM phosphocholine, N-phosphocholine/N-sodiumcholate: 1.42
109
-
1,2-dinonanoyl-sn-glycero-3-phosphocholine as substrate
11
-
isoform Tpu-E6a, presence of deoxycholate, 37°C, pH 7.4
11.7
-
isoform Tbo-E6, presence of deoxycholate, 37°C, pH 7.4
110
-
recombinant enzyme, substrate: 1-palmitoyl-2-linoleoylphosphatidylethanolamine
1129
-
substrate: 1,2-diacyl-phosphatidylcholine
1140
-
substrate: egg yolk emulsion
11400
-
substrate: 1,2-dioctanoyl-sn-glycero-3-phosphocholine
1150
-
substrate: egg yolk emulsion, PLA2 isoenzyme
118
-
substrate: 1,2-didecanoyl-sn-glycero-3-phosphocholine
1180
-
substrate: egg yolk emulsion, PLA2 isoenzyme
119000
purified wild-type enzyme
12.6
-
substrate: phosphatidylcholine
1220
-
substrate: 1,2-dioctanoyl-sn-glycero-3-phosphoglycol
123
-
isoform NN-XI-PLA2, 37°C
124
-
substrate: 1,2-dilaureoyl-sn-glycero-3-phosphocholine
125
-
substrate: 1,2-dinonanoyl-sn-glycero-3-phosphocholine
127
-
1,2-diocytanoyl-sn-glycero-3-phosphocholine as substrate
1270
-
active PLA2, substrate: egg yolk emulsion
1300
-
egg yolk lipoprotein assay
133
-
isoenzyme NK-PLA2-II, substrate phosphatidylcholine, sn-2 fatty acid C16:0, 25°C
138
-
isoform NN-XIa-PLA2, 37°C
14.4
-
purified recombinant AtsPLA2-alpha, substrate 1,2-dioctanoyl-sn-glycero-3-phosphocholine
1450
-
substrate: phosphatidylcholine
15
-
4-nitrophenylcaprate as substrate
15.3
-
purified recombinant AtsPLA2-alpha, substrate 1,2-dioleoyl-sn-glycero-3-phosphorac-(1-glycerol)
15.6
-
purified recombinant AtsPLA2-alpha, substrate 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine
150
-
5 mM phosphocholine, N-phosphocholine/N-sodiumcholate: 0.36
1500
-
de-/renatured acidic PLA2, PC for substrate
153.9
-
isoenzyme NK-PLA2-II, substrate phosphatidylcholine, sn-2 fatty acid C18:0, 25°C
155
-
substrate: dioleolyl-sn-phosphatidylethanolamine
159.9
-
purified enzyme, pH and temperature not specified in the publication
16.5
-
purified recombinant AtsPLA2-alpha, substrate 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine
16.7
-
purified recombinant AtsPLA2-alpha, substrate 1,2-dioleoyl-sn-glycero-3-phosphocholine
1600
-
de-/renatured basic-acidic PLA2, PA for substrate
16000
-
substrate: 1,2-dioctanoyl-sn-glycero-3-phosphoglycol
162
-
substrate: 1,2-dioctanoyl-sn-glycero-3-phosphocholine
1648
-
pH6, micellar 1,2-dioctanoyl-sn-glycero-3-phosphocholine, isoenzyme of e-amidinated PLA, 0.71 mM Ca2+
1670
-
phospholipid/Triton X-100: 1/3
1693
-
pH6, micellar 1,2-dioctanoyl-sn-glycero-3-phosphocholine, 0.42 mM Ca2+
17.8
-
purified recombinant AtsPLA2-alpha, substrate 1-oleoyl-2-stearoyl-sn-glycero-3-phosphocholine
171
-
substrate: 1,2-dinonanoyl-sn-glycero-3-phosphocholine
172
-
substrate: 1,2-dioctanoyl-sn-glycero-3-phosphocholine
1750
-
de-/renatured basic PLA2, PA for substrate
178.4
-
isoenzyme NK-PLA2-I, substrate phosphatidylcholine, sn-2 fatty acid C18:1, 25°C
18
-
purified recombinant AtsPLA2-alpha, substrate 1-oleoyl-2-palmitoyl-sn-glycero-3-phosphocholine
180
-
250fold purified enzyme, at 50°C and pH 8.5, with phosphatidylcholine liposomes as a substrate in the presence of 4 mM sodium taurodeoxycholate and 6 mM CaCl2
19.5
-
purified recombinant AtsPLA2-alpha, substrate 1,2-dilinoleoyl-sn-glycero-3-phosphocholine
2
-
iPLA2 in a 30000fold purification, substrate: 1-palmitoyl-2-arachidonoylphosphatidylcholine
2.08
25°C, pH not specified in the publication
20
-
fundus, substrate: mixed micelles of 1-palmitoyl-2-oleolyl-sn-glycero-3-phosphoethanolamine and deoxycholate
20.6
-
purified recombinant AtsPLA2-alpha, substrate 1,2-dipalmitoyl-sn-glycero-3-phosphocholine
202.3
-
isoenzyme NK-PLA2-I, substrate phosphatidylcholine, sn-2 fatty acid C18:2, 25°C
2038
-
pH6, micellar 1,2-dioctanoyl-sn-glycero-3-phosphocholine, 0.64 mM Ca2+
208
-
substrate: dioleolyl phosphatidylglycerol
210
-
substrate: dioleolyl-sn-phosphatidylethanolamine
2100
-
phospholipid/Triton X-100: 1/2
2170
-
pH8, micellar 1,2-dioctanoyl-sn-glycero-3-phosphocholine, iso-AMPA, 0.30 mM Ca2+
218.4
-
isoenzyme NK-PLA2-II, substrate phosphatidylcholine, sn-2 fatty acid C18:2, 25°C
220.5
-
isoenzyme NK-PLA2-I, substrate phosphatidylcholine, sn-2 fatty acid C16:0, 25°C
221
-
natural enzyme, substrate: 1-palmitoyl-2-linoleoylphosphatidylethanolamine
229.9
-
isoenzyme NK-PLA2-II, substrate phosphatidylcholine, sn-2 fatty acid C18:1, 25°C
2312
-
purified enzyme, pH and temperature not specified in the publication
243.1
-
isoenzyme NK-PLA2-I, substrate phosphatidylcholine, sn-2 fatty acid C18:0, 25°C
25
-
substrate: dioleolyl-sn-phosphatidylcholine
25.3
-
purified recombinant AtsPLA2-alpha, substrate 1-palmitoyl-2-linoleoyl-sn-glycero-3-phosphocholine
27.3
-
purified recombinant AtsPLA2-alpha, substrate 1,2-dimyristoyl-sn-glycero-3-phosphocholine
2725
-
pH8, micellar 1,2-dioctanoyl-sn-glycero-3-phosphocholine, 2.0 mM Ca2+
29.3
-
purified recombinant AtsPLA2-alpha, substrate 1,2-dilauroyl-sn-glycero-3-phosphocholine
2910
-
pH6, micellar 1,2-dioctanoyl-sn-glycero-3-phosphocholine, 8.1 mM Ca2+
295
-
substrate: dioleolyl-sn-phosphatidylethanolamine
3
-
iPLA2 in a 30000fold purification, substrate: 1-palmitoyl-2-oleolylphosphatidylcholine
3.13
-
isoform Tpu-E6b, presence of deoxycholate, 37°C, pH 7.4
3.22
-
substrate: 1,2-dipalmitoyl-phosphatidylcholine
30
-
substrate: 1,2-dipalmitoyl-phosphatidylcholine
306
-
purified PLA2 from ileal mucosa, substrate: 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol
3150
-
substrate: phosphatidylcholine
320
-
substrate: dioleolyl-sn-phosphatidylcholine
3235
-
substrate: 1,2-didecanoyl-sn-glycero-3-phosphocholine
3250
-
substrate: phosphatidylcholine
33
construct A (Leu-1 mutated to an alanine) and construct B (extra glycine inserted between the start methionine and Leu-1)
330
-
freshly dialyzed PLA2
35
-
HSD-PLA2, 21fold purification, platelet activating factor for substrate
35.5
-
purified recombinant AtsPLA2-alpha, substrate 1,2-didecanoyl-sn-glycero-3-phosphocholine
37.08
Bothrops spp.
-
BthTX-II
38 - 61
-
enzyme from intervertebral disc
383
-
5 mM phosphocholine, N-phosphocholine/N-sodiumcholate: 0.67
4.3
-
iPLA2 in a 30000fold purification, substrate: 1,2-dipalmitoyl-phosphatidylcholine
4.5
-
isoform Tbo-G6D49, presence of deoxycholate, 37°C, pH 7.4
4.65
-
isoform Tpu-G6D49, presence of deoxycholate, 37°C, pH 7.4
4.725
-
substrate: phosphatidylcholine
400
-
2000fold purified enzyme, at pH 9.5, 37°C, in the presence of 1 mM sodium taurodeoxycholate, 4 mM CaCl2 with phosphatidylcholine as substrate
408.3
-
after 1361.7fold purification, in 10 mM Tris-HCl, 10 mM CaCl2 and 100 mM NaCl, pH 8.0, at 37°C
410
-
substrate: dioleolyl-sn-phosphatidylcholine
460
-
7.5 mM phosphocholine, N-phosphocholine/N-sodiumcholate: 0.67
4650
-
substrate: 1,2-dilaureoyl-sn-glycero-3-phosphocholine
500
-
de-/renatured basic PLA2, PC for substrate
5000
-
substrate: phosphatidylethanolamine
520
-
10 mM phosphocholine, N-phosphocholine/N-sodiumcholate: 0.67
530
-
substrate: dioleolyl phosphatidylglycerol
57
-
substrate: dimyristoyl-sn-phosphatidylcholine
573
-
pH 8, micellar 1,2-dioctanoyl-sn-glycero-3-phosphocholine, 0.013 mM Ca2+
576
-
5 mM phosphocholine, N-phosphocholine/N-sodiumcholate: 1.0
6.5
-
isoform Tpu-E6a, presence of Triton X-100, 37°C, pH 7.4
615
-
substrate: dioleolyl phosphatidylglycerol
628.1
purified recombinant His-tagged Lp-PLA2
63
-
in 20 mM HEPES buffer, 20 mM NaCl, 1 mM CaCl2, pH and temperature not specified in the publication
637.9
purified native Lp-PLA2
6410
-
substrate: egg yolk suspension
650
-
de-/renatured basic-acidic PLA2, PC for substrate
6671
-
pH6, micellar 1,2-dioctanoyl-sn-glycero-3-phosphocholine, 0.79 mM Ca2+
68
-
substrate: dimyristoyl-sn-phosphatidylcholine
69.2
-
isoenzyme NK-PLA2-II, substrate phosphatidylethanolamine, sn-2 fatty acid C18:1, 25°C
69.3
-
enzyme from crude venom, pH and temperature not specified in the publication
7.9
-
isoform Tbo-E6, presence of Triton X-100, 37°C, pH 7.4
74.3
-
isoform Tpu-E6c, presence of Triton X-100, 37°C, pH 7.4
741
-
5 mM phosphocholine, N-phosphocholine/N-sodiumcholate: 1.42
76.3
-
isoenzyme NK-PLA2-II, substrate phosphatidylethanolamine, sn-2 fatty acid C18:2, 25°C
775
-
7.5 mM phosphocholine, N-phosphocholine/N-sodiumcholate: 1.0
79
-
isoenzyme NK-PLA2-I, substrate phosphatidylethanolamine, sn-2 fatty acid C18:2, 25°C
8.3
-
isoform Tbo-G6D49, presence of Triton X-100, 37°C, pH 7.4
8.56
-
substrate 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine
80
-
substrate: 1,2-dilaureoyl-sn-glycero-3-phosphocholine
800
-
isoenzyme b-PLA2, substrate: egg yolk emulsion
804
-
10 mM phosphocholine, N-phosphocholine/N-sodiumcholate: 1.0
81
-
substrate: 1,2-didecanoyl-sn-glycero-3-phosphocholine
82
-
5 mM phosphocholine, N-phosphocholine/N-sodiumcholate: 0.20
870
-
7.5 mM phosphocholine, N-phosphocholine/N-sodiumcholate: 1.42
8870
-
substrate: 1,2-dinonanoyl-sn-glycero-3-phosphocholine
89.3
-
isoenzyme NK-PLA2-I, substrate phosphatidylcholine, sn-2 fatty acid C20:4, 25°C
9.9
-
purified recombinant AtsPLA2-alpha, substrate 1,2-dioleoyl-sn-glycero-3-phosphoserine
9300
-
substrate: 1,2-dioctanoyl-sn-glycero-3-phosphoglycol
933
-
5 mM phosphocholine, N-phosphocholine/N-sodiumcholate: 2.0
950
purified mutant enzyme
96.3
-
isoenzyme NK-PLA2-II, substrate phosphatidylserine, sn-2 fatty acid C18:1, 25°C
0.000015
-
microsomal colon mucosa PLA2, substrate: 1-palmitoyl-2-oleolylphosphatidylcholine
0.000015
-
isoform cPLA2epsilon, using 1-palmitoyl-2-arachidonyl-sn-glycerol-3-phosphocholine as substrate, in 10 mM MOPS, pH 7.2, 0.5 mM EGTA, 100 mM KCl, 0.5 mg/ml bovine serum albumin, in the absence of Ca2+, at 37°C
0.0003
-
isoform cPLA2gamma, using 1-palmitoyl-2-arachidonyl-sn-glycerol-3-phosphocholine as substrate, in 10 mM MOPS, pH 7.2, 0.5 mM EGTA, 100 mM KCl, 0.5 mg/ml bovine serum albumin, 0.02 mM Ca2+, at 37°C
0.0003
-
isoform cPLA2gamma, using 1-palmitoyl-2-arachidonyl-sn-glycerol-3-phosphocholine as substrate, in 10 mM MOPS, pH 7.2, 0.5 mM EGTA, 100 mM KCl, 0.5 mg/ml bovine serum albumin, in the absence of Ca2+, at 37°C
0.0225
1-palmitoyl-2-arachidonylphosphoethanolamine as substrate
0.0225
-
isoform cPLA2delta, using 1-palmitoyl-sn-glycero-3-phosphocholine as substrate, in 10 mM MOPS, pH 7.2, 0.5 mM EGTA, 100 mM KCl, 0.5 mg/ml bovine serum albumin, in the absence of Ca2+, at 37°C
0.5
-
substrate: 1-palmitoyl-2-arachidonylphosphatidylcholine
0.5
-
substrate: 1-palmitoyl-2-arachidonylphosphatidylcholine
0.847
-
pH 7.5, 40°C
0.847
-
pH 7.5, 40°C, recombinant enzyme
10
-
iPLA2 in a 30000fold purification, substrate: 1-palmitoyl-2-linoleoylphosphatidylcholine
10
substrate: monomeric dihexanoyl-dithio-phosphatidylcholine, proPLA2
1000
-
gastric juice, substrate: 1-palmitoyl-2-oleolyl-sn-glycero-3-phosphoethanolamine
1000
-
substrate: egg yolk emulsion
1100
-
phospholipid/Triton X-100: 1/4
1100
-
12.5 mM phosphocholine, N-phosphocholine/N-sodiumcholate: 1.42
1100
-
15 mM phosphocholine, N-phosphocholine/N-sodiumcholate: 1.42
2000
-
Triton X-100/phospholipid: 2/1
2000
substrate: micellar 1,2-dioctanoyl-sn-glycero-3-phosphocholine, active PLA2
29
-
recombinant enzyme
29
-
substrate: 1,2-dipalmitoyl-phosphatidylcholine
290
-
isoform SIIISPIIA
290
-
pH 9.5, 45°C, presence of sodium deoxycholate and CaCl2
290
-
substrate: 1-palmitoyl-2-oleolylphosphatidylcholine
5.9
-
purified recombinant AtsPLA2-alpha, substrate 1,2-diheptanoyl-sn-glycero-3-phosphocholine
5.9
-
substrate: phosphatidylcholine
5.9
-
iPLA2 in a 30000fold purification, substrate: 1-palmitoyl-2-linoleoylphosphatidylethanolamine
5.9
-
isoform Tpu-G6D49, presence of Triton X-100, 37°C, pH 7.4
550
-
12.5 mM phosphocholine, N-phosphocholine/N-sodiumcholate: 0.67
550
-
15 mM phosphocholine, N-phosphocholine/N-sodiumcholate: 0.67
61
-
isoenzyme NK-PLA2-I, substrate phosphatidylethanolamine, sn-2 fatty acid C18:1, 25°C
61
-
isoenzyme NK-PLA2-II, substrate phosphatidylcholine, sn-2 fatty acid C20:4, 25°C
750
-
purified enzyme, in the presence of 4 mM sodium taurodeoxycholate and 8 mM CaCl2 using phosphatidylcholine as substrate, at pH 8.0 and 40°C
750
-
de-/renatured acidic PLA2, PA for substrate
750
-
substrate: dimyristoyl-sn-phosphatidylcholine
8.4
-
gastric juice, substrate: mixed micelles of 1-palmitoyl-2-oleolyl-sn-glycero-3-phosphoethanolamine and deoxycholate
8.4
-
isoform Tpu-E6c, presence of deoxycholate, 37°C, pH 7.4
900
-
12.5 mM phosphocholine, N-phosphocholine/N-sodiumcholate: 1.0
900
-
15 mM phosphocholine, N-phosphocholine/N-sodiumcholate: 1.0
additional information
-
synthesis of fluorogenic substrate analogues for rapid determination of head group modification on cell signaling
additional information
-
substrate application in micelles
additional information
-
synthesis of fluorogenic substrate analogues for rapid determination of head group modification on cell signaling
additional information
-
-
additional information
Bothrops spp.
-
BthTX-I has no enzymatic activity
additional information
-
crude enzyme has a specific activity of 0.00012 units/mg, after 7fold purification the enzyme has a specific activity of 0.00084 units/mg, at pH 8.0 and 37°C, one unit of activity is defined as the amount of protein which produces a decrease in 0.01 absorbance in 10 min at 740 nm
additional information
-
RVV-7 cytotoxic activity versus B16F10 melanoma cells, overview
additional information
-
synthesis of fluorogenic substrate analogues for rapid determination of head group modification on cell signaling
additional information
-
sPLA2-X antiviral effect, overview
additional information
-
-
additional information
-
synthesis of fluorogenic substrate analogues for rapid determination of head group modification on cell signaling
additional information
-
sensitive activity assay using radioiodinatable long-chain phosphatidylcholine, detection limit is 0.25 ng enzyme or 0.05 ng substrate
additional information
-
-
additional information
-
-
additional information
-
synthesis of fluorogenic substrate analogues for rapid determination of head group modification on cell signaling
additional information
-
kinetic investigation of hydrophobic/hydrophilic effect in various W7O microemulsions, using isooctane as main solvents and alcohols from 1-butanol to 1-octanol as co-solvent, giving yields of more than 90%. Water-content in the microemulsion phase dominantly governed the initial reaction rate
additional information
fluorimetric assay for the determination of total phospholipase A2 activity in biological samples introducing the innovation of immobilized substrates on crosslinked polymeric membranes. The immobilized 1-palmitoyl-2-{12-[(7-nitro-2-1,3-benzoxadiazol-4-yl)amino]dodecanoyl}-sn-glycero-3-phosphocholine, a fluorescent analogue of phosphatidylcholine, exhibits high stability for 3 months at 4°C and is not desorbed in the aqueous reaction mixture during analysis
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.